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Executive Summary  
Background. Medical cannabis encompasses all cannabis-based products which are used for med-
ical treatment. The so far most studied cannabinoids, and thought to be the most important in terms 
of clinical effects, are tetrahydrocannabinol (THC) and cannabidiol (CBD). General reimbursement 
by the compulsory health insurance for medical cannabis does not exist in Switzerland. Medical 
cannabis can be used to treat various symptoms and is predominantly used as add-on therapy or 
after other therapeutic options are unsuccessful. Preceding this Health Technology Assessment 
(HTA) report, a scoping review was conducted of which the results were published in the scoping 
report. The scoping report describes the evidence base for the use of medical cannabis for treating 
the following symptoms: chronic pain, spasticity, unintentional weight loss, and nausea and vomiting 
related to cancer treatment. For the latter two symptoms, the evidence from the randomised con-
trolled trials (RCTs) was insufficient to make pertinent recommendations and it was therefore de-
cided not to continue with complete data extraction and cost-effectiveness modelling for these two 
symptoms in the HTA phase. The overall aim of this HTA report was to investigate the efficacy, 
effectiveness, safety, cost-effectiveness, and budget impact of medical cannabis use in chronic pain 
and spasticity in Switzerland.  
Methods. Systematic reviews were conducted adhering to international methodological standards. 
Systematic literature searches were performed in PubMed (MEDLINE), Embase.com, and other 
complementary databases to identify relevant efficacy, effectiveness, safety, and cost-effectiveness 
evidence. Only RCTs and economic evaluations were included in the corresponding searches. Data 
were extracted from the included studies in evidence tables, and the outcomes of the quality as-
sessment were reported. The data on medical cannabis use for chronic pain was stratified in three 
subpopulations: cancer pain, neuropathic pain, and musculoskeletal pain. Data on medical cannabis 
use for spasticity was stratified in two subpopulations: multiple sclerosis (MS) and motor neuron 
disease.  
During the scoping phase, the systematic literature search on the cost-effectiveness of medical can-
nabis use in chronic pain and spasticity did not provide evidence for Switzerland. Therefore, cost-
effectiveness models were developed, characterising the natural history of the disease in a patient’s 
lifetime in the Swiss clinical practice. The models were used to determine the cost-effectiveness of 
medical cannabis in addition to standard of care (SOC) to SOC alone for all subpopulations for which 
usable efficacy evidence was available. Non-systematic searches were performed to identify cost 
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and health-related quality of life (expressed in utilities on a scale from 0 to 1) input for cost-effec-
tiveness modelling. The uncertainty around input parameters was explored in sensitivity and sce-
nario analyses. In addition, the projected budget impact was calculated, using input for the budget 
impact calculations were derived via a survey among clinical experts. Websites of HTA agencies 
were searched for information on social, legal, ethical, and organisational aspects related to pre-
scribing medical cannabis. For these HTA domains, the evidence was described narratively.  
Results. Heterogeneity between studies in outcomes and outcome measures, data skewness, and 
incompleteness of study results precluded the calculation of pooled estimates for efficacy data for 
the stratified pain and spasticity populations. Overall, the efficacy data on medical cannabis use for 
chronic pain and spasticity was inconsistent (i.e. studies with comparable patient populations and 
similar type of medical cannabis did not show consistent results pointing in the same direction) and 
inconclusive (i.e. none of the studies was able to draw a definitive conclusion on the efficacy of 
medical cannabis). Furthermore, multiple factors increase the risk of bias in studies on medical can-
nabis, however the extent as well as the direction of the potential bias are difficult to comprehend. 
Although it was possible to calculate pooled estimates for part of the safety outcomes and some 
patient populations, the issues highlighted for efficacy also apply to safety, resulting in an incomplete 
safety profile of medical cannabis. 
For cost-effectiveness modelling, the absolute change in numeric rating scale (NRS) score was the 
preferred efficacy outcome measure in the chronic pain models, and the proportion of responders 
at ≥30% reduction in NRS score was the preferred efficacy outcome in the spasticity models. Re-
sulting from this, usable efficacy evidence for cost-effectiveness modelling was available for two 
chronic pain populations (neuropathic pain and musculoskeletal pain) and two spasticity populations 
(MS and motor neuron disease). These studies reported the efficacy of THC:CBD spray (Sativex®). 
Using a healthcare perspective, lifetime horizon, and 3% discounting of costs and effects, THC:CBD 
spray in addition to SOC resulted in a minimal loss in quality-adjusted life years (QALYs) for neuro-
pathic pain compared to SOC alone, and only small QALY gains for the other populations. In all 
models, the costs of THC:CBD spray in addition to SOC were higher than SOC alone. Sensitivity 
analyses showed that treatment effect, utility values, and baseline pain or spasticity scores were the 
most influential parameters. The budget impact estimates were surrounded by substantial uncer-
tainty. Websites and documents from HTA agencies pointed out several relevant legal, social, ethi-
cal, and organisational issues related to the use and reimbursement of medical cannabis.  
Conclusions. While the research question encompassed all chronic pain and all spasticity popula-
tions, there was only sufficient evidence to assess the efficacy and safety of the use of medical 
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cannabis for people with neuropathic pain, musculoskeletal pain, cancer pain, spasticity in MS and 
spasticity in motor neuron disease. However, due to incomplete, inconclusive, and inconsistent 
study findings, no conclusions could be drawn on the efficacy and safety of medical cannabis in 
these patient populations. In studies on medical cannabis, an unpredictable bias and uncertainty in 
the evidence base arises caused by the risk of unblinding of patients to their treatment allocation in 
combination with the patient-reported outcomes for the symptoms chronic pain and spasticity. Given 
these considerations it is neither possible to conclude that medical cannabis is an efficacious and 
safe treatment option for chronic pain and spasticity, nor to conclude that medical cannabis is not 
efficacious and safe for the treatment of chronic pain and spasticity. Future studies on medical can-
nabis to treat these symptoms will likely be exposed to similar challenges and limitations, of which 
only part can be solved with improved study designs and complete reporting of results.  
Modelling was performed to provide indicative cost-effectiveness estimates, and showed that 
THC:CBD spray in addition to SOC was associated with minimal changes in QALYs against addi-
tional costs compared to SOC alone. The generalisability of the cost-effectiveness and budget im-
pact estimates to other populations, other medical cannabis products or other routes of administra-
tion is unknown.  
When considering reimbursement of medical cannabis for certain populations, relevant legal, social, 
ethical, and organisational issues should also be considered. For example, reimbursement of med-
ical cannabis will be subject to different and interconnected Swiss laws with regard to cultivation, 
consumption, distribution, and prescription. In addition, reimbursement of medical cannabis may 
have social and ethical consequences, for example as a result of a gap between patient expecta-
tions and scientific evidence. Other concerns include accessibility restrictions, vulnerable popula-
tions at risk of unintended consequences, and illicit use. Furthermore, organisational challenges 
may arise in the supply and quality control of medical cannabis products. 
Zusammenfassung  
Hintergrund. Der Begriff medizinischer Cannabis umfasst alle Produkte auf Cannabisbasis, die zur 
medizinischen Behandlung eingesetzt werden. Die bisher am meisten untersuchten Cannabinoide, 
von denen die grösste Bedeutung in Hinsicht auf die klinische Wirkung angenommen wird, sind Tet-
rahydrocannabinol (THC) und Cannabidiol (CBD). In der Schweiz werden die Kosten für medizini-
sches Cannabis nicht generell durch die obligatorische Krankenversicherung übernommen. Medizi-
nischer Cannabis kann zur Behandlung verschiedener Symptome eingesetzt werden und wird über-
wiegend als Zusatztherapie oder nachdem andere sich andere therapeutische Optionen als erfolglos 
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erwiesen hatten, angewendet. Vor der Verfassung dieses HTA-Berichts (Health Technology Asses-
sment) wurde ein Scoping-Review durchgeführt, dessen Ergebnisse im Scoping-Bericht veröffentlicht 
wurden. Der Scoping-Bericht beschreibt die Evidenzbasis für die Anwendung von medizinischem 
Cannabis zur Behandlung folgender Symptome: chronische Schmerzen, Spastik, ungewollter Ge-
wichtsverlust sowie Übelkeit und Erbrechen im Zusammenhang mit einer Krebstherapie. Die rando-
misierten kontrollierten Studien (RCTs) lieferten für die beiden letztgenannten Symptome keine aus-
reihende Evidenz, die entsprechende Empfehlungen erlauben würde. Es wurde daher beschlossen, 
in der HTA-Phase die vollständige Datenextraktion und Modellierung der Kosteneffektivität für diese 
Symptome nicht fortzusetzen. Das übergeordnete Ziel dieses HTA-Berichts bestand darin, die Wirk-
samkeit, Effektivität, Sicherheit, Kosteneffektivität sowie den Budgeteinfluss der Anwendung von me-
dizinischem Cannabis bei chronischen Schmerzen und Spastik in der Schweiz zu untersuchen.  
Methoden. Systematische Reviews erfolgten unter Einhaltung internationaler methodischer Stan-
dards. Systematische Literaturrecherchen wurden in PubMed (MEDLINE), Embase.com und anderen 
ergänzenden Datenbanken durchgeführt, um relevante Evidenz zur Wirksamkeit, Effektivität, Sicher-
heit und Kosteneffektivität zu identifizieren. Nur RCTs und ökonomische Evaluationen wurden in die 
entsprechenden Recherchen einbezogen. Die Daten wurden aus den eingeschlossenen Studien in 
Evidenztabellen extrahiert, und die Ergebnisse der Qualitätsbewertung wurden erfasst. Die Daten 
zum medizinischen Cannabiskonsum bei chronischen Schmerzen wurden in drei Subpopulationen 
stratifiziert: onkologische, neuropathische und muskuloskelettale Schmerzen. Die Daten bezüglich 
der Anwendung von medizinischem Cannabis zur Behandlung von Spastik wurden in zwei Subpopu-
lationen stratifiziert: Multiple Sklerose (MS) und Motoneuronerkrankung.  
Während der Scoping-Phase lieferte die systematische Literaturrecherche zur Kosteneffektivität der 
Anwendung von medizinischem Cannabis bei chronischen Schmerzen und Spastik keine Evidenz für 
die Schweiz. Daher wurden Modelle zur Kosteneffektivität entwickelt, die den natürlichen Verlauf der 
Erkrankung im Leben eines Patienten in der Schweizer klinischen Praxis charakterisieren. Die Mo-
delle wurden verwendet, um die Kosteneffektivität von medizinischem Cannabis zusätzlich zur Stan-
dardbehandlung (SOC) im Vergleich zur SOC allein für alle Subpopulationen zu ermitteln, für die 
verwertbare Wirksamkeitsnachweise vorlagen. Es wurden nicht-systematische Suchen durchgeführt, 
um Kosten und gesundheitsbezogene Lebensqualität (ausgedrückt in Nutzen auf einer Skala von 0 
bis 1) als Input für die Kosten-Effektivitäts-Modellierung zu identifizieren. Die Unsicherheit hinsichtlich 
der die Inputparameter wurde in Sensitivitäts- und Szenarioanalysen untersucht. Zudem wurde der 
voraussichtliche Budgeteinfluss berechnet, wobei der Input für die Berechnung des Budgeteinflusses 
von einer Umfrage unter klinischen Experten abgeleitet wurde. Websites von HTA-Agenturen wurden 
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nach Informationen über soziale, rechtliche, ethische und organisatorische Aspekte im Zusammen-
hang mit der Verschreibung von medizinischem Cannabis durchsucht. Für diese HTA-Domänen 
wurde die Evidenz narrativ beschrieben.  
Ergebnisse. Aufgrund der Heterogenität der Studien in Bezug auf Ergebnisse und Endpunkte, Da-
tenverzerrungen sowie die Unvollständigkeit der Studienergebnisse war die Erstellung gepoolter 
Schätzungen für die Wirksamkeitsdaten zu stratifizierten Populationen mit Schmerzen und Spastik 
ausgeschlossen. Insgesamt waren die Daten zur Wirksamkeit der Anwendung von medizinischem 
Cannabis bei chronischen Schmerzen und Spastik inkonsistent (d. h. Studien mit vergleichbaren Pa-
tientenpopulationen und ähnlicher Art von medizinischem Cannabis zeigten keine konsistenten Er-
gebnisse, die in dieselbe Richtung weisen würden) und nicht schlüssig (d. h. keine der Studien er-
laubte es, eine endgültige Schlussfolgerung zur Wirksamkeit von medizinischem Cannabis zu zie-
hen). Darüber hinaus erhöhen mehrere Faktoren das Risiko einer Verzerrung in Studien zu medizi-
nischem Cannabis, wobei sowohl das Ausmaß als auch die Richtung der möglichen Verzerrung 
schwer zu erfassen sind. Obwohl es möglich war, gepoolte Schätzungen für einen Teil der Sicher-
heitsergebnisse und einige Patientenpopulationen zu erstelle, gelten die für die Wirksamkeit hervor-
gehobenen Probleme auch für die Sicherheit, woraus sich die Unvollständigkeit des Sicherheitsprofils 
von medizinischem Cannabis ergibt. 
Hinsichtlich der Modellierung der Kosteneffektivität war die absolute Veränderung des NRS-Scores 
(Numeric Rating Scale) in den Modellen zu chronischen Schmerzen der bevorzugte Wirksamkeits-
endpunkt. Der Anteil der Responder mit einer ≥30%igen Reduktion des NRS-Scores stellte den be-
vorzugten Wirksamkeitsendpunkt in den Modellen zur Spastik dar. Daraus ergaben sich verwertbare 
Wirksamkeitsnachweise für die Modellierung der Kosteneffektivität bei zwei Populationen mit chroni-
schen Schmerzen (neuropathische und muskuloskelettale Schmerzen) sowie zwei Populationen mit 
Spastik (MS und Motoneuronerkrankung). Diese Studien befassten sich mit der Wirksamkeit des 
THC/CBD-Sprays (Sativex®). Unter Verwendung einer Gesundheitsperspektive, eines Lebenszeit-
horizonts und einer 3 %igen Diskontierung von Kosten und Effekten führte das das zusätzlich zur 
SOC angewendete THC/CBD-Spray zu einem minimalen Verlust an qualitätsbereinigten Lebensjah-
ren (QALYs) bei neuropathischen Schmerzen im Vergleich zu SOC allein und nur zu geringen QALY-
Gewinnen bei den anderen Populationen. In allen Modellen waren die Kosten für SOC und THC/CBD-
Spray höher als für SOC allein. In Sensitivitätsanalysen haben aufgezeigt, dass der Behandlungsef-
fekt, die Nutzenbewertung und die Schmerz- oder Spastik-Scores bei Baseline die wichtigsten Para-
meter waren. Die Schätzungen des Budgeteinflusses waren mit erheblichen Unsicherheiten behaftet. 
Websites und Dokumente von HTA-Agenturen verwiesen auf mehrere relevanten rechtlichen, sozia-
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len, ethischen und organisatorischen Probleme im Zusammenhang mit der Anwendung und Erstat-
tung von medizinischem Cannabis.  
Fazit. Während die Forschungsfrage alle chronischen Populationen mit Schmerzen und Spastik ein-
schloss, erlaubte die vorliegende Evidenz nur die Beurteilung der Wirksamkeit und Sicherheit der 
Anwendung von medizinischem Cannabis bei Menschen mit neuropathischen Schmerzen, Schmer-
zen des Bewegungsapparats, onkologischen Schmerzen sowie Spastik bei MS und Motoneuroner-
krankungen. Aufgrund der unvollständigen, nicht schlüssigen und inkonsistenten Studienergebnisse 
konnten jedoch keine Schlussfolgerungen hinsichtlich der Wirksamkeit und Sicherheit von medizini-
schem Cannabis in diesen Patientenpopulationen gezogen werden. Studien zu medizinischem Can-
nabis gingen mit einer unvorhersehbaren Verzerrung und Unsicherheit in der Evidenzbasis einher, 
die durch das Risiko der Entblindung der Patienten hinsichtlich ihrer Behandlungszuweisung in Kom-
bination mit den von den Patienten berichteten Ergebnissen bezüglich der Symptome chronische 
Schmerzen und Spastik verursacht wurde. Vor diesem Hintergrund ist es weder möglich, zu dem 
Schluss zu kommen, dass medizinischer Cannabis eine wirksame und sichere Behandlungsoption 
für chronische Schmerzen und Spastik darstellt, noch dies zu verneinen. Zukünftige Studien zu me-
dizinischem Cannabis zur Behandlung dieser Symptome werden wahrscheinlich ähnlichen Heraus-
forderungen und Einschränkungen ausgesetzt sein, wobei nur ein Teil davon durch verbesserte Stu-
diendesigns und vollständige Ergebnis-Berichterstattung gelöst werden kann.  
Die Modellierung der Kosteneffektivität hat aufgezeigt, dass die Anwendung des THC/CBD-Sprays 
zur Behandlung der Symptome Schmerzen oder Spastik im Vergleich zu SOC allein mit minimalen 
Veränderungen der QALYs bei zusätzlichen Kosten verbunden war. Es ist nicht bekannt, inwiefern 
die Schätzungen der Kostenwirksamkeit und des Budgeteinflusses auf andere Bevölkerungsgrup-
pen, andere medizinische Cannabisprodukte oder andere Verabreichungswege übertragen werden 
kann.  
Bei der Erwägung der Erstattung von medizinischem Cannabis für bestimmte Populationen sollten 
auch relevante rechtliche, soziale, ethische und organisatorische Probleme berücksichtigt werden. 
So wird beispielsweise die Erstattung von medizinischem Cannabis verschiedenen und miteinander 
zusammenhängenden in der Schweiz geltenden Gesetzen betreffend Anbau, Konsum, Vertrieb und 
Verschreibung unterliegen. Zudem kann die Erstattung von medizinischem Cannabis soziale und 
ethische Folgen haben, zum Beispiel aufgrund einer Kluft zwischen den Erwartungen der Patienten 
und der wissenschaftlichen Evidenz. Weitere Bedenken betreffen die eingeschränkte Zugänglichkeit, 
vulnerable Bevölkerungsgruppen, bei denen das Risiko von unbeabsichtigten Folgen besteht, sowie 
die illegale Verwendung. Darüber hinaus können sich im Hinblick auf die Lieferung und Qualitätskon-
trolle von medizinischen Cannabisprodukten organisatorische Herausforderungen ergeben. 
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Résumé  
Contexte. Le cannabis médical comprend tous les produits à base de cannabis utilisés à des fins 
thérapeutiques. Les cannabinoïdes les plus étudiés jusqu’à présent, et considérés comme les plus 
importants en termes d’effets cliniques, sont le tétrahydrocannabinol (THC) et le cannabidiol (CBD). 
L’assurance obligatoire des soins ne rembourse pas le cannabis médical de manière générale en 
Suisse. Le cannabis médical peut être utilisé pour traiter divers symptômes, principalement en tant 
que traitement d’appoint ou si d’autres options thérapeutiques se sont avérées inefficaces. En amont 
du présent rapport d’évaluation des technologies de la santé (ETS ou HTA pour health technology 
assessment), une étude a été menée, dont les résultats ont fait l’objet d’un scoping report décrivant 
les preuves de l’efficacité du cannabis médical pour le traitement des douleurs chroniques, de la 
spasticité, de la perte de poids involontaire ainsi que des nausées et vomissements dus à une théra-
pie oncologique. Pour ces deux derniers symptômes, les essais contrôlés randomisés (RCT pour 
randomized controlled trials) n’ont pas fourni suffisamment de preuves permettant de formuler des 
recommandations pertinentes, raison pour laquelle il a été décidé de ne pas poursuivre l’extraction 
complète des données et l’élaboration de modèles d’économicité à ce sujet dans la phase d’ETS. Le 
présent rapport d’ETS vise essentiellement à évaluer les preuves de l’efficacité, de l’innocuité et de 
l’économicité ainsi que l’impact budgétaire du cannabis médical pour le traitement des douleurs chro-
niques et de la spasticité en Suisse. 
Méthodologie. Les analyses systématiques se sont basées sur les normes internationales. Des re-
cherches systématiques ont été réalisées dans PubMed (MEDLINE), Embase.com et d’autres bases 
de données complémentaires pour identifier des publications attestant l’efficacité, l’innocuité et l’éco-
nomicité du cannabis médical. Seuls des RCT et des évaluations économiques ont été inclus dans 
les recherches. Les données extraites des études réalisées ont été présentées sous forme de ta-
bleaux synoptiques, et les résultats de l’évaluation de la qualité ont été présentés. Les données rela-
tives au cannabis médical pour le traitement des douleurs chroniques ont été stratifiées en trois sous-
populations : douleurs cancéreuses, douleurs neuropathiques et douleurs musculosquelettiques. Les 
données relatives au cannabis médical pour le traitement de la spasticité ont été stratifiées en deux 
sous-populations : sclérose en plaques (SEP) et maladie du motoneurone. 
Durant la phase d’étude, les recherches systématiques dans la littérature n’ont pas fourni de preuve 
sur l’économicité du cannabis médical pour traiter les douleurs chroniques et la spasticité en Suisse. 
Des modèles d’économicité ont donc été élaborés, compte tenu de l’histoire naturelle de la maladie 
tout au long de la vie du patient dans la pratique clinique en Suisse. Ces modèles visaient à détermi-
ner l’économicité du cannabis médical associé au traitement Standard Of Care (SOC) par rapport au 
traitement SOC seul pour toutes les sous-populations pour lesquelles des données probantes sur 
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l’efficacité étaient disponibles. Des recherches non systématiques ont été effectuées pour identifier 
les données relatives aux coûts et à la qualité de vie liée à la santé (exprimée en utilités sur une 
échelle de 0 à 1) pour la modélisation du rapport coût-efficacité. Les incertitudes liées aux paramètres 
ont été examinées dans des analyses de sensibilité et de scénarios. Par ailleurs, l’impact budgétaire 
projeté a été calculé sur la base d’une étude menée auprès d’experts cliniques. Les aspects sociaux, 
légaux, éthiques et organisationnels liés au cannabis médical ont fait l’objet de recherches sur les 
sites internet des agences d’ETS. Pour ces domaines d’ETS, les preuves étaient décrites de façon 
narrative. 
Résultats. Du fait de l’hétérogénéité des résultats et des méthodes pour mesurer les résultats, de 
l’asymétrie des données et des résultats incomplets, il n’a pas été possible de procéder à une éva-
luation globale des données d’efficacité concernant les populations stratifiées d’après les critères de 
la douleur et de la spasticité. D’une manière générale, les données d’efficacité du cannabis médical 
pour traiter les douleurs chroniques et la spasticité étaient contradictoires (les études portant sur des 
populations de patients comparables et le même type de cannabis médical n’ont pas débouché sur 
des résultats cohérents allant dans le même sens) et non concluantes (aucune étude n’a permis de 
tirer de conclusion définitive sur l’efficacité du cannabis médical). En outre, de multiples facteurs 
augmentent le risque de biais dans les études sur le cannabis médical, mais l'ampleur ainsi que la 
direction du biais potentiel sont difficiles à appréhender. Même si une évaluation globale a pu être 
effectuée pour une partie des résultats d’innocuité et certains patients, les problèmes rencontrés au 
niveau de l’efficacité concernent également l’innocuité, d’où un profil d’innocuité incomplet. 
S’agissant des modèles d’économicité, les résultats d’efficacité des modèles concernant les douleurs 
chroniques ont été mesurés en fonction de la modification en chiffres absolus du score de l’échelle 
numérique (EN), et la proportion de répondants indiquant une réduction de ≥ 30 % pour le score de 
l’EN a servi de base pour établir l’efficacité des modèles pour la spasticité. Ainsi, des preuves avérées 
de l’efficacité des modèles d’économicité étaient disponibles pour deux populations de patients souf-
frant de douleurs chroniques (douleurs neuropathiques et douleurs musculosquelettiques) et deux 
populations de patients atteints de spasticité (sclérose en plaques et maladie du motoneurone). Ces 
études ont porté sur l’efficacité du spray Sativex® à base de THC/CBD. Sous l’angle des soins de 
santé, avec un horizon temporel de la vie entière et avec un taux d’actualisation de 3 % pour les coûts 
et les effets, le spray à base de THC/CBD associé à un traitement SOC a montré une perte minime 
en termes d’années de vie pondérées par la qualité (QALY) pour les douleurs neuropathiques par 
rapport au seul traitement SOC et seulement de faibles gains de QALY pour les autres populations. 
Dans tous les modèles, les coûts du spray à base de THC/CBD associé au traitement SOC étaient 
plus élevés qu’avec le traitement SOC uniquement. Les analyses de sensibilité montrent que les 
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effets du traitement, les valeurs d’utilité, ainsi que les scores de la douleur ou de la spasticité sont les 
paramètres les plus pertinents. Une grande incertitude entoure les estimations budgétaires. Les sites 
internet et les documents d’agences d’ETS soulignent un certain nombre de problèmes importants 
sur les plans légaux, sociaux, éthiques et organisationnels concernant l’usage et le remboursement 
du cannabis médical. 
Conclusions. Tandis que la recherche s’étendait à toutes les populations atteintes de douleurs chro-
niques et de spasticité, les preuves disponibles n’ont permis d’évaluer l’efficacité et l’innocuité du 
cannabis médical que pour les personnes souffrant de douleurs neuropathiques, musculosquelet-
tiques ou cancéreuses, de spasticité en cas de sclérose en plaques ou de maladie du motoneurone. 
Toutefois, étant donné que les résultats des études étaient incomplets, non concluants et contradic-
toires, il n’a pas été possible de tirer de conclusions sur l’efficacité et l’innocuité du cannabis médical 
pour ces patients. Il ressort des études sur le cannabis médical un parti pris imprévisible ainsi que 
des incertitudes au niveau des preuves en raison du risque d’une levée de l’insu pour l’allocation du 
traitement ainsi que des résultats rapportés par les patients pour les symptômes de douleurs chro-
niques et de spasticité. Dans ces conditions, s’il est impossible de conclure que le cannabis médical 
est efficace et sans danger pour traiter les douleurs chroniques et la spasticité, on ne saurait non plus 
conclure que le cannabis médical n’est pas efficace ni sans danger pour ces traitements. Les futures 
études à ce sujet devront probablement faire face aux mêmes difficultés et restrictions, qui ne pour-
ront être résolues qu’en partie grâce à l’amélioration des études et à la production de rapports com-
plets. 
Les modèles d’économicité ont montré que le spray à base de THC/CBD pour le traitement de la 
douleur ou de la spasticité n’avait qu’une faible incidence sur la QALY mais qu’il occasionnait des 
coûts supplémentaires par rapport au seul traitement SOC. On ignore si l’économicité et les estima-
tions budgétaires peuvent être généralisées à d’autres populations, produits à base de cannabis mé-
dical ou voies d’administration. 
S’agissant de rembourser le cannabis médical pour certaines populations, il convient également de 
tenir compte des aspects légaux, sociaux, éthiques et organisationnels. À titre d’exemple, le rem-
boursement du cannabis médical sera soumis à différentes lois suisses interdépendantes concernant 
la culture des plants, la consommation, la distribution et la prescription. De plus, il peut y avoir des 
conséquences sociales et éthiques, par exemple en raison de la disparité entre les attentes des pa-
tients et les preuves scientifiques. Les restrictions en termes d’accessibilité, les patients vulnérables 
susceptibles de subir des conséquences involontaires et l’usage illicite sont source d’inquiétudes 
supplémentaires. Enfin, des problèmes d’ordre organisationnel peuvent se poser au niveau de l’ap-
provisionnement et du contrôle de la qualité des produits à base de cannabis médical. 
 
HTA Report 11 
Riepilogo Situazione iniziale. Per canapa medicinale si intendono tutti i prodotti a base di canapa 
utilizzati nei trattamenti medici. I cannabinoidi finora più studiati, e ritenuti i più importanti in termini di 
effetti clinici, sono il tetraidrocannabinolo (THC) e il cannabidiolo (CBD). In Svizzera, per la canapa 
medicinale non è prevista una rimunerazione generale da parte dell’assicurazione obbligatoria delle 
cure medico-sanitarie (AOMS). La canapa medicinale può essere utilizzata per trattare diversi sintomi 
ed è impiegata prevalentemente come terapia aggiuntiva o dopo che altre opzioni terapeutiche sono 
risultate inefficaci. Prima del presente rapporto di Health Technology Assessment (HTA), è stata con-
dotta una scoping review i cui risultati sono stati pubblicati nel rapporto di scoping. Il rapporto descrive 
la base di evidenze scientifiche per l’utilizzo della canapa medicinale nel trattamento dei seguenti 
sintomi: dolore cronico, spasticità, perdita involontaria di peso, nausea e vomito associati al tratta-
mento del cancro. Riguardo agli ultimi due sintomi, l’evidenza degli studi randomizzati controllati 
(RCT) si è rivelata insufficiente per formulare raccomandazioni pertinenti e si è pertanto deciso di non 
procedere all’estrazione completa dei dati e allo sviluppo di un modello del rapporto costo-efficacia 
per questi due sintomi nella fase HTA. L’obiettivo generale del rapporto HTA è di analizzare l’efficacia, 
l’efficienza, la sicurezza, il rapporto costo-efficacia e l’incidenza sul bilancio dell’utilizzo della canapa 
medicinale per il dolore cronico e la spasticità in Svizzera. 
Metodi. Le revisioni sistematiche sono state condotte rispettando gli standard metodologici interna-
zionali. Le ricerche sistematiche nella letteratura scientifica sono state svolte in PubMed (MEDLINE), 
Embase.com e in altre banche dati complementari per identificare le pertinenti evidenze di efficacia, 
efficienza, sicurezza e rapporto costo-efficacia. Nelle relative ricerche sono stati inclusi solo gli RCT 
e le valutazioni economiche. Si è proceduto quindi all’organizzazione dei dati degli studi in tabelle di 
evidenza e alla pubblicazione dei risultati della valutazione della qualità. I dati relativi all’utilizzo della 
canapa medicinale per il dolore cronico sono stati classificati in tre sottogruppi: dolore da cancro, 
dolore neuropatico e dolore muscolo-scheletrico. I dati relativi all’utilizzo della canapa per la spasticità 
sono stati classificati in due sottogruppi: sclerosi multipla (SM) e malattia del motoneurone. 
Durante la fase di scoping, le ricerche sistematiche nella letteratura riguardo al rapporto costo-effica-
cia dell’utilizzo della canapa medicinale per il dolore cronico e la spasticità non hanno fornito evidenze 
per la Svizzera. Pertanto, sono stati sviluppati modelli di costo-efficacia basati sul decorso naturale 
della malattia durante la vita di un paziente nella prassi clinica svizzera. I modelli sono stati impiegati 
per determinare il rapporto costo-efficacia della canapa medicinale in aggiunta allo standard di cura 
(SOC) rispetto al solo SOC in tutti i sottogruppi per i quali fossero disponibili evidenze di efficacia 
utilizzabili. Sono state effettuate ricerche non sistematiche per identificare i costi e la qualità della vita 
correlata alla salute (espressa in utilità su una scala da 0 a 1) per la modellazione del rapporto costo-
efficacia. L’incertezza riguardo ai parametri di calcolo è stata oggetto di analisi di sensibilità e di analisi 
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di scenario. Inoltre, è stata calcolata l’incidenza prevista sul bilancio utilizzando fattori per i calcoli 
dell’incidenza sul bilancio derivati da un sondaggio tra esperti clinici. Sono stati consultati i s iti web 
delle agenzie HTA per ottenere informazioni sugli aspetti sociali, legali, etici e organizzativi relativi 
alla prescrizione di canapa medicinale. Per questi ambiti HTA, le evidenze sono state descritte in 
modo narrativo. 
Risultati. L’eterogeneità tra gli studi sui risultati e sulle misure di risultato, l’asimmetria dei dati e 
l’incompletezza dei risultati degli studi non hanno permesso di calcolare stime aggregate per i dati 
sull’efficacia relativi ai gruppi di popolazione affetti da dolore e spasticità. Nel complesso, i dati sull’ef-
ficacia dell’utilizzo della canapa medicinale per il dolore cronico e la spasticità sono risultati incoerenti 
(vale a dire che gli studi con gruppi di pazienti comparabili e con tipologie simili di canapa medicinale 
non hanno prodotto risultati coerenti che andassero nella stessa direzione) e inconcludenti (vale a 
dire che nessuno studio è stato in grado di trarre una conclusione definitiva sull’efficacia della canapa 
medicinale). Inoltre, molteplici fattori aumentano il rischio di distorsioni negli studi sulla cannabis me-
dica, tuttavia l'estensione e la direzione delle potenziali distorsioni sono difficili da comprendere. Seb-
bene sia stato possibile calcolare stime aggregate per una parte dei risultati relativi alla sicurezza e 
per alcuni gruppi di pazienti, le questioni emerse in merito all’efficacia si applicano anche alla sicu-
rezza, il che implica un profilo di sicurezza incompleto per la canapa medicinale. 
Per elaborare un modello del rapporto costo-efficacia, nei modelli di dolore cronico la misura di effi-
cacia preferita è stato il cambiamento assoluto nel punteggio della scala numerica di valutazione 
(NRS), mentre nei modelli di spasticità tale misura è stata la proporzione di responder con una ridu-
zione ≥30 per cento del punteggio NRS. Di conseguenza, per l’elaborazione di un modello del rap-
porto costo-efficacia sono disponibili evidenze di efficacia utilizzabili per due gruppi di popolazione 
affetti da dolore cronico (dolore neuropatico e dolore muscolo-scheletrico) e due gruppi affetti da 
spasticità (nella SM e nella malattia del motoneurone). Tali studi hanno valutato l’efficacia dello spray 
THC:CBD (Sativex). Applicando una prospettiva sanitaria, una stima dei costi e dei benefici in tempo-
vita e un tasso di sconto del 3 per cento del rapporto costo-efficacia, lo spray THC:CBD in aggiunta 
al SOC ha mostrato una perdita minima in termini di anni di vita ponderati per la qualità (QALY) per 
il dolore neuropatico rispetto al solo SOC, e solo piccoli benefici in termini di QALY per gli altri gruppi. 
In tutti i modelli, i costi dello spray THC:CBD in aggiunta al SOC erano maggiori rispetto al solo SOC. 
Le analisi di sensibilità hanno mostrato che i parametri più influenti sono gli effetti del trattamento, i 
valori di utilità e i punteggi di dolore o spasticità al basale. Le stime relative all’incidenza sul bilancio 
sono caratterizzate da una sostanziale incertezza. I siti web e la documentazione delle agenzie HTA 
sollevano numerose questioni legali, sociali, etiche e organizzative legate all’utilizzo e al rimborso 
della canapa medicinale. 
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Conclusioni. Mentre la domanda di ricerca comprendeva tutti i gruppi di popolazione affetti da dolore 
cronico e spasticità, vi erano evidenze appena sufficienti per valutare l’efficacia e la sicurezza dell’uti-
lizzo della canapa medicinale per le persone affette da dolore neuropatico, dolore muscolo-schele-
trico, dolore da cancro, spasticità nella SM e spasticità nella malattia del motoneurone. Tuttavia, a 
causa dei risultati incompleti, inconcludenti e incoerenti emersi dagli studi, non è stato possibile trarre 
conclusioni in merito all’efficacia e alla sicurezza della canapa medicinale in questi gruppi di pazienti. 
Negli studi sulla canapa medicinale si verificano distorsioni (bias) e incertezze nella base delle evi-
denze scientifiche, a causa del rischio di smascheramento del trattamento assegnato ai pazienti in 
combinazione con i risultati riferiti dai pazienti per i sintomi del dolore cronico e della spasticità. Per 
questi motivi, non è possibile concludere che la canapa medicinale non sia un’opzione di trattamento 
efficace e sicura per il dolore cronico e la spasticità, né che non sia affatto efficace e sicura per il 
trattamento del dolore cronico e della spasticità. Gli studi futuri sulla canapa medicinale per il tratta-
mento di questi sintomi dovranno probabilmente affrontare difficoltà e restrizioni simili, di cui solo una 
parte potrà essere risolta con migliori tipologie di studio e un’analisi completa dei risultati. 
L’elaborazione del modello del rapporto costo-efficacia ha mostrato che l’utilizzo dello spray 
THC:CBD per il trattamento del dolore o dei sintomi della spasticità comporta variazioni minime nei 
QALY, a fronte di costi aggiuntivi rispetto al solo SOC. Si ignora se sia possibile estrapolare le stime 
di costo-efficacia e di incidenza sul budget ad altri gruppi, altri prodotti a base di canapa medicinale 
o altre vie di somministrazione. 
Nel considerare la rimunerazione della canapa medicinale per determinati gruppi, andrebbe tenuto 
conto anche delle questioni legali, sociali, etiche e organizzative attinenti. Ad esempio, la rimunera-
zione della canapa medicinale sarà soggetta a diverse leggi svizzere, interconnesse tra loro, in ma-
teria di coltivazione, consumo, consegna e prescrizione. Inoltre, la rimunerazione della canapa me-
dicinale potrebbe avere implicazioni sociali ed etiche, per esempio come risultato di un divario tra le 
aspettative dei pazienti e le evidenze scientifiche. Altre preoccupazioni potrebbero riguardare le re-
strizioni di accessibilità, i gruppi vulnerabili a rischio di conseguenze indesiderate e l’uso illecito. Inol-
tre, potrebbero sorgere difficoltà di natura organizzativa nella fornitura e nel controllo della qualità dei 
prodotti a base di canapa medicinale. 
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Objective of the HTA report 
The objective of a health technology assessment (HTA) is to generate a focused assessment of various 
aspects of a health technology. The analytic methods applied to assess the value of using a health 
technology are described. The analytical process is comparative, systematic, transparent, and involves 
multiple stakeholders. The domains covered in an HTA report include 1) efficacy, effectiveness, and 
safety, 2) cost-effectiveness and budget impact, and 3) legal, social, ethical, and organisational issues. 
The purpose is to inform health policy and decision-making to promote an efficient, sustainable, equita-
ble, and high-quality health system.  
The process involved three phases: 1) pre-scoping phase, 2) scoping phase, and 3) HTA phase. This 
document represents the outcome of the HTA phase. 
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1 Policy question and context 
Medical cannabis is available in Switzerland for patients upon narcotic individual prescription (NIP). The 
physicians obtain for each specific patient a timely limited exceptional license (TLEL) from the Federal 
Office of Public Health (FOPH) for preparations that contain more than 1% (-)-trans-delta-9-Tetrahydro-
cannabinol (THC). Currently, patients need to pay for medical cannabis themselves or they may get 
exceptional reimbursement in special cases. General reimbursement by the compulsory health insur-
ance for medical cannabis does not currently exist. 
In response to the political calls for better access, possible reimbursement of medical cannabis, and the 
increasing number of TLEL, the FOPH investigates the evidence for efficacy, effectiveness, safety, and 
cost-effectiveness of medical cannabis for the treatment of the most common symptoms where medical 
cannabis may be indicated. 
2 Research question 
What is the efficacya, effectivenessb, and safetyc, as well as the cost-effectiveness and budget impact 
of medical cannabis compared to placebo, no treatment, or standard of care, in patients of all ages with 
one of the four pre-specified symptoms chronic pain, spasticity, unintentional weight loss, or nausea and 
vomiting related to cancer treatment?  
 
                                                     
 
 
a Efficacy is the extent to which a specific health technology produces a beneficial, reproducible result under study conditions 
compared with alternative technologies (i.e. internal validity). 
b Effectiveness is the extent to which a specific health technology, when applied in real world circumstances in the target group, 
does what it is intended to do for a diagnostic or therapeutic purpose regarding the benefits compared with alternative technologies 
(i.e. external validity). 
c Safety is a judgement of the harmful effects and their severity using the health technology. Relevant adverse events are those 
that result in death, are life-threatening, require inpatient hospitalisation or cause prolongation of existing hospitalisation (i.e. 
serious adverse events) and those that occur repetitively and the most frequent (highest rate). 
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3 Summary of the scoping phase findings 
A first appreciation of the available evidence on medical cannabis at the start of the project revealed a 
wide variety of symptoms on which medical cannabis can potentially have a positive effect. For a de-
tailed investigation into the efficacy, effectiveness, and safety, as well as the cost-effectiveness and 
budget impact of medical cannabis, the focus of the HTA had to be narrowed down to a pre-specified 
selection of symptoms. A preliminary literature search for systematic reviews (search period 2014 to 
November 13, 2019) was conducted to help decide on the selection of symptoms to be included in the 
HTA report. The methods and results of this preliminary literature search are described in the scoping 
reportd. The final selection of symptoms was based on the availability of literature and HTA appraisal 
documents from various countries on the use of medical cannabis for treating the symptom, as well as 
information on the main symptoms for which medical cannabis has been previously prescribed in Swit-
zerland. In dialogue with the FOPH it was decided to focus the scoping phase on the symptoms chronic 
pain, spasticity, unintentional weight loss, and nausea and vomiting related to cancer treatment. Other 
symptoms which may be treated with medical cannabis may be considered to be the subject of a future 
HTA. Details on the systematic literature search and preliminary data extraction for these four symptoms 
are reported in the scoping reportd.   
Based on the preliminary data extraction of the selected RCTs in the scoping phase, the conclusion was 
drawn that the evidence base for the symptoms chronic pain and spasticity was sufficient and could be 
further extracted and implemented in robust cost-effectiveness models. For the symptoms unintentional 
weight loss and nausea and vomiting related to cancer treatment the evidence from the RCTs found 
during the scoping phase was scarce. After extensive discussion with the FOPH, it was concluded that 
the evidence was insufficient to make pertinent recommendations for the use of medical cannabis in 
unintentional weight loss and nausea and vomiting related to cancer treatment and it was therefore not 
feasible to continue with complete data extraction for these two symptoms. The following reasons led to 
this conclusion: 
Unintentional weight loss 
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 With a broad systematic literature search and broad selection criteria, only five RCTs describing 
the efficacy of medical cannabis use for unintentional weight loss were found. This number of 
RCTs is limited and the methodological quality was low (e.g. in two studies the sample size was 
very small (N<25) and in another study the treatment duration was not reported). When the 
more strict exclusion criteria for a minimal treatment duration and sample size would be applied 
to these RCTs (see section 'Selection procedure' in 8.1.1), most RCTs would have been ex-
cluded in the HTA phase.  
 The preliminary data extraction showed large heterogeneity, for example a variety of outcomes 
were reported to determine the amount of weight loss, and only few outcomes were comparable 
and a quantitative comparison of study results would not be feasible. Therefore, it would not be 
possible to draw a generally representative conclusion on the efficacy and safety of medical 
cannabis in unintentional weight loss.   
Nausea and vomiting related to cancer treatment 
 The RCTs found with a broad systematic literature search and broad selection criteria in the 
scoping phase for nausea and vomiting related to cancer treatment were outdated (i.e. 19 of 
the 22 RCTs were published before 1990) and the most recent RCT was published 13 years 
ago. When the more strict exclusion criteria for sample size would be applied to these RCTs 
(see section 'Selection procedure' in 8.1.1), part of these RCTs would have been excluded in 
the HTA phase. In general, reporting of older studies is of less quality compared to recent stud-
ies. The description of the study characteristics and applied statistical analyses are often limited 
in older publications. Recent RCTs are required, because of new developments in the field of 
cancer treatment and anti-emetic therapies. Despite the progress achieved in the last 30 years, 
nausea and vomiting continue to be two of the most distressing side-effects of cancer chemo-
therapy.1 It is therefore remarkable that no recent RCTs were found with our systematic litera-
ture search in the scoping phase on medical cannabis use for nausea and vomiting related to 
cancer treatment.  
 Generally, anti-emetic therapy should be customised to the type of chemotherapeutic agents 
administered to a patient.1 In current guidelines the first choice for anti-emetic therapy is a 5-
HT3 antagonist in combination with dexamethasone; with an addition of NK-1 receptor antago-
nist and/or olanzapine in highly emetic cancer treatments.1 Many different types of anti-emetic 
therapy as comparator treatment to medical cannabis were used in the RCTs found with the 
systematic literature search in the scoping phase, though no RCTs compared these new anti-
emetic regimens with medical cannabis. As a consequence, the comparator treatment in these 
RCTs may be inadequate and the applicability of the evidence might be limited. In 2015, the 
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evidence on cannabinoids for nausea and vomiting in adults with cancer receiving chemother-
apy was summarised in a Cochrane review.31 The authors concluded that medical cannabis 
may be useful for treating refractory chemotherapy-induced nausea and vomiting. However, 
they emphasised the methodological limitations with respect to the study design of the RCTs, 
lacking reflection of current chemotherapy and anti-emetic treatment regimens, and the low 
quality of evidence when combined with meta-analyses. 
 The preliminary data extraction showed large heterogeneity, for example a variety of outcomes 
were reported to determine the frequency or severity of nausea or vomiting. Moreover, only few 
outcomes were comparable and a quantitative comparison of study results would not be feasi-
ble. Therefore, it would not be possible to draw a generally representative conclusion on the 
efficacy and safety of medical cannabis in nausea and vomiting related to cancer treatment.  
Overall, more and higher quality RCTs are needed to give insight in the efficacy of medical cannabis 
use for the symptoms unintentional weight loss and nausea and vomiting related to cancer treatment. 
Future RTCs should at least be designed according to current high standards for RCTs, have sufficient 
power to detect differences between study arms, avoid unnecessary heterogeneity in outcomes and 
outcome measures, and be more complete in the reporting of their data (i.e. baseline data, follow-up 
data, treatment differences, measures of spread, and p-values) to allow for future meta-analyses. Only 
when these kind of RCTs will become available complete data extraction and the development of cost-
effectiveness models could be re-considered. As it was decided not to continue with data extraction for 
the symptoms unintentional weight loss and nausea and vomiting related to cancer treatment, the re-
maining of the HTA report will focus on the symptoms chronic pain and spasticity only.  
4 Medical background 
4.1 Background on chronic pain 
Chronic pain is defined as persistent or recurrent pain lasting longer than 3 months.2 Chronic pain is a 
highly prevalent condition, affecting about 20% of the people worldwide and is associated with a signif-
icant personal, social, medical, and economic burden.3 The distribution of type and pattern of chronic 
pain symptoms varies between people and can be a result of various underlying causes, such as cancer, 
spinal cord injury (SCI), diabetes, multiple sclerosis (MS), human immuno-deficiency virus (HIV), and 
postoperative or traumatic peripheral nerve lesions.2,3 The treatment of chronic pain is multimodal, but 
mostly contains a pharmacological agent.2 Existing medications for the treatment of chronic pain, such 
as opioids, have limited efficacy and come with considerable side-effects. In addition, the increase in 
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the prescription rate of opioids is associated with an increase in opioid use disorders and opioid-related 
mortality.4,5 Since chronic pain is difficult to treat, other treatment options such as medical cannabis or 
other pharmacotherapies, are explored with different mechanisms of action for treatment or the various 
conditions underlying the pain.3,4 This HTA will explore the available evidence on the efficacy of medical 
cannabis on all types of chronic pain, not limited to a specific underlying disease. 
4.2 Background on spasticity 
Spasticity is often inconsistently defined in scientific studies and also the applied outcome measures do 
not always correspond to the reported spasticity definition.6 The most commonly used definition of spas-
ticity was formulated by Lance in 1980 as a motor disorder characterised by a velocity-dependent in-
crease in muscle tone with exaggerated tendon jerks, resulting from hyper-excitability of the stretch 
reflex as one component of the upper motor neurone syndrome.7 This definition changed during the 
years by adding other features of spasticity such as spasm and clonus.7 Spasticity results from a lesion 
of the descending motor pathways due to pathologies such as stroke, SCI, or MS, and is a common and 
distressing symptom in these diseases.8 MS is a progressive disease and eventually up to 90% of peo-
ple with MS will suffer from the symptom muscle spasticity.9 Also in SCI the epidemiology of spasticity 
affirms the significance of this medical problem.10 Spasticity may be mild as the feeling of tightness of 
muscles or more severe and be associated with spasms, sleep disturbance, and pain, which contributes 
to reduced mobility and increases the burden of disease for both the patients and their caregivers.11–13 
Furthermore, these symptoms may cause severe complications such as fibrous contractures and pres-
sure sores, and eventually disability resulting from spasticity can lead to patients requiring extensive 
healthcare.11  
Medicinal treatment is prescribed to reduce spasticity, but may be insufficiently effective, difficult to ob-
tain, or associated with intolerable side-effects.8 As a consequence, people with MS or SCI have exper-
imented with alternative therapies, including cannabis, to ease their physical problems.9,10 Medical can-
nabis is suggested as an effective and tolerable alternative treatment for patients with residual spasticity 
not adequately controlled using existing treatments.8  
5 Technology 
5.1 Technology description 
The use of cannabis or cannabis-based products for medical purposes has a long history and its appli-
cations have been influenced by multiple factors, such as the development of standardised drugs to 
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treat specific symptoms and the inclusion of cannabis in laws regarding narcotics.14,15 After discovery of 
the human endocannabinoid system in the early 1990s, developments in the legalisation of medical 
cannabis, and an increasing number of clinical trials, there has been a resurgence of interest in medical 
cannabis use for a variety of symptoms and diseases.14,15 Nowadays, most European Union (EU) coun-
tries allow or are considering allowing the medical use of cannabis. However, the approaches vary 
widely in the products allowed, as well as the regulatory frameworks governing their provision.14  
5.2 Mechanism of action  
Medical cannabis includes all cannabis-based products which are used for medical treatment. Medical 
cannabis can be taken in herbal form (e.g. dried cannabis flowers, cannabis resin (hashish)), extracted 
naturally from the plant (e.g. sativa oil), or manufactured synthetically (e.g. dronabinol). Cannabinoids 
are the main active ingredients in both the medicinal products derived from cannabis and cannabis 
preparations. The cannabis plant can produce over 100 cannabinoids.16 The so far most studied can-
nabinoids, and thought to be the most important in terms of clinical effects, are THC and cannabidiol 
(CBD).14,15 Medical cannabis products are therefore often referred to by their composition of THC and 
CBD, or by the ratio of these components. While the exact mechanism, interaction, and magnitude of 
effects of THC and CBD are not yet fully understood, they are both known for binding to Cannabinoid 
receptor type 1 (CB1) and Cannabinoid receptor type 2 (CB2) in the body. The endocannabinoid system 
is composed of these cannabinoid receptors, their endogenous ligands (endocannabinoids), and endo-
cannabinoid-degrading enzymes as part of the central and peripheral nervous system that perform a 
large role in maintaining homeostasis in many physiological functions.17 The effects of cannabinoids are 
primarily mediated by CB1 and CB2 receptors. CB1 receptors are predominantly located in the central 
nervous system, mainly in the cortex, basal ganglia, hippocampus, and cerebellum.17,18 The distribution 
of these receptors within the central nervous system correlates to their roles in the control of physical 
functions, such as motor function, analgesia, cognition, and memory.17,18 CB2 receptors play a role in 
immune cell activation and inflammation and are mainly expressed in peripheral immune-related organs 
.17,18  
Since CB1 and CB2 receptors are widespread in the human body and their ligands trigger a variety of 
physiological actions, medical cannabis can potentially have an effect on a variety of symptoms and 
underlying diseases. Short-term effects of THC include amongst others muscle relaxation, increased 
heart rate, reduction in intra-ocular pressure, increase in appetite, and it has antiemetic and analgesic 
properties.14,15,19 THC is also the main psychoactive component of cannabis, producing the psychoactive 
effects sought by recreational users, such as euphoria, relaxation, and heightened sensory experi-
ences.15 CBD is a non-psychoactive constituent of cannabis, and may reduce the psychoactive and 
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appetite stimulating effects caused by THC. CBD contains therapeutic (sedative and anticonvulsant) 
properties, and potential effects include seizure reduction, decreased anxiety, and improved mental 
health outcomes in schizophrenia.20,21 Synthetic cannabinoids for therapeutic use typically mimic the 
effects of natural cannabinoids, such as THC and CBD. THC and CBD may have pharmacokinetic or 
pharmacodynamic interactions that influence their effects on physiological functions. This so-called en-
tourage effect is a topic of ongoing research.  
5.3 Mode of administration 
Medical cannabis products come with several different modes of administration, including oral, sublin-
gual, topical, smoked, inhaled, mixed into food, or infused as tea. The mode of administration of canna-
bis can affect the onset, intensity, and duration of the therapeutic effects, the addictive potential, and 
negative consequences associated with its use.22 As the harms associated with smoking are well known, 
and safer and more precise methods of administration are available, countries in the European Union 
(EU) do not recommend or reimburse smoking as a mode of consumption for medical cannabis prepa-
rations.14 The appropriate dose of medical cannabis is generally found with the “start low, go slow” 
approach (start with a low dose and wait to see the effects before increasing the dose) and varies with 
the treated symptoms. Duration of the treatment depends on the symptoms to be treated, its effective-
ness, experienced side-effects by the patient, and costs.23  
5.4 Safety 
The rising interest in the medical use of cannabis also raises safety concerns. An example of a system-
atic review (SR) of safety studies of medical cannabis reporting a wide range of non-serious adverse 
events found that the rate of non-serious adverse events was 1.86 times higher among people using 
medical cannabis for short-term versus controls.24 Dizziness was the most commonly reported non-
serious adverse event among medical cannabis users. There was no evidence of a higher incidence of 
serious adverse events (SAEs) following medical cannabis use compared with control. The most com-
mon SAEs were relapse of MS, vomiting, and urinary tract infection. The difference in mortality between 
the medical cannabis and the control groups was not statistically significant. The authors highlight that 
the risks associated with long-term medical cannabis use were poorly characterised in published RCTs 
and observational studies.  
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5.5 Types of medical cannabis products 
Within medical cannabis, the distinction can be made between products that have a marketing authori-
sation for medical use and those that do not. Several (plant-derived and synthetic) cannabinoid-contain-
ing products have been authorised for marketing in EU countries. Having a marketing authorisation 
generally implies that the drug has been studied extensively in clinical trials and that the drug has been 
tested for safety, efficacy, and side-effects.25,26 Table 1 contains the details of the most commonly re-
ferred to licensed medical products (LMPs).14,15  
Table 1. Medical cannabis products with marketing authorisation in at least one EU country 









quantities of THC and 
CBD from two cannabis 
plant varieties 






similar to THC  








Synthetic THC (1) Anorexia associated with weight loss in pa-
tients with acquired immune deficiency syn-
drome (AIDS) and (2) Nausea and vomiting as-
sociated with cancer chemotherapy 
Epidiolex® CBD Oral solu-
tion (oil) 
Plant-derived CBD Epileptic seizures associated with Lennox-Gas-
taut syndrome or Dravet syndrome in patients 
aged ≥ 2 years 
Keys: AIDS = acquired immune deficiency syndrome, CBD = cannabidiol, MS = multiple sclerosis, THC = tetrahydrocannabinol 
Apart from these LMPs, the raw cannabis may be transformed by a pharmacist into a magistral prepa-
ration for consumption in accordance with a specified medical prescription for an individual patient, or 
the raw cannabis may already have been transformed by the manufacturer in larger batches (standard-
ised preparation). Such products, which do not have a marketing authorisation for medical use may 
include the raw cannabis, such as the flowers, compressed resin or hash; oils extracted from the plant; 
concentrated cannabis extracts; and other cannabis preparations, such as soft gels, tinctures, or edi-
bles. A variety of pharmacy-prepared, magistral preparations of medical cannabis is available in Swit-
zerland, as shown in Table 2.27  
Table 2. Description of Swiss Extemporaneous Preparations and Sativex® 
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2.5mg THC ised canna-
bis tincture  
ised canna-








2.7mg THC  
THC content 
(mg/ml)  
10  25  10  10  27  10  27  
THC:CBD 1:0.3  1:1  1:2  1:2  1:1  1:2.2  1:0.9  






Oily solution  Oily solution  
Costs per mg 
THC (CHF)  
1.46  1.60-1.80  1.10  1.60  0.89  1.60  1.57  
Keys: CHF = Swiss Franc, CBD = cannabidiol, THC = tetrahydrocannabinol, mg = milligram  
5.6 Alternative technologies  
Medical cannabis is predominantly used as add-on therapy or after other therapeutic options were un-
successful. Hence, alternative treatments are standards of care for the pertaining symptoms. 
5.7 Regulatory status / provider 
Regulation in Switzerland 
The cultivation, the trade, and the consumption of cannabis with a THC content of more than 1% is 
forbidden in Switzerland, although the possession of a small amount (10 grams of cannabis) for own 
consumption is only mildly punished.28,29 CBD is not considered a psychoactive compound. Hence, its 
consumption and use are not restricted by the Federal Act on Narcotics and Psychotropic Substances. 
Since 2011 the access to cannabis for medical use was allowed with an obtained TLEL from the FOPH. 
To obtain medical cannabis in Switzerland, the following criteria should be met: 
 a patient must suffer from a non-curable disease 
 their suffering is expected to diminish with the use of medical cannabis 
 all therapeutic alternatives have not shown any improvement 
 due to the use of medical cannabis the patient maintains or gains an independent life style.30  
Between 2012 and 2019 approximately 15’000 patients received access to medical cannabis via TLEL, 
with around 3’000 authorisations being granted in 2019 alone.31,32 These figures exclude patients who 
obtain cannabis from the black market (i.e. illicit users). The number of patients who use medical can-
nabis in Switzerland is therefore estimated to be higher, ranging from from 66’000 to 110’000.33,34 Sa-
tivex® is currently the only LMP containing medical cannabis in Switzerland. It is indicated to improve 
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symptoms in patients with moderate to severe spasticity due to MS who have not responded adequately 
to other anti-spastic drug therapy and who show a clinically significant improvement in spasticity-related 
symptoms during an initial trial therapy. Medical cannabis is generally not reimbursed by the Swiss 
compulsory health insurance, but individual patients may get reimbursement on a case-to-case basis.  
 
Regulation in Other Countries 
Regulation and reimbursement policies of medical cannabis differ substantially between countries. To 
date, the number of countries who fully or partially authorise the use of medical cannabis is growing. For 
illustration, the regulation in some European countries has been described below.  
Germany 
In Germany the use of medical cannabis is legalised since March 2017. Besides the prescription, no 
special permit is required to obtain medical cannabis.35 Reimbursement of medical cannabis is not re-
stricted to a specific indication. Medical cannabis is reimbursed (a) if no therapeutic alternative is avail-
able or (b) if therapeutic alternatives are not effective.36 The Deutscher Bundestag revealed the six most-
reported diagnoses for which medical cannabis has been prescribed and covered by statutory health 
insurers from 2018 to September 2019: pain (70.9%), spasticity (10.8%), anorexia (6.9%), epilepsy 
(1.6%), Attention Deficit Hyperactivity Disorder (ADHD) (1.5%), and Tourette Syndrome (1.0%).37 
Denmark 
Since January 2018, medical doctors can prescribe medical cannabis in Denmark as part of a 4-year 
trial period. The pilot programme aims to offer patients a legal access to medical cannabis if they have 
not benefitted from authorised medicines. An assessment after the trial period intends to provide better 
basis for the use of medical cannabis. People in Denmark are reimbursed at the rate of 50% for cannabis 
products in the pilot programme, people who have been granted reimbursement for the terminally ill 
receiving 100% reimbursement.38 The use of medical cannabis in Denmark is restricted to certain indi-
cations, namely painful spasms caused by MS or SCI, nausea after chemotherapy, or neuropathic pain.  
France 
The French Senate recently authorised an experiment that allows doctors to prescribe medical cannabis 
for the following indications: treatment-resistant epilepsy, neuropathic pain that does not respond to 
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other treatment, involuntary muscle spasms and/or other nervous system conditions, side-effects of 
chemotherapy, or palliative care.39  
Belgium 
In 2015, Belgium legalised the use of approved medical cannabis products. Currently, only Sativex® 
can be prescribed and reimbursed to patients with moderate to severe spasticity in MS patients resistant 
to existing therapies. A draft resolution was submitted in September 2019, which calls for approval of 
and research into the use of medical cannabis in indications beyond MS, namely in amyotrophic lateral 
sclerosis and epilepsy.40  
The Netherlands 
In the Netherlands patients are allowed to use cannabis for medical use. Since 2001 the government 
agency Office of Medical Cannabis (OMC) is responsible for overseeing the production of cannabis for 
medical and scientific purposes. The OMC has a monopoly position on supplying medical cannabis to 
pharmacies, and on its import and export. Medical cannabis provided by the OMC is of pharmaceutical 
quality and complies with strict requirements.41 Pharmacies can supply medical cannabis on doctor’s 
prescription only. While it is up to medical doctors to determine which conditions would benefit from 
treatment with medical cannabis, the OMC states that current data shows that medical cannabis can 
help relieve pain and muscle spasms associated with MS or SCI; nausea, reduced appetite, weight loss, 
and debilitation associated with cancer and AIDS; nausea and vomiting caused by medication or radio-
therapy for cancer and HIV/AIDS; long-term neuropathic pain, phantom limb pain, facial neuralgia, or 
chronic pain following an attack of shingles; and tics associated with Tourette Syndrome.42 Medical 
cannabis is not generally reimbursed in the Netherlands, but health insurers may decide to cover (part 
of) the costs for individual cases.  
6 PICO 
The PICO framework was used to further specify the research question and facilitate the systematic 
literature search; PICO is an acronym for Population, Intervention, Comparator, and Outcome.42 
Table 3. PICO (population - intervention - comparator - outcome) box 
P:  1. Patients (all ages) with the symptom chronic pain with any underlying 
cause 
2. Patients (all ages) with the symptom treatment-resistant residual spas-
ticity with any underlying cause 
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I: Medical cannabis, prescribed as standalone treatment or add-on treatment 
C:  Placebo 
 No treatment for the symptom of interest  
 Standard of care according to the treatment guidelines (i.e. conventional 
drugs for the chronic pain condition, spasticity) 
O (clinical): 1. Efficacy/effectiveness of medical cannabis; chronic pain 
a. Clinically relevant patient-reported pain relief 
b. Withdrawal due to lack of pain relief efficacy of medical cannabis 
c. Improvement in health-related quality of life (HRQoL) 
2. Efficacy/effectiveness of medical cannabis; spasticity 
a. Clinically relevant improvement in a specific spasticity aspect  
b. Withdrawal due to lack of anti-spasticity efficacy of medical cannabis 
c. Improvement in HRQoL 
3. Safety of medical cannabis: 
a. Occurrence of cannabis-associated serious adverse event 




1. Resource use due to serious adverse events 
2. Health-care costs (total and incremental) from a healthcare perspective  
3. Quality adjusted cost comparison after 6 months, 2 years, 5 years, (…), 
lifetime  
4. ICERs, incremental/total costs, QALYs and life years gained, after 6 
months, 2 years, 5 years, (…), lifetime  
Keys: HRQoL = health-related quality of life, ICERs = incremental cost-effectiveness ratios, QALYs = quality-adjusted-life-years 
7 HTA key questions 
For the evaluation of medical cannabis the following key questions covering the central HTA domains, 
as designated by the European Network for Health Technology Assessment (EUnetHTA) Core Model40 
(efficacy, effectiveness, safety, cost-effectiveness, budget impact, legal, social, ethical, and organisa-
tional aspects), are addressed for the symptoms chronic pain and spasticity. 
Key questions - efficacy, effectiveness, and safety 
For the evaluation of the technology the following key questions covering the efficacy, effectiveness, 
and safety were addressed (definitions provided by the FOPH): 
1. What is the efficacy of medical cannabis (prescribed as standalone treatment or add-on treat-
ment) compared to placebo, no treatment, or standard of care (depending on the symptom), in 
patients of all ages with chronic pain or spasticity with any underlying cause? 
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2. What is the effectiveness of medical cannabis (prescribed as standalone treatment or add-on 
treatment) compared to placebo, no treatment, or standard of care (depending on the symptom), 
in patients of all ages with chronic pain or spasticity with any underlying cause? 
3. What is the safety of medical cannabis (prescribed as standalone treatment or add-on treat-
ment) compared to placebo, no treatment, or standard of care (depending on the symptom), in 
patients of all ages with chronic pain or spasticity with any underlying cause? 
 
Key questions - costs, budget impact, and cost-effectiveness 
For the evaluation of the technology the following key questions covering the cost-effectiveness were 
addressed: 
1. What is the healthcare resource use of patients of all ages with chronic pain or spasticity with 
any underlying cause with and without medical cannabis (resource-use identification)? 
2. What are the Swiss unit costs of the resources identified in question 1? 
3. What are the utilities associated with the use of medical cannabis (including administration), 
serious adverse events, and chronic pain or spasticity? 
4. What are the estimated differences in costs and outcomes of medical cannabis use compared 
to no treatment, or standard of care (depending on the symptom), in patients of all ages with 
chronic pain or spasticity with any underlying cause? 
5. What is the likely budget impact of the reimbursement of medical cannabis in patients of all ages 
with chronic pain or spasticity with any underlying cause? 
6. What are the uncertainties surrounding the costs and outcomes of medical cannabis compared 
to no medical cannabis in patients of all ages with chronic pain or spasticity with any underlying 
cause? 
Key questions - legal, social, ethical, and organisational issues 
For the evaluation of the technology the following key questions covering the legal, social, ethical, and 
organisational issues were addressed: 
1. Are there specific legal issues associated with potential reimbursement of medical cannabis for 
patients of all ages with chronic pain or spasticity with any underlying cause?  
2. What are the socially and ethically relevant consequences of potential reimbursement of medi-
cal cannabis for patients of all ages with chronic pain or spasticity with any underlying cause?  
3. What organisational issues are attached to the use of medical cannabis in patients of all ages 
with chronic pain or spasticity with any underlying cause? 
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7.1 Additional question(s) 
No additional questions have been formulated.  
 
8 Efficacy, effectiveness, and safety 
A systematic review (SR) is a method to collect, critically appraise, and summarise the best available 
evidence in a transparent and systematic way using generally accepted evidence-based principles. The 
SR was designed to search for up-to-date and high-quality evidence, according to current standards 
and clinical practice. The applied methodology follows international standards, such as the Cochrane 
Collaboration guidelines for performing SRs, and the reporting of the SR follows the recommendations 
of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).41,42  
The SR process consists of the following fundamental steps:  
1. Formulation of the research questions 
2. Comprehensive information search, including defining data sources and search strategy 
3. Selection procedure, applying pre-determined inclusion and exclusion criteria  
4. Critical appraisal (quality and risk of bias assessment) 
5. Data extraction 
6. Data synthesis 
7. Quality control 
In addition, a stepwise approach could be implemented within the SR: 
I. Search for original RCTs 
II. Based on the data extraction of the selected RCTs it was discussed with the FOPH whether a 
systematic literature search would be conducted for comparative non-randomised studies. It 
was decided during the project not to proceed with this step. 
The following sections describe the SR methodology of the efficacy, effectiveness, and safety of medical 
cannabis as applied to this HTA. 
8.1 Methodology efficacy, effectiveness, and safety 
8.1.1 Databases and search strategy 
Search strategy 
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PubMed (MEDLINE) and Embase.com databases were searched for RCTs on medical cannabis use 
for chronic pain and spasticity published in the peer-reviewed scientific literature. Since there is consid-
erable overlap in studies included in other literature databases (such as Cochrane Library), the decision 
was made to search in these two main databases. The searches were built using the PICO-framework 
(see Chapter 6). Given the various outcomes of interest, it was decided to keep the search broad. Only 
search strings on ‘population’ and ‘intervention’ were applied in combination with a search string for the 
study design RCTs. The applied search filters were time period (i.e. 1980 - 22th January 2020) and the 
language of publications (i.e. English, French, German, and Dutch). Since a large amount of medical 
cannabis studies was published in the eighties and nineties, a time horizon of forty years was chosen. 
Furthermore, animal studies and SRs were excluded with additional search strings. Two separate 
search strategies were developed for RCTs on medical cannabis use for chronic pain and spasticity 
(Appendix 15.1). The literature database output, including all indexed fields per record (e.g. title, authors, 
and abstract), was exported to Endnote version X7.8. Duplicates in Endnote were automatically re-
moved and manually deleted. 
Selection procedure 
From the articles retrieved from PubMed (MEDLINE) and Embase.com the relevant references were 
selected by a three-step selection procedure, based on:  
1. Screening of title and abstract: this step yielded the articles that were assessed in full-text. The 
major topics of the articles were assessed on relevancy for the objectives by the title and ab-
stract. In this step, articles that seemed to contain relevant data for the objectives were selected 
for full-text screening, while articles that did not seem to contain relevant data were not selected 
for full-text assessment. In case of doubt, the study was assessed in full-text. 
2. Screening of full article: the articles selected during the first phase were assessed in full-text. 
Articles were included if the reported information was relevant and of sufficient quality, based 
on the inclusion and exclusion criteria (see below).  
3. Screening during data extraction phase: further scrutiny of the article during the data extraction 
phase might lead to exclusion. To gain insight in the amount and quality of the available evi-
dence on medical cannabis no strict criteria were applied yet for the quality of RCTs during the 
scoping phase. To avoid the inclusion of RCTs of very low quality, during the HTA phase more 
strict exclusion criteria were applied for a minimal treatment duration of two weeks3 and for the 
sample size of RCTs: a. small sample size (n<50) without an a priori power calculation pre-
sented in the article; b. small sample size (n<25) with a priori power calculation presented in the 
article; and c. small sample size (n<50) while the presented a priori power calculation showed 
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that a higher number of patients was needed than actually included. In most of the additionally 
excluded RCTs due to these two exclusion criteria multiple quality issues were identified and 
sample size or treatment duration were considered as main reason for exclusion. 
The process of selection and inclusion and exclusion of articles was registered in Excel and an Endnote 
library. The overall exclusion criteria applied are reported in PRISMA flow charts (Section 8.2.2) and in 
tables with an overview of the reasons for exclusion per excluded RCT (Appendix 15.2). The imple-
mented quality control during the selection process is described in a next section. 
Inclusion and exclusion criteria 
The inclusion and exclusion criteria applied during the selection processes are presented in Table 4 . 




Period of publication 1980-January 2020 Publications before 1980 
Language of publication English, German, French, Dutch All other languages 
Country of study All countries - 
Study design/type  RCT 
 Open-label extension study of an RCT 
 Review 
 Phase I RCT (i.e. testing of drug on healthy 
volunteers) 
 (Irrelevant) post-hoc/subgroup analysis of an 
RCT included in the systematic literature 
search 
 Secondary analyses of an RCT excluded in 
the systematic literature search 
 Open-label extension study of an excluded 
RCT 
 Non-comparative extension trial 
 Experimental study (e.g. with pain stimuli) 
 Observational study 
 Case report 
 Study protocol 
 Abstract only 
 Non-pertinent publication type (e.g. expert 
opinion, letter, editorial, comment) 
Study quality Sufficient study quality and sample size  Insufficient methodological quality (both inher-
ent methodology as well as insufficient de-
scription of methodology provided, e.g. incor-
rect flow of patient numbers without an expla-
nation for loss to follow-up or studies without 
appropriate statistical testing) 
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 Small sample size (n<50) without a power cal-
culation presented in the article 
 Small sample size (n<25) with power calcula-
tion presented in the article 
 Small sample size (n<50) while the presented 
power calculation showed that a higher num-
ber of patients was needed than actually in-
cluded 
 Studies only presenting preliminary/interim re-
sults 
 No extractable data, e.g. Figures only 
Study population Patients (all ages) with chronic pain or spas-
ticity 
 No population of interest 
 No or lacking information on study population 
 Patients with acute pain 
 Patients in whom medical cannabis is not pri-
marily prescribed for the symptom chronic 
pain or spasticity 
 No or lacking definition of spasticity 
Study intervention  Medical cannabis, prescribed as 
standalone treatment or add-on treatment  
 Treatment duration of at least 2 weeks3 
 Non-prescribed/recreational cannabis  
 Short treatment duration (<2 weeks) 
 No washout periods between study interven-
tions in cross-over trial 
Study comparison  Placebo 
 No treatment for chronic pain or spasticity 
 Standard of care according to the treat-
ment guidelines (i.e. conventional drugs 
for the chronic pain condition or spasticity) 
 Comparisons with other treatments than 
standard of care 
 No comparison 
Study outcomes  See pre-specified outcomes in PICO table 
(Chapter 6)  
 The outcome measures must be in line 
with the reported definition for spasticity 
 No efficacy outcomes or no useful results for 
efficacy 
Keys: RCT= randomised-controlled trial, PICO = Patient Intervention Comparator Outcome  
Quality control 
The following quality control measures were applied during the selection process: 
 The first 30% of titles and abstracts from the peer-reviewed literature were screened in duplicate 
by two independent researchers. The results were compared and discussed before the remain-
ing references were assessed by one researcher. Both researchers categorised the titles as 
'include for full-text assessment', 'exclude for full-text assessment', or 'doubt'. If there were dif-
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ferences between the two researchers regarding more than 2% of the articles selected as 'in-
clude for full-text assessment', another 10% of the articles would have been screened in dupli-
cate. This would have been repeated if necessary. If there was still more than 2% discrepancy 
at 50% of the duplicate selection, the screening of title and abstracts would have been done 
fully in duplicate by two independent researchers. If the two reviewers disagreed on the rele-
vance of a study, this was discussed. If the differences remained after discussion, the study was 
assessed in full text. During screening of the first 30% of titles and abstracts there was less than 
2% discrepancy between the two researchers. 
 The first 10% of the full-text articles from the peer-reviewed literature were assessed for rele-
vancy and critically appraised in duplicate by two independent researchers. The results were 
compared and discussed early in the process. If there were differences between the two re-
searchers regarding more than 5% of the articles screened in duplicate, another 10% of the 
articles would have been screened in duplicate. This would have been repeated if necessary. If 
there was still more than 5% discrepancy at 50% of the duplicate selection, the screening of full-
text articles would have been done fully in duplicate by two independent researchers. During 
screening of the first 10% of the full-text articles there was less than 5% discrepancy between 
the two researchers. The remaining full-text selection was done by one researcher in close col-
laboration with a second reviewer; any doubts were discussed in detail. In case of discrepancy 
or disagreements during the selection phase, a third researcher was consulted. The study was 
discussed until consensus was reached. 
8.1.2 Other sources 
During the full-text screening phase, reference lists of the included studies in the scoping report were 
checked to find any other studies that were not captured with our literature search. For the efficacy, 
effectiveness, and safety systematic literature search no additional studies were included by this pro-
cess.  
8.1.3 Assessment of quality of evidence 
Based on the key risk of bias criteria used in the Grading of Recommendations, Assessment, Develop-
ment and Evaluations (GRADE) approach, the risk of bias of the study designs of the included RCTs 
was assessed.43 These key study limitations or risk of bias of RCTs include: 
 Lack of allocation concealment (i.e. those enrolling patients are aware of the study arm or period 
to which the next enrolled patient will be allocated, e.g. based on birth date or chart number) 
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 Lack of blinding (i.e. patient, caregivers, those recording outcomes, those adjudicating out-
comes, or data analysts are aware of the arm to which patients are allocated) 
 Incomplete accounting of patients and outcome events: 
- Loss to follow-up (i.e. the significance of particular rates of loss to follow-up varies 
widely and is dependent on the relation between loss to follow-up and number of events; 
the higher the proportion lost to follow-up in relation to intervention and control arm 
event rates, and differences between intervention and control arm, the greater the threat 
of bias) 
- Intention to treat (i.e. failure to adhere to the intention-to-treat principle) 
 Selective outcome reporting (i.e. incomplete or absent reporting of some outcomes and not 
others on the basis of the results) 
 Other limitations (e.g. use of unvalidated outcome measures; carryover effects in crossover trial) 
Each risk of bias criterion of the included RCTs was rated as low risk of bias, moderate or unclear (i.e. 
not reported in the article) risk of bias, or high risk of bias. Based on the crucial limitations for one or 
more of these criteria, the risk of bias of the study design within the whole study was rated in one of the 
three categories: low risk of bias, moderate risk of bias, or high risk of bias. For outcomes for which it 
was possible to calculate pooled estimates, a GRADE assessment for the level the quality or certainty 
of the evidence on outcome level was implemented. Within GRADE, the risk of bias of the study design 
is one of the features on which the certainty of the evidence is assessed (see below). The risk of bias 
was assessed by two independent researchers. In case of discrepancy a third researcher was consulted 
to reach consensus. 
The GRADE approach is a system for rating the certainty of a body of evidence in SRs, which for a 
specific outcome is rated across studies instead of a quality assessment of individual studies.41 The 
certainty of the evidence is assessed by looking at the following features of the evidence found for each 
outcome:  
 Study limitations (risk of bias) – the ‘internal validity’ of the evidence 
 Inconsistency – the heterogeneity or variability in the estimates of treatment effect across stud-
ies 
 Indirectness – the degree of differences between the population, intervention, comparator for 
the intervention, and outcome of interest across studies 
 Imprecision (random error) – the extent to which confidence in the effect estimate is adequate 
to support a particular decision 
 Publication/other bias – the degree of selective publication of studies 
The certainty of the evidence is classified as high, moderate, low, or very low:  
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 High – further research is very unlikely to change our confidence in the estimate of effect 
 Moderate – further research is likely to have an important impact on our confidence in the esti-
mate of effect and may change the estimate 
 Low – further research is very likely to have an important impact on our confidence in the esti-
mate of effect and is likely to change the estimate 
 Very low – any estimate of effect is very uncertain 
8.1.4 Methodology data analyses efficacy, effectiveness, and safety 
Different levels of heterogeneity in patient populations, outcomes, and outcome measures were ob-
served for the RCTs on medical cannabis use for chronic pain and spasticity. After the full data extraction 
it was explored which level of data merging/stratification was possible and for which outcomes it was 
possible to calculate pooled estimates and implement a GRADE assessment for the certainty of the 
evidence on outcome level (see Section 8.1.3).  
Data stratification 
The options for clinically relevant data merging/stratification were discussed with clinical experts, based 
on the patient groups reported in the included RCTs. The clinical experts were blinded for the study 
results. Giving the differences in mechanisms underlying pain, the data on medical cannabis use for 
chronic pain was stratified in four groups: 
 Cancer pain 
 Neuropathic pain 
 Musculoskeletal pain 
 Nociceptive pain 
The latter category, nociceptive pain, is reported here for a complete overview of the pain categories, 
however no RCTs were included for this specific chronic pain population. 
The symptom spasticity arises from injury of upper motor neurons along the descending motor path-
ways. This damage can be caused by different pathologies, such as MS, stroke, or spinal cord injury. 
Since these diseases have identical origins of spasticity, the mechanisms of action of medical cannabis 
on spasticity symptoms are comparable, and the patient populations with spasticity could be merged. 
However, the conditions of the included RCTs differed largely regarding disease progression and life 
expectancy, therefore it was decided to stratify the data on medical cannabis use for spasticity in two 
populations: 
 MS 
 Motor neuron disease (i.e. amyotrophic lateral sclerosis (ALS) or primary lateral sclerosis (PLS)) 
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Data synthesis 
Pooled estimates were calculated and a GRADE assessment for the certainty of the evidence on out-
come level was made, when 1) two or more studies within the above mentioned stratifications reported 
on the same outcome, and 2) sufficient data were reported in the studies (i.e. for efficacy data: mean 
change from baseline and standard deviation in the treatment arms; or number of patients with an out-
come and total number of patients in the treatment arms; plus treatment difference between the treat-
ment arms; for safety data: number of patients with an outcome and total number of patients in the 
treatment arms). This could be done for two outcomes: mortality and withdrawal of treatment due to 
adverse events. Pooling of data were done with the number of patients provided in the articles (i.e. for 
safety the data based on the number of randomised patients) and an unadjusted risk ratio (RR) was 
calculated. Considering the heterogeneity in the data, a random-effects model (DerSimonian & Laird) 
was used for the analyses. All analyses were conducted using the MetaXL (www.epigear.com) add-in 
for Microsoft Excel. The evidence on these outcomes was summarised in GRADE evidence profiles. 
For most efficacy and safety outcomes it was, however, not possible to calculate pooled estimates and 
implement a GRADE assessment: for the efficacy outcomes clinically relevant patient-reported pain 
relief, improvement in a specific spasticity aspect, withdrawal due to lack of efficacy of medical cannabis, 
and improvement in HRQoL; and for the safety outcome occurrence of cannabis-associated SAEs. 
These outcomes were presented in summary tables and descriptively summarised per outcome meas-
ure.  
8.2 Results efficacy, effectiveness, and safety 
8.2.1 Evidence base pertaining to efficacy, effectiveness, and safety 
The evaluation of the overall effectiveness of the technology encompasses its efficacy, effectiveness, 
and its safety.  
 Efficacy is the extent to which a specific health technology produces a beneficial, reproducible 
result under study conditions compared with alternative technologies (internal validity).  
 Effectiveness is the extent to which a specific health technology, when applied in real world 
circumstances in the target group, does what it is intended to do for a diagnostic or therapeutic 
purpose regarding the benefits compared with alternative technologies (external validity). 
 Safety is a judgement of the harmful effects and their severity using the health technology. Rel-
evant adverse events are those that result in death, are life-threatening, require inpatient hos-
pitalisation, or cause prolongation of existing hospitalisation (SAEs). 
 




































n = 114 
Embase.com 
 
n = 873 
Unique records  
after duplicates removal 
n = 871 
Records excluded based on 
title and abstract 
n = 813 
Selection of full-text RCTs 
n = 58 
Excluded RCTs: n = 50 
- No data on review objectives: n = 12 
- No RCT: n = 1 
- Secondary analyses of an RCT excluded in the 
systematic review: n = 1 
- Open-label extension study of an excluded RCT: n = 1 
- Non-comparative extension trial and no useful results for 
safety: n = 1 
- Data presented in a Figure, not possible to extract all 
exact data from the text: n = 1 
- No useful results for efficacy: n = 2 
- No efficacy data reported for the complete group of 
patients, only stratified for different doses: n = 1 
- Number of patients and number of dropouts in treatment 
armgroups not reported: n = 1 
- No population of interest (i.e. not aimed at chronic pain; 
or population out of scope, e.g. medication overuse 
headache): n = 6 
- Short treatment duration (<2 weeks): n = 6 
- Subjects were titrated up on medical cannabis over 4 
weeks, of which only the last week of treatment was at 1 
mg twice daily: n = 1 
- Cross-over trial without washout periods: n = 1 
- Case report: n = 1 
- Study protocol: n = 1 
- Non-pertinent publication type: n = 4 
- Small sample size (n<50) without power calculation: n = 5 
- Small sample size (n<25) with power calculation: n = 1 
- Small sample size (n<50) & no sufficient size as in power 
calculation: n = 3 
Total included RCTs 
n = 8 
  
 Original RCT: n = 8 
 
Figure 1. PRISMA flow chart of the efficacy, effectiveness, and safety systematic literature search on 
medical cannabis use for chronic pain symptoms 
8.2.2 PRISMA flow diagram 
Chronic pain 
In total, 871 unique records were identified in PubMed (MEDLINE) and Embase.com on the use of 
medical cannabis for the symptom chronic pain. Of those, 813 records were excluded based on their 
title and abstract, resulting in 58 RCTs selected to be screened in full-text. After applying the inclusion 
and exclusion criteria, eight original RCTs were finally included. The main reasons for exclusion were 
no data on review objectives (n=12 studies), different categories of a small sample size (n=9 studies, in 
total), no population of interest such as patients with non-chronic pain (n=6 studies), and a short treat-
ment duration with medical cannabis of less than 2 weeks (n=6 studies). A complete overview of the 
reasons for exclusion is given in the PRISMA flow chart (Figure 1). An overview of the reasons for 
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Spasticity 
In the literature databases PubMed (MEDLINE) and Embase.com 187 unique records were found on 
medical cannabis use for the symptom spasticity. In total, 159 records were excluded based on their 
title and abstract and 23 studies based on the full-text article. The reasons for exclusion after full-text 
screening of the articles are listed in the PRISMA flow chart (Figure 2). In total, five studies were in-
cluded: four original RCTs and one follow-up study of one of these original RCTs. An overview of the 



































n = 56 
Embase.com 
n = 182 
Records excluded based 
on title and abstract 
n = 159 
Selection of full-text RCTs 
n = 28 
Excluded RCTs: n = 23 
- No data on review objectives: n = 3 
- No useful results for efficacy: n = 1  
- High risk of selection bias and no useful 
results for efficacy: n = 2 
- (Irrelevant) post-hoc/subgroup analysis of  
an RCT included in the systematic literature 
search: n = 1 
- Open-label extension study of an excluded 
RCT: n = 1 
- Non-comparative extension trial and no 
useful results for safety: n = 1 
- No population of interest (i.e. not aimed at 
spasticity): n = 1 
- Short treatment duration (<2 weeks): n = 1 
- Non-pertinent publication type: n = 4 
- Small sample size (n<50) without power 
calculation: n = 5 
- Small sample size (n<25) with power 
calculation: n = 1 
- Small sample size (n<50) & no sufficient 
size as in power calculation: n = 2 
Total included RCTs 
n = 5 
 
 Original RCT: n = 4 
 Follow-up study of RCT: n = 1 
Unique records  
after duplicates removal 
n = 187 
Figure 2. PRISMA flow chart of the efficacy, effectiveness, and safety systematic literature search 
on medical cannabis use for spasticity symptoms 
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8.2.3 Study characteristics and risk of bias of the included studies 
Chronic pain 
Eight original RCTs on medical cannabis use in adults with chronic pain were included in this HTA. All 
studies were RCTs with a parallel design, providing data on efficacy and safety outcomes. Two RCTs 
were conducted in patients with cancer pain44,45; five RCTs in a population with neuropathic pain (i.e. 
three RCTs in MS patients46–48 and two RCTs in patients with allodynia49,50); and one RCT on medical 
cannabis use for musculoskeletal pain (i.e. rheumatoid arthritis51). THC:CBD spray (Sativex®) was the 
most frequently studied form of medical cannabis (in seven RCTs). A summary of the study character-
istics is included in Table 5 and the risk of bias of the study designs of the individual RCTs in Table 6. 
In all RCTs bias arises for the study limitation blinding and subjective outcome measures. Unpredictable 
bias and uncertainty in the evidence base arise in research on medication with a characteristic well-
known adverse event profile of medical cannabis (e.g. dizzy/light-headedness, fatigue, ‘feeling high’), 
possibly leading to unblinding of patients to their treatment allocation. The patient-reported outcomes 
for chronic pain further increase this unpredictability and uncertainty, however, no fully objective meas-
ure is available for pain. 
Cancer pain 
Two multicentre RCTs were included on medical cannabis use in cancer patients, these studies were 
conducted in a mix of different countries (see Table 5). Fallon et al. described two RCTs, only the first 
study fulfilled our selection criteria. In Study I, patients were randomised to THC:CBD spray (n=200) or 
placebo (n=199), and then self-titrated study medication over a 2-week period, followed by a 3-week 
treatment period.44 In the RCT of Lichtman et al., patients with advanced cancer and chronic pain were 
studied during 3 weeks of treatment with THC:CBD spray (n=199) or placebo (n=198).45 The study 
designs of both RCTs had a moderate risk of bias (see Table 6).  
Neuropathic pain 
Three RCTs on chronic pain were included for the diagnosis MS in adults. The RCT of Langford et al.46 
was conducted in multiple countries (i.e. Canada, Czech Republic, France, Spain, and the UK) and the 
other RCTs47,48 in a single European country (i.e. the UK and Germany). The total sample size ranged 
from 65 to 339 patients. THC:CBD spray (100 ųl containing 2.7 mg THC and 2.5 mg CBD) was studied 
in two RCTs and the third RCT investigated dronabinol (THC). In all RCTs medical cannabis was com-
pared to a placebo. The treatment duration ranged from 4 to 16 weeks. The study designs of these 
RCTs had a moderate risk of bias (see Table 6).  
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Allodynia is a condition where pain is caused by a stimulus that would not normally provoke pain. Nur-
mikko et al. conducted an RCT in Belgium and the UK and studied 63 patients in a THC:CBD spray arm 
and 62 patients in a placebo arm during a four-week treatment period.49 The study design of this RCT 
had a moderate risk of bias. During 14 weeks, Serpell et al. compared 123 patients using THC:CBD 
spray with 117 patients receiving a placebo spray in a multicenter RCT (i.e. in Belgium, Canada, Czech 
Republic, Romania, and the UK).50 The design of this RCT was assessed with a high risk of bias (see 
Table 6).  
Musculoskeletal pain 
One RCT, conducted in the UK, was included on chronic pain in rheumatoid arthritis. Treatment with 
THC:CBD spray (n=31) was compared to placebo (n=27) over the course of 5 weeks of treatment, 
including a titration phase of 2 weeks.51 The risk of bias of the study design of this RCT was high (see 
Table 6).  










Comparator Sample size 
intention to 






, Bulgaria , Czech 
Republic, Estonia, 
Germany, Hun-
gary, India, Israel, 








Adult patients with 
advanced cancer suf-
fering from cancer-re-
lated pain, various 
types of cancer 
 
Age (mean ± SD in y) 
Study I: MC: 60.0 ± 
11.0; P: 59.6 ± 11.0 
 
Sex (% female) 





alleviated by an 
optimised 
maintenance 
dose of Step 3 
opioid therapy 
THC:CBD spray 
100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; 
self-titration to 
optimal dose; 





Study I, total: 
399 / 399 
THC:CBD 
spray:  200 / 
200 
Placebo: 
199 / 199 
 
 
- Titration phase:  
study I 2 weeks 
- Study treatment:  
study I 3 weeks  
- Follow-up:  















Adult patients with 
advanced cancer, 
various types of can-
cer 
 
Age (mean ± SD in y) 
MC: 59.2 ± 12.0;  
P: 60.7 ± 11.1 
 
Sex (% female) 







dose of Step 3 
opioid therapy 
THC:CBD spray 
100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; 
self-titration to 
optimal dose; 





Total: 397 / 
397 
THC:CBD 
spray:  199 / 
199 
Placebo: 
198 / 198 
- Titration phase:  
2 weeks 
- Study treatment:  
3 weeks 
- Follow-up:  
at end of treatment 
period 
 










Comparator Sample size 
intention to 











Adult patients with 
MS 
 
Age (mean ± SD in y) 
48.97 ± 10.47 
 
Sex (% female) 
68% 
Central neuro-
pathic pain due 
to MS ≥3 
months 
THC:CBD spray 
100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; 
self-titration to 
optimal dose; 







Total: 339 / 
339 
THC:CBD 
spray:  167 / 
167 
Placebo:  
172 / 172 
- Titration phase:  
1 week 
- Study treatment:  
14 weeks 
- Follow-up:  











Adult patients with 
MS 
 
Age (mean ± SD in y) 
49.2 ± 8.3 
 
Sex (% female) 
78.8% 







100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; 
self-titration to 
optimal dose; 







Total: 65 / 66 
THC:CBD 
spray:   
33 / 34 
Placebo:  
32 / 32 
- Titration phase:  
1 week 
- Study treatment:  
4 weeks 
- Follow-up:  












Adult patients with 
MS 
 
Age (mean ± SD in y) 
47.7 ± 9.7 
 






mal pain area 
for ≥3 months 
Dronabinol  
THC; daily dose 




Total: 240 / 
240 
Dronabinol: 
124 / 124 
Placebo:  
116 / 116 
- Titration phase:  
first 4 weeks of 
treatment 
- Study treatment:  
16 weeks 
 - Follow-up:  









Adult patients with a 
current history of uni-
lateral peripheral 
neuropathic pain and 
allodynia 
 
Age (mean ± SD in y) 
MC: 52.4 ± 15.8;  
P: 54.3 ± 15.2 
 
Sex (% female) 
MC: 55.6%; P: 62.9% 
≥6 months pain 




THC:CBD spray  
100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; 
self-titration to 
optimal dose; 






odour and taste  
 




63 / 63 
Placebo:  
62 / 62 
- Titration phase:  
1 week 
- Study treatment:  
4 weeks 
- Follow-up:  












Adult patients with al-
lodynia 
 
Age (mean ± SD in y) 
57.3 ± 14.2 
 





100 ųl containing: 
2.7 mg THC and 













123 / 128 
Placebo: 
117 / 118 
- Titration phase:  
1 week 
- Study treatment:  
14 weeks 
- Follow-up:  
at end of treatment 
period 
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treat & safety 
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Adult patients with 
pain due to rheuma-
toid arthritis 
 
Age (mean ± SD in y) 
62.8 ± 9.8 
 
Sex (% female) 
79% 




100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; 
self-titration to 
optimal dose; 




Total: 58 / 58 
THC:CBD 
spray:  
31 / 31 
Placebo:  
27 / 27 
- Titration phase:  
2 weeks 
- Study treatment:  
3 weeks 
- Follow-up:  
at end of treatment 
period 
Keys: CBD = cannabidiol, MC = medical cannabis, MS = multiple sclerosis, NR = not reported, P = placebo, RCT = randomised controlled 
trial, SD = standard deviation, THC = tetrahydrocannabinol, UK = United Kingdom, y = years. 




















NR Double blind; not fully de-
scribed; despite the dou-
ble blind design, the risk of 
bias associated with un-
masking as a result of 
treatment side-effects can-




Yes No Subjective outcome 
measures; differences 
between multi-country 
study centers NR; 






NR Double blind; not fully de-
scribed; despite the dou-
ble blind design, the risk of 
bias associated with un-
masking as a result of 
treatment side-effects can-




Yes No Subjective outcome 
measures; differences 
between multi-country 
study centers NR; 







NR Double blind; not fully de-
scribed; despite the dou-
ble blind design, the risk of 
bias associated with un-
masking as a result of 
treatment side-effects can-




Yes No Subjective outcome 
measures; differences 
between multi-country 
study centers NR; 








Reported Despite the double blind 
design, the risk of bias as-
sociated with unmasking 
as a result of treatment 





Yes No Subjective outcome 







NR Double blind; not fully de-
scribed; despite the dou-
ble blind design, the risk of 
bias associated with un-
masking as a result of 
treatment side-effects can-




Yes No Subjective outcome 







Reported Double blind; not fully de-
scribed; despite the dou-
ble blind design, the risk of 
bias associated with un-
masking as a result of 
treatment side-effects can-




Yes No Subjective outcome 






Reported Despite the double blind 
design, the risk of bias as-
sociated with unmasking 
as a result of treatment 





Yes No Subjective outcome 








NR Double blind; not de-
scribed; despite the dou-
ble blind design, the risk of 
bias associated with un-
masking as a result of 
treatment side-effects can-




Yes No Error and deviations in 
results table for primary 
outcomes; subjective 
outcome measures; 
funded by industry 
High 
 Keys: NR = not reported. Low risk of bias; Moderate or unclear risk of bias; High risk of bias * Relative high percentage of loss to 
follow-up due to mortality in a population of patients with advanced cancer. 
Spasticity 
In total, five studies (four original RCTs and one randomised follow-up of an RCT) were included in this 
HTA on the efficacy of medical cannabis use for spasticity symptoms. Three RCTs were conducted in 
adults patients with MS and one RCT in a population of adult patients with motor neuron disease. 
THC:CBD spray was the most frequently studied form of medical cannabis (in three RCTs). A summary 
of the study characteristics is included in Table 7 and the risk of bias of the study designs of the individual 
RCTs in Table 8. In all RCTs bias arises for the study limitation blinding and subjective outcome 
measures. Unpredictable bias and uncertainty in the evidence base arise in research on medication with 
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a characteristic well-known adverse event profile like medical cannabis (e.g. dizzy/light-headedness, 
fatigue, ‘feeling high’), possibly leading to unblinding of patients to their treatment allocation. The sub-
jective outcomes for the symptom spasticity further increase this unpredictability and uncertainty, how-
ever, no fully objective measure is available. 
Spasticity in patients with multiple sclerosis 
Four studies were included on adult patients with spasticity caused by MS: three original RCTs with a 
parallel design9,11,52 and one randomised follow-up of an RCT.53 These RCTs were conducted in one 
western European country (UK) or a combination of western and eastern European countries (UK and 
Romania; UK and Czech Republic). The total sample size ranged from 184 to 630 patients. THC:CBD 
spray (100 ųl actuation containing 2.7 mg THC and 2.5 mg CBD) was studied in three RCTs and one 
RCT investigated Dronabinol (delta-9-THC) and THC:CBD capsules (2.5 mg THC and 1.25 mg CBD). 
In all RCTs medical cannabis was compared with a placebo. The treatment duration ranged from 6 to 
14 weeks and the follow-up study had a duration of 12 months. The study design of the RCTs and the 
follow-up study had a moderate risk of bias (see Table 8).  
Spasticity in patients with motor neuron disease 
One RCT with a parallel design was included on the efficacy of medical cannabis use for the symptom 
spasticity in patients with motor neuron disease, ALS or PLS.54 This multicentre Italian RCT included 59 
adults for 4 weeks of study treatment, of whom 29 were randomly assigned to be treated with THC:CBD 
spray and 30 with a placebo. The risk of bias of the study design of this RCT was moderate (see Table 
8). 










Comparator Sample size in-

















Adult patients with MS, 
stable disease for ≥3 
months before study 
entry, and significant 
spasticity in ≥2 muscle 
groups 
 
Age (mean ± SD in y) 
MC: 49.7 ± 10.2 /  







score of ≥2 
 
THC:CBD spray 
100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; self-ti-
tration to optimal 
dose; max. of 48 
sprays/day 
 
Dose (mean ± SD): 






Dose (mean ± 
SD): 
14.7 ± 8.4 sprays 
/day 
Total: 184 / 189 
THC:CBD 
spray:  
120 / 124 
Placebo:  
64 / 65 
- Titration phase:  
2 weeks 
- Study treatment:  
6 weeks 
- Follow-up:  
at end of treatment 
period 
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Adult patients with any 
disease subtype of MS 
of ≥6 months duration 
and ≥3 month history 
of spasticity 
 
Age (mean ± SD in y) 
MC: 48.0 ± 10.06 /  
P: 47.1 ± 9.15 
 
Sex (% female) 




verity on a 0-
10 NRS had 




score of 4 out 
of 10) 
THC:CBD spray 
100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; self-ti-
tration to optimal 








Each actuation of 
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Total: 305 / 337 
THC:CBD 
spray:  
150 / 167 
Placebo:  
155 / 170 
- Titration phase:  
1 week 
- Study treatment:  
14 weeks 
- Follow-up:  
























Adult patients with sta-
ble MS ≥6 months and 
problematic spasticity 
 
Age (mean ± SD in y) 
Dronabinol: 50.2 ± 8.2 
/ THC:CBD capsules: 
50.5 ± 7.6 / P: 50.9 ± 
7.6 
 
Sex (% female) 
Dronabinol: 69.4% / 
THC:CBD capsules: 





score of ≥2 in  









Capsules with 2.5 
mg THC, 1.25 mg 
CBD, <5% other 
cannabinoids; dose 
based on body-
























- Titration phase:  
5 weeks 
- Study treatment:  
8 weeks 
- Study treatment 
reduction to 0:  
2 weeks 
- Follow-up:  
• at end of treat-
ment period 
• at 12 months fol-
low-up 










Adult patients with 
MND (i.e. amyotrophic 
lateral sclerosis or pri-
mary lateral sclerosis) 
and spasticity for ≥3 
months 
 
Age (mean ± SD in y) 
MC: 58.4 ± 10.6 /  
P: 57.2 ± 13.8 
 
Sex (% female) 
MC: 38% / P: 47% 
Spasticity 
score of ≥1  
on the 5-point 
Modified Ash-
worth Scale 






100 ųl containing: 
2.7 mg THC and 
2.5 mg CBD; self-ti-
tration to optimal 
dose; max. of 12 
sprays/day 
 








Dose (mean ± 
SD): 
11.2 ± 1.4 
sprays/day 
Total: 59 / 59 
Nabiximols: 
29 / 29 
Placebo:  
30 / 30 
- Titration phase:  
2 weeks 
- Study treatment:  
4 weeks 
- Follow-up:  
at end of treatment 
period 
 










Comparator Sample size in-
tention to treat 
& safety 
Duration 
8.03 ± 2.9 
sprays/day 
Keys: CBD = cannabidiol, MC = medical cannabis, MND = motor neuron disease, NR = not reported, NRS = numeric rating scale, P 
= placebo, RCT = randomised controlled trial, SD = standard deviation, THC = tetrahydrocannabinol, y = years. 


















NR Double blind, not fully 
described; despite the 
double blind design, 
the risk of bias associ-
ated with unmasking 
as a result of treat-
ment side-effects can-





Yes No Subjective outcome 
measures; differences 
between multi-country 
study centers NR; 





NR Double blind, not fully 
described; despite the 
double blind design, 
the risk of bias associ-
ated with unmasking 
as a result of treat-
ment side-effects can-





Yes No Subjective outcome 
measures; differences 
between multi-country 
study centers NR; 







Reported Expected unmasking 
of both treating doc-
tors and patients and 
known side-effects of 
cannabinoids, blinding 









Yes Ashworth scale 
assessed at 6 
time points, but 
only reported for 






Motor neuron disease 
 
Riva, 201954 Reported Despite the double 
blind design, the risk 
of bias associated with 
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Keys: NR = not reported. Low risk of bias; Moderate or unclear risk of bias 
8.2.4 Findings efficacy 
Chronic pain 
Clinically relevant patient-reported pain relief was presented in different ways. RCTs tended to report 
average pain scores or average changes in pain scores; a patient-reported pain score ranges from zero 
(no pain) to ten (being the worst pain). However, this outcome has been described as problematic, 
because amongst others small average pain differences between the intervention and placebo arm hide 
the fact that a substantial minority of the patients achieve extremely good levels of pain relief .55 Cur-
rently, the preferred outcome in chronic pain RCTs is pain intensity reduction of at least 30% or at least 
50%, no worse than mild pain, tolerable adverse events, or being able to continue with medication with-
out withdrawal for (ideally) 12 weeks.3,55 However, dichotomising continuous variables also has limita-
tions.56 
Cancer pain 
Two RCTs on THC:CBD spray in patients with cancer pain reported efficacy results measured with the 
patient-rated numeric rating scale (NRS) pain score, NRS worst pain score, and median percentage 
change in average NRS pain score.44,45 No statistically significant treatment differences were found in 
favour of THC:CBD spray (Table 9).  
Table 9. Efficacy results on medical cannabis use for cancer pain: NRS pain (patient-rated) 
of treatment side-ef-
fects cannot be ex-
cluded 
Reference 






NRS pain score (0-10) NRS worst pain score (0-
10) 
Median % change in  




































(2.7 mg THC/2.5 
mg CBD) 






7.2% (NR) -1.84%  
(-6.19–1.50) 
p=0.274 





(2.7 mg THC/2.5 
mg CBD) 
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Keys: CBD = cannabidiol, CI = confidence interval, IQR = interquartile range, ITT = intention to treat, NR = not reported, NRS = 
numeric rating scale, RCT = randomised controlled trial, SD = standard deviation, THC = tetrahydrocannabinol.  
Neuropathic pain 
In total, four RCTs were included which compared the efficacy of THC:CBD spray versus placebo in 
patients with neuropathic pain.46,47,49,50 Efficacy results were reported for a range of outcomes (i.e. NRS 
pain score, NRS peripheral neural pain score, NRS neuropathic pain score, ≥30% reduction in NRS 
pain score, ≥50% reduction in NRS pain score, and ≥30% reduction in NRS peripheral neuropathic pain 
score), but only few statistically significant results were found. Two of the four RCTs reported statistically 
significant treatment differences in favour of THC:CBD spray, as measured with the NRS pain and NRS 
neuropathic pain scores (Table 10). Serpell et al. reported 28% treatment responders, as defined by a 
≥30% reduction in NRS peripheral neuropathic pain score, in the THC:CBD spray arm versus 16% in 
patients receiving placebo treatment (OR=1.97; 95% CI 1.05–3.70; p=0.034; Table 10. Efficacy results 
on medical cannabis use for neuropathic pain: NRS pain score (patient-rated)Table 11). Furthermore, 
health-related quality of life (HRQoL) was measured with different methods, i.e. the EQ-5D health index, 
EQ-5D visual analogue scales (VAS) score, and pain disability index. Only Nurmikko et al. found a 
statistically significant change in HRQoL for patients receiving THC:CBD spray compared to placebo, 
with an improvement in the pain disability index (treatment difference -5.85; 95% CI -9.62– -2.09; 
p=0.003; Table 12).49 The unadjusted pooled estimates for respectively a ≥30% and ≥50% reduction in 
NRS pain score were non-significant ORs of 1.36 (95% CI 0.92-2.00) and 1.59 (0.62-4.04). 





Placebo 198 NR NR 4.5% (NR) 
Reference 










NRS pain score (0-10) NRS peripheral 

















































Moderate risk of 
bias 
MS THC:CBD spray 








- - - -   
Placebo 172 -1.76 
(NR) 
- - - -   
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Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, MS = multiple sclerosis, NR = not reported, NRS = 
numeric rating scale, RCT = randomised controlled trial, SD = standard deviation, THC = tetrahydrocannabinol. Statistically sig-
nificant results 
Table 11. Efficacy results on medical cannabis use for neuropathic pain: treatment responders 
based on NRS pain 
Reference 








≥30% reduction in 
NRS pain score 
≥50% reduction in 
NRS pain score 




n (%) OR (95% 
CI); p-value 
n (%) OR (95% 
CI); p-value 




Moderate risk of bias 
MS THC:CBD spray 
(2.7 mg THC/2.5 
mg CBD) 
167 NR (50) 1.31 
(0.84–2.04) 
p=0.234 
NR (30) NR (NR) 
p=0.714 
- - 
Placebo 172 NR (45) NR (28)  - - 
Nurmikko, 200749 
 
Moderate risk of bias 
Allodynia THC:CBD spray 
(2.7 mg THC/2.5 
mg CBD) 
63 NR (26) NR NR (20) NR - - 
Placebo 62 NR (15) NR (8) - - 
Serpell, 201450 
 
High risk of bias 
Allodynia THC:CBD spray 
(2.7 mg THC/2.5 
mg CBD) 






117 - - - - 19 (16) 
Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, MS = multiple sclerosis, NR = not reported, NRS = 




Moderate risk of 
bias 
MS THC:CBD spray 
(2.7 mg THC/2.5 
mg CBD) 
33 - - NR -1.25  
(-2.11–   
-0.39) 
p=0.005 














(2.7 mg THC/2.5 
mg CBD) 






- -   
Placebo 
 
62 - - -0.52 
(NR) 
- -   
Serpell, 201450 
 




(2.7 mg THC/2.5 
mg CBD) 










117 - - - - NR NR 
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Table 12. Efficacy results on medical cannabis use for neuropathic pain: quality of life 
Reference 






































Moderate risk of 
bias 
MS THC:CBD spray (2.7 
mg THC/2.5 mg 
CBD) 
167 0.05 (NR) -0.01 (NR) 
p=0.396 
7.20 (NR) 1.94 (NR) 
p=0.383 
- - 
Placebo 172 0.07 (NR) 5.26 (NR) - - 
Nurmikko, 200749 
 




THC:CBD spray (2.7 
mg THC/2.5 mg 
CBD) 





Placebo 62 - - - - 0.24 (NR) 
Serpell, 201450 
 
High risk of bias 
Allo-
dynia 
THC:CBD spray (2.7 
mg THC/2.5 mg 
CBD) 







117 - - NR - - 
Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, MS = multiple sclerosis, NR = not reported, RCT = 
randomised controlled trial, SD = standard deviation, THC = tetrahydrocannabinol, VAS = visual analogue scale. Statistically 
significant results 
The RCT on dronabinol versus placebo in MS patients with neuropathic pain reported limited efficacy 
on NRS pain scores and quality of life.48 Schimrigk et al. did not find a statistically significant treatment 
difference for NRS pain score (mean change from baseline dronabinol and placebo: -1.92±2.01 vs. -
1.81±1.94; treatment difference not reported; 95% CI not reported; p=0.676).48 The quality of life as-
sessment with the SF-36 showed improvement within both study arms (physical component summary 
for dronabinol -3.50 and placebo -3.18), however the treatment difference between study arms was 
not statistically significant (treatment difference, 95% CI, and p-value not reported).48 
Musculoskeletal pain 
Blake et al. compared the efficacy of THC:CBD spray with placebo in patients with chronic pain symp-
toms caused by rheumatoid arthritis.51 A statistically significant treatment difference was found of -1.04 
in favour of THC:CBD spray for the outcome NRS morning pain at rest (95% CI -1.90– -0.18; p=0.018; 
Table 13). 
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Table 13. Efficacy results on medical cannabis use for musculoskeletal pain: NRS pain (patient-
rated) 
Keys: CBD = cannabidiol, CI = confidence interval, IQR = interquartile range, ITT = intention to treat, NR = not reported, NRS = 
numeric rating scale, RCT = randomised controlled trial, THC = tetrahydrocannabinol. * Data on the outcome ‘NRS morning pain 
on movement (0-10)’ was not extracted from the study of Blake, 2006, because it was not possible to recalculate their reported 
unadjusted difference between the THC:CBD spray and placebo arm. Statistically significant results 
Spasticity 
The most common assessments of spasticity in clinical practice and research are the Ashworth scale, 
modified Ashworth scale, and the spasticity 0-10 NRS. The original Ashworth Scale was published in 
1964 and enables the evaluator to grade spasticity on a 5-point muscle tone numeric scale, ranging 
from 0 (normal) to 4 (severe spasticity in a limb rigid in flexion or extension).57,58 In 1987, the Ashworth 
scale was modified by adding 1+ to the scale to increase sensitivity.57,58 The usability of the Ashworth 
scale as an outcome for spasticity is complicated by these two versions and both have limitations, e.g. 
they only measure one aspect of spasticity and the grading is largely dependent on the evaluator, which 
influences the intra and interrater reliability.57,58 As the reliability and sensitivity of the Ashworth scale to 
measure significant functional change in spasticity has been questioned, spasticity NRS scores or VAS 
scores have been used in spasticity studies. The NRS was developed to capture information from the 
patient’s perspective and the severity of spasticity is rated on a scale ranging from 0 (no spasticity) to 
10 (worst possible spasticity).57 The test-retest reliability of the NRS is better than the Ashworth Scale, 
however quantitative evaluation methods of spasticity are still difficult and subjective and currently no 
ideal objective measure of this highly complex symptom is available.57  
Spasticity in patients with MS 
Two RCTs on THC:CBD spray in patients with spasticity caused by MS reported efficacy results meas-
ured with the Ashworth scale, modified Ashworth scale, and patient-rated NRS spasticity score. They 
also reported the treatment response based on the NRS spasticity score and quality of life.11,52 Only 
statistically significant treatment differences were found in the RCT of Collin et al., 2007 for two out-
comes: a treatment difference in favour of THC:CBD spray on the NRS spasticity score of -0.52 (95% 
CI -1.029– -0.004; p=0.048; Table 14) and 18.1% more treatment responders in the THC:CBD spray 
arm as defined by a ≥30% reduction in NRS spasticity (95% CI 4.73–31.52; p=0.014; Table 15). The 
Reference 





NRS morning pain at rest (0-10)* 
Median (IQR) change from base-
line 
Treatment difference (95% CI); p-value 
Blake, 200651 
 
High risk of bias 
 
THC:CBD spray 
(2.7 mg THC/2.5 
mg CBD) 





27 -1.2 (NR) 
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unadjusted pooled estimate for a ≥30% reduction in NRS spasticity for both studies of Collin et al. was 
an OR of 1.70 (95% CI 0.99-2.92). 
Table 14. Efficacy results on medical cannabis use for spasticity symptoms in patients with MS: 
Ashworth scale (observer rated) and NRS spasticity (patient-rated) 
Reference 







































Moderate risk of 
bias 
THC:CBD spray 
(2.7 mg THC/2.5 mg 
CBD) 
120 -0.64 (NR) -0.11  
(-0.29–0.07) 
p=0.218 
- - -1.18 (NR) -0.52 
(-1.029–     
-0.004) 
p=0.048 
Placebo 64 -0.53 (NR) - - -0.63 (NR) 
Collin, 201011 
 
Moderate risk of 
bias 
THC:CBD spray 
(2.7 mg THC/2.5 mg 
CBD) 
150 - - -2.17 (NR) -0.16 
(NR) 
p=0.857 
-1.05 (NR) -0.23 (NR) 
p=0.219 
Placebo 155 - - -2.01 (NR) -0.82 (NR) 
Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, NR = not reported, NRS = numeric rating scale, RCT 
= randomised controlled trial, SD = standard deviation, THC = tetrahydrocannabinol. Statistically significant results 
Table 15. Efficacy results on medical cannabis use for spasticity symptoms in patients with MS: 
treatment responders based on NRS spasticity 
Reference 






≥30% reduction  
in NRS spasticity 
≥50% reduction  
in NRS spasticity 
n (%) Treatment differ-
ence (95% CI); 
p-value  
OR (95% CI); 
p-value 
n (%) Treatment differ-




Moderate risk of bias 
THC:CBD spray (2.7 
mg THC/2.5 mg 
CBD) 
120 48 (40.0%) 18.1%  
(4.73–31.52) 
p=0.014 
- 21 (17.5%) 8.1%  
(-1.73–17.98) 
p=0.189 
Placebo 64 14 (21.9%) - 6 (9.4%) 
Collin, 201011 
 
Moderate risk of bias 
THC:CBD spray (2.7 
mg THC/2.5 mg 
CBD) 







Placebo 155 NR (25%) - - 
Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, NRS = numeric rating scale, OR = odds ratio, RCT 
= randomised controlled trial, THC = tetrahydrocannabinol. Statistically significant results 
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Table 16. Efficacy results on medical cannabis use for spasticity symptoms in patients with MS: 
quality of life 
Reference 




















Moderate risk of bias 
THC:CBD spray (2.7 
mg THC/2.5 mg 
CBD) 
150 0.03 (NR) 0.02 (NR) 
p=0.175 
4.29 (NR) 1.42 (NR) 
p=0.538 
Placebo 155 0.01 (NR) 2.87 (NR) 
Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, NR = not reported, RCT = randomised controlled 
trial, SD = standard deviation, THC = tetrahydrocannabinol, VAS = visual analogue scale. 
Zajicek et al. studied three study arms of MS patients receiving Dronabinol, THC:CBD capsules, or 
placebo capsules for their spasticity symptoms and assessed the efficacy with the Ashworth scale.9,53 
A small statistically significant (p=0.01) treatment difference of 2.05 was found for the change in Ash-
worth score from baseline to 52 weeks’ follow-up for Dronabinol compared to placebo and they did not 
find a statistically significant effect of treatment with THC:CBD capsules (Table 17). 
Table 17. Efficacy results on medical cannabis use for spasticity symptoms in patients with MS: 
Ashworth scale (observer rated) 
Reference 






Mean change (SD) from baseline Treatment difference (95% CI); p-value 
Zajicek, 20039 & 
Zajicek, 200553 
 




206* -1.86 (7.95) 0.94 (-0.44–2.31)  
NS‡ 





THC:CBD capsules  
(2.5 mg THC/1.25 mg 
CBD) 
211* -1.24 (6.60) 0.32 (-1.04–1.67)  
NS‡ 
172† -0.10 (7.25) -0.13 (NR) 
NS§ 
Placebo 213* -0.92 (6.56) - 
176† 0.23 (7.87) - 
Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, NR = not reported, NS = not significant, RCT = ran-
domised controlled trial, S = significant, SD = standard deviation, THC = tetrahydrocannabinol. * At end of 5 weeks titration and 8 
weeks of treatment period of the original RCT; † At end of 12 months follow-up; ‡ Comparison of the 3 groups using analysis of 
variance on the change in total Ashworth score showed no treatment effect with an unadjusted p-value of 0.40 and adjusted p-
value of 0.29; § Comparison of the 3 study arms using analysis of variance on the change in total Ashworth score showed a small 
treatment effect with an unadjusted p-value of 0.04 and adjusted p-value of 0.01. Statistically significant results 
Spasticity in patients with motor neuron disease 
The RCT on THC:CBD spray for spasticity in ALS/PLS patients reported efficacy results measured with 
the modified Ashworth scale and patient-rated NRS spasticity score, and also reported the treatment 
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response based on the NRS spasticity score.54 The mean change in Modified Ashworth Scale (assessed 
at baseline and after 6 weeks) improved with 0.11 in the THC:CBD spray arm and deteriorated with 0.16 
in the placebo arm, resulting in a statistically significant treatment difference of -0.32 (95% CI -0.57– -
0.07; p=0.013) (Table 18). However, no statistically significant difference was found between the 
THC:CBD spray and placebo arm for the change from baseline in spasticity as measured with the pa-
tient-rated NRS spasticity score (Table 18), nor a statistically significant reduction in the ≥30% or ≥50% 
reduction in NRS spasticity score (Table 19). 
Table 18. Efficacy results on medical cannabis use for spasticity in patients with motor neuron 
disease: Ashworth scale (observer rated) and NRS spasticity score (patient-rated) 
Reference 




















Moderate risk of bias 
THC:CBD spray 
(2.7 mg THC/2.5 
mg CBD) 
29 -0.11 (0.48) -0.32 
(-0.57– -0.07) 
p=0.013 
-0.32 (2.15)  -0.49  
(-1.48–0.50) 
p=0.324 
Placebo 30 0.16 (0.47) -0.12 (1.40) 
Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, NRS = numeric rating scale, RCT = randomised 
controlled trial, SD = standard deviation, THC = tetrahydrocannabinol. Statistically significant results 
Table 19. Efficacy results on medical cannabis use for spasticity symptoms in patients with mo-
tor neuron disease: treatment responders based on NRS spasticity score 
Reference 





≥30% reduction  
in NRS spasticity score 
≥50% reduction  
in NRS spasticity score 
n (%) OR (95% CI); p-
value 




Moderate risk of bias 
THC:CBD spray (2.7 mg 
THC/2.5 mg CBD) 
29 6 (21%) 1.70 (0.42–6.77) 
p=0.45 
3 (10%) 1.61 (0.25–10.45) 
p=0.61 
Placebo 30 4 (13%) 2 (7%) 
Keys: CBD = cannabidiol, CI = confidence interval, ITT = intention to treat, NRS = numeric rating scale, OR = odds ratio, RCT = 
randomised controlled trial, THC = tetrahydrocannabinol. 
8.2.5 Findings effectiveness 
During the project it was decided not to proceed with an additional systematic literature search for com-
parative non-randomised studies, because sufficient data were found for the outcomes of interest on 
the highest possible level of evidence (i.e. from RCTs) and we do not expect that additional data from 
comparative non-randomised studies will have essential impact on the conclusions formulated in this 
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HTA. Therefore, no data is included on the effectiveness of medical cannabis for chronic pain or spas-
ticity. 
8.2.6 Findings safety 
It was not possible to extract/synthesise data on individual SAEs of medical cannabis use from the 
included RCTs for a number of reasons: 1) the SAEs were mostly not clearly defined in the articles; 2) 
the events were reported incompletely (e.g. adverse events were reported only when they occurred in 
at least 5% or 10% of the participants); and 3) only numbers and/or percentages of adverse events were 
reported without statistical comparisons between the intervention and placebo arm or presenting risk 
ratios. The definitions of the safety outcomes deaths and withdrawal from treatment due to adverse 
events were in line between the RCTs and data were extracted and, if possible, pooled. In the individual 
RCTs only the number and percentages were reported for deaths and withdrawal from treatment, with-
out a statistical comparison or risk ratio between the medical cannabis and placebo arm. 
Chronic pain 
Cancer pain 
Two large multi-country RCTs compared the safety of THC:CBD spray versus placebo in patients with 
cancer pain. No statistically significant effects were found for treatment with THC:CBD spray on the 
occurrence of deaths (RR 0.90; 95% CI 0.62-1.30; high certainty; Table 20) and withdrawal from treat-
ment due to adverse events (RR 1.21; 95% CI 0.90-1.63; moderate certainty; Table 20).44,45 
Neuropathic pain 
In two RCTs on THC:CBD spray, one in MS patients47 and one in patients with allodynia 50, no deaths 
were reported in the THC:CBD spray and placebo arms. Two other RCTs, also in a population with MS 
and allodynia, did not report on the number of deaths.46,49 Concerning the outcome withdrawal from 
treatment due to adverse events, the pooled analysis of these four RCTs showed that THC:CBD spray 
resulted in a statistically significant increase in withdrawals from treatment due to adverse events: 13.3% 
in the THC:CBD spray arm versus 5.5% in the placebo arm (RR 2.45; 95% CI 1.23-4.87; moderate 
certainty; Table 21). Another RCT compared the safety of dronabinol versus placebo in MS patients with 
neuropathic pain.48 No deaths were reported during the 20-week study period and 12 subjects (9.7 %) 
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Musculoskeletal pain 
The RCT on THC:CBD spray for treatment of pain in patients with rheumatoid arthritis did not report on 
the number of deaths.51 In the THC:CBD spray arm none of the subjects withdrew from treatment due 
to adverse events during five weeks of treatment versus 3 subjects (11.1%) in the placebo arm.  
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Table 20. GRADE evidence profile: safety of medical cannabis use in patients with cancer pain 
a Not downgraded for risk of bias, since the risk of bias issues have little impact on the objective outcome death. 
b Downgraded for serious risk of bias due to bias associated with unmasking as a result of treatment side-effects cannot be excluded in combination with a subjective outcome, and differences in inclusion/results 
between multi-country study centers not reported in Fallon et al., 2017 and Lichtman et al., 2018. 
 
 




Study       
design 
Risk of bias Inconsistency Indirectness Imprecision Other consid-
erations 
THC:CBD spray Placebo Relative 
(95% CI) 
Absolute                                     
(95% CI) 
 












(0.62 to 1.30) 
14 fewer per 1,000 
(from 32 fewer to 60 more) 
⨁⨁⨁⨁ 
HIGH 












(0.90 to 1.63) 
34 more per 1,000  
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 Table 21. GRADE evidence profile: safety of medical cannabis use in patients with neuropathic pain 
 a Downgraded for serious risk of bias due to bias associated with unmasking as a result of treatment side-effects cannot be excluded in combination with a subjective outcome in Nurmikko et al., 2007, Serpell 






Certainty assessment № of patients Effect 
Certainty 






Absolute                                     
(95% CI) 
 
Withdrawal from treatment due to adverse events (in patients with neuropathic pain) 
4[Nurmikko, 200749; Serpell, 









(1.23 to 4.87) 
79 more per 1,000  
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Spasticity 
Spasticity in patients with MS 
In two RCTs, Collin et al. studied THC:CBD spray in patients with spasticity caused by MS.11,52 In the 
first RCT no deaths were reported in the THC:CBD spray and placebo arm during the 8-week study 
period.52 The second 15-week RCT reported two deaths (i.e. due to gastrointestinal carcinoma with liver 
metastases and metastatic oesophageal carcinoma), considered not to be related to the study medica-
tion.11 However, the authors did not report if these deaths occurred in the THC:CBD spray and/or pla-
cebo arm. The pooled analysis of both RCTs showed that THC:CBD spray did not result in a statistically 
significant increase in withdrawals from treatment due to adverse events: 5.2% in the THC:CBD spray 
arm versus 3.0% in the placebo arm (RR 1.75; 95% CI 0.72-4.23; moderate certainty; Table 22). Zajicek 
et al. studied three arms of MS patients receiving either Dronabinol, THC:CBD capsules, or placebo 
capsules.9,53 One subject (0.6%), randomised to the Dronabinol arm, died from pneumonia during the 
15-week RCT. Seven subjects (4.5%) in the Dronabinol arm, two subjects (1.2%) in the THC:CBD cap-
sules arm, and none of the subjects receiving placebo withdrew from treatment due to adverse events. 
During the 12 month follow-up phase of the RCT there were six deaths, however not all details were 
reported in the article. Two subjects chose to continue medication during follow-up, two subjects chose 
to discontinue medication, and for two subjects this was not reported. The two subjects who continued 
medication died from pneumonia and seizure and were randomised to THC:CBD capsules treatment. 
Spasticity in patients with motor neuron disease 
The RCT on THC:CBD spray for spasticity in ALS/PLS patients did not report data on the number of 
deaths.54 In both the THC:CBD spray and placebo arm none of the subjects withdrew from treatment 
due to adverse events. 
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Table 22. GRADE evidence profile: safety of medical cannabis use for spasticity in patients with MS 
 a Downgraded for serious risk of bias due to bias associated with unmasking as a result of treatment side-effects cannot be excluded in combination with a subjective outcome, and differences in inclusion/results 
between multi-country study centers not reported in Collin et al., 2007 and Collin et al., 2010. 
Certainty assessment № of patients Effect 
Certainty 






Absolute                                     
(95% CI) 
 
Withdrawal from treatment due to adverse events (in patients with spasticity caused by MS) 
2[Collin, 200752; Collin 201011] randomised tri-
als 





(0.72 to 4.23) 
21 more per 1,000  
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8.3 Summary statement efficacy, effectiveness, and safety 
 
In this HTA, eight RCTs (moderate risk of bias n=6; high risk of bias n=2) were included on medical 
cannabis use in adults with chronic pain caused by cancer (n=2), neuropathic disease (n=5), and 
musculoskeletal disease (n=1). Four RCTs and one randomised follow-up of an RCT (all with mod-
erate risk of bias) were included on medical cannabis use in adults with spasticity caused by MS 
(n=4) and motor neuron disease (n=1). THC:CBD spray (Sativex®) was the most frequently studied 
form of medical cannabis.  
Heterogeneity between studies in outcomes and outcome measures, data skewness, and incom-
pleteness of study results (i.e. studies omitting to report detailed results such as treatment effects 
in the intervention and placebo arms or measures of variability) precluded the calculation of pooled 
estimates for efficacy data for the stratified pain and spasticity populations. Overall, the efficacy 
data on medical cannabis use for chronic pain and spasticity was inconsistent (i.e. studies with 
comparable patient populations and similar type of medical cannabis did not show consistent re-
sults) and inconclusive (i.e. none of the studies was able to draw a definitive conclusion on the 
efficacy of medical cannabis). Furthermore, multiple factors increase the risk of bias in studies on 
medical cannabis, however the extent as well as the direction of the potential bias are difficult to 
comprehend. Although it was possible to calculate pooled estimates for part of the safety outcomes 
and some patient populations, the issues highlighted for efficacy also apply to safety, resulting in 
an incomplete safety profile of medical cannabis use for chronic pain and spasticity. 
In studies on medical cannabis, an unpredictable bias and uncertainty in the evidence base arises 
caused by the risk of unblinding of patients to their treatment allocation in combination with the 
patient-reported outcomes for the symptoms chronic pain and spasticity. Given these considera-
tions it is neither possible to conclude that medical cannabis is an efficacious and safe treatment 
option for chronic pain and spasticity, nor to conclude that medical cannabis is not efficacious and 
safe for the treatment of chronic pain and spasticity. 
Future studies on medical cannabis in these symptoms will likely be exposed to similar challenges 
and limitations, of which only part can be solved with improved study designs and complete report-
ing of results. 
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9 Cost-effectiveness and budget impact 
SRs were conducted to identify cost-effectiveness studies on medical cannabis use for chronic pain and 
spasticity. In addition, two cost-effectiveness models were developed to calculate the cost-effectiveness 
and budget impact of medical cannabis for the Swiss context specifically. In this chapter, the employed 
methods are further detailed starting with the SRs on medical cannabis use for chronic pain and spasticity, 
followed by a description of the conceptual cost-effectiveness models, additional searches for model inputs, 
and cost-effectiveness and budget impact analyses for the symptoms chronic pain and spasticity (Chapters 
9.1.1 – 9.1.3). Finally, the results of the SRs, the cost-effectiveness models, and the budget impact analyses 
are presented (Chapter 9.2.1 – 9.2.3).  
9.1 Methodology cost-effectiveness and budget impact 
9.1.1 Databases and search strategy 
In line with the principles outlined for the systematic literature search on efficacy, effectiveness, and safety, 
a systematic literature search was performed on the cost-effectiveness of medical cannabis use for chronic 
pain and spasticity. The methods of this systematic literature search will be discussed in this section.  
Search strategy 
PubMed (MEDLINE), Embase.com, and NHS Economic Evaluation Database (NHS EED) were searched 
for peer-reviewed scientific literature. The PICO method was used to specify the research questions. Chap-
ter 6 outlines the utilised PICO for the cost-effectiveness review. Based on expert opinion, the time period 
of the search was not restricted. Due to this, it is important to be aware of the influence of inflation and 
discount rates on the cost-effectiveness outcomes of medical cannabis throughout the search period. Pub-
lications in English, French, German, and Dutch were included.  
The search terms of the efficacy, effectiveness, and safety literature search were combined with search 
terms to find economic evaluations (e.g. cost-effectiveness, cost-utility, economic evaluation, budget im-
pact). The search terms for economic evaluations were developed together with an information specialist 
of the Erasmus University Medical Centre. Two separate search strategies were developed, one on medical 
cannabis use in chronic pain and one on medical cannabis use in spasticity (Appendix 15.3). 
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The search for economic evaluations on medical cannabis use for chronic pain and spasticity was executed 
on January 27th, 2020. The literature database output, including all indexed fields per record (e.g. title, 
authors, and abstract) was exported to Endnote version X7.8. Duplicates in Endnote were automatically 
removed and/or manually deleted. 
Inclusion and exclusion criteria 
The inclusion and exclusion criteria applied during the selection processes for the economic evaluations 
are presented in Table 23. The list of excluded studies can be found in Appendix 15.4. The process of 
selection of articles was registered in an Endnote library by one of the researchers. The exclusion criteria 
applied during the full-text screening phase are reported in PRISMA flow charts (Section 9.2.1).  
Table 23. Inclusion and exclusion criteria for economic evaluations of medical cannabis use for 
chronic pain and spasticity 
 
Inclusion Exclusion 
Period of publication Start database - January 2020 
 
Language of publication English, French, German, Dutch All other languages 
Country of study All countries - 
Study design/type Economic evaluations (CEA, CUA), 
Budget impact analyses 
 
Other economic evaluations 
Study quality All economic evaluations 
 
Study population Patients (all ages) with chronic pain 
or spasticity 
No or lacking information on study population 
Patients (all ages) with chronic pain  
 Patients without chronic pain 
 Patients in whom medical cannabis is not pri-
marily prescribed for the symptom chronic 
pain 
Patients (all ages) with spasticity 
 Patients in whom medical cannabis is not pri-
marily prescribed for the symptom spasticity 
 No or lacking definition of spasticity 
Study intervention Medical cannabis, prescribed as 
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Study comparison 
 Placebo 
 No treatment for chronic pain 
 Standard of care according to 
the treatment guidelines (i.e. 
conventional drugs for the 
chronic pain condition or spas-
ticity condition) 
Comparisons with other treatments than standard 
of care 
Study outcomes Incremental costs 
Incremental QALYs 
ICERs  
No/other cost-effectiveness outcomes  
 
Keys: CEA = cost-effectiveness analysis, CUA = cost-utility analysis, ICER = incremental cost-effectiveness ratio, QALY = quality-
adjusted life year 
Quality control 
The same quality control measures were put in place in the cost-effectiveness literature search as for the 
effectiveness, efficacy, and safety literature search: 
 The first 30% of titles and abstracts from the peer-reviewed literature were screened in duplicate 
by two independent researchers. The results were compared and discussed before the remaining 
references were assessed by one researcher. During screening there was more than 5% discrep-
ancy between the two researchers, therefore all titles and abstracts were screened in duplicate. 
Any conflicts were discussed and amended accordingly. 
 The first 10% of the full-text articles from the peer-reviewed literature were assessed for relevance 
and critically appraised in duplicate by two independent researchers. Again, during screening there 
was more than 5% discrepancy between the two researchers, therefore all full-text articles were 
screened in duplicate. Any conflicts were discussed and amended accordingly. 
9.1.2 Other sources 
Hand search of reference lists  
During the full-text screening phase of the cost-effectiveness systematic literature search, reference lists of 
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Clinical guidelines and technology assessments from the major national HTA agency websites (e.g. EU-
netHTA for Europe, National Institute for Health and Care Excellence (NICE) from the United Kingdom 
(UK), Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) from Germany, Haute Auto-
rité de santé (HAS) from France, National Health Care Institute (ZiN) from the Netherlands, Canadian 
Agency for Drugs and Technologies in Health (CADTH) from Canada, and Pharmaceutical Benefits Advi-
sory Committee (PBAC) and Therapeutic Goods Administration (TGA) from Australia) were searched for 
documents addressing medical cannabis use for chronic pain and spasticity (i.e. search terms ‘medical 
cannabis’ in relevant language). The aim of this search was to check whether the search for economic 
evaluations possibly missed relevant evidence on the cost-effectiveness of medical cannabis. The initial 
search yielded NICE guidelines on the symptoms chronic pain59 and spasticity60, SRs on the CADTH 
webpage for the symptoms chronic pain61 and spasticity62, SRs on the TGA website for the symptoms 
chronic pain63 and spasticity64, one evaluation on the IQWiG website for the symptom spasticity65, and a 
stance document on medical cannabis in various symptoms from ZiN66. No missed studies were identified 
in these clinical guidelines and technology assessments. However, as the NICE guidelines for chronic pain 
and spasticity included de novo cost-effectiveness models based on input from their own SRs, these were 
included for the cost-effectiveness systematic literature search.  
9.1.3 Assessment of quality of evidence 
The Consensus Health Economics Checklist (CHEC) was used for the appraisal of the methodological 
quality of the economic evaluations.67 The CHEC was preferred over the Drummond checklist, because of 
the decreasing use of the Drummond checklist in the field68 and the experienced feasibility of completing 
the checklist. The CHEC is one of the two most frequently used checklists in recent studies, the other 
checklist is the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist.69 The 
CHEC was chosen over the CHEERS as the CHEC can be used to assess the methodological quality of 
economic evaluations, while the CHEERS was primarily intended for use as a reporting checklist.  
The CHEC is a 19-item checklist67 with clear questions about the economic evaluation that will give insight 
into the general quality of the study for a preliminary critical appraisal of the quality of the included studies. 
The studies were judged on whether the criteria were fulfilled (“1”), not fulfilled (“0”), or inconclusive (“0.5”).  
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9.1.4 Methodology cost-effectiveness modelling  
Considering the lack of cost-effectiveness studies on medical cannabis in the Swiss context, cost-effective-
ness models were developed that incorporated the most recent and (where possible) Switzerland-specific 
effectiveness, costs, and HRQoL (expressed in utilities on a scale from 0 to 1) evidence. However, cost-
effectiveness models were available for the UK setting where the cost-effectiveness of medical cannabis in 
addition to standard of care (SOC) was compared to SOC alone in the indications of chronic pain and 
spasticity. These two UK models, which were developed by NICE, were used as starting point for the current 
cost-effectiveness models and adapted to better represent the Swiss context. First, the aspects that were 
equal for all Swiss cost-effectiveness models are described, including the model structure and the incorpo-
ration of discontinuation and SAE. Then, the input parameters specific for the chronic pain models will be 
described, followed by the input parameters specific for the spasticity models.  
9.1.4.1 General model settings and assumptions 
To model the cost-effectiveness of medical cannabis, a decision had to be made on the preferred outcome 
measure for efficacy. Based on previous cost-effectiveness models in spasticity and chronic pain popula-
tions, and taking into account data availability (for the efficacy measure itself as well as for relatable utility 
and resource use data), the absolute change in numeric rating scale (NRS) score was the preferred efficacy 
outcome measure in the chronic pain models, and the proportion of responders at ≥30% reduction in NRS 
score was the preferred efficacy outcome in the spasticity models. As a result, usable efficacy evidence for 
cost-effectiveness modelling was available for two chronic pain populations (neuropathic pain and muscu-
loskeletal pain) and two spasticity populations (MS and motor neuron disease). No usable efficacy usable 
evidence was available for modelling the cost-effectiveness of medical cannabis in cancer pain as the effi-
cacy data were not reported for both arms separately. All studies that reported efficacy using the preferred 
outcome measure compared THC:CBD spray (Sativex®) in addition to SOC to SOC alone. Consequently, 
as no usable efficacy data were available for other medical cannabis products or routes of administration, 
the Swiss models were developed comparing THC:CBD spray in addition to SOC to SOC alone. The stand-
ard of care is defined as any interventions that would usually be prescribed in these patient populations, 
including licensed oral anti-spasticity drugs or analgesics if appropriate. 
The models adopted a cycle length of four weeks, following a lifetime horizon. The analyses were performed 
from a healthcare perspective (i.e. only including all direct medical costs). Costs were reported in Swiss 
franc (CHF) using the prices from the year 2020 from an insurance perspective. Health outcomes were 
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reported in quality-adjusted life years (QALYs). In the base case analysis, costs and effects were dis-
counted with a factor of 3% from the second year onwards. The models were programmed in R 3.6.1 using 
RStudio 1.2.1335.  
All subpopulations were investigated separately in the Swiss cost-effectiveness models as the cost-effec-
tiveness results may differ depending on the underlying cause of the symptom. For chronic pain, the main 
cost-effectiveness model was developed using information on neuropathic pain as for this subpopulation 
the availability of model input was most comprehensive. For the same reason, information on MS served 
as a basis for the main spasticity cost-effectiveness model. For the other subpopulations the neuropathic 
pain and MS cost-effectiveness models were adapted using the efficacy data available for this population 
as identified during the SR on efficacy, effectiveness, and safety. If input for a certain parameter was not 
available for the specific subpopulation (i.e. utilities or resource use), the input from the neuropathic pain 
(for chronic pain subpopulations) and MS (for spasticity subpopulations) cost-effectiveness models were 
assumed.  
Model structure 
The Swiss cost-effectiveness models were designed as Markov models with three health states (Figure 3). 
The health states included treatment response, no treatment response and a dead health state. The model 
structure was the same for the THC:CBD spray in addition to SOC arm and the SOC alone arm (from here 
on the THC:CBD spray arm and the SOC arm). Treatment response was defined as ≥30% reduction in the 
NRS pain score for chronic pain indications, and as ≥30% reduction in the NRS spasticity score in the 
models for spasticity subpopulations in line with the assumptions made by the NICE expert committee.60 It 
was assumed that patients who do not achieve the ≥30% response criterium will discontinue THC:CBD 
spray and hence transition to the SOC arm. The models adopted a cycle length of 4-weeks, meaning that 





Figure 3. Model structure 
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Discontinuation 
In both arms, patients could discontinue THC:CBD spray or placebo from the second cycle onwards (i.e. 
after a 4-week trial period). Patients could discontinue because they did not achieve the ≥30% reduction 
criterion or stopped achieving this criterion, or because of adverse events. Long-term discontinuation was 
derived from the SA.FE study which investigated discontinuation of THC:CBD spray using real-world data 
of an Italian sample of MS patients.70 Using the data from this study, discontinuation for the THC:CBD spray 
arm is modelled using survival analyses. Similar to the NICE models, a Gompertz model was fitted to the 
curve. The long-term discontinuation is presented in Figure 4 (dashed lines represent upper and lower 
confidence limits). For the SOC arm, long-term discontinuation due to adverse events was not considered 
realistic, since patients do not receive an active treatment. Therefore, a competing risks model was esti-
mated, separating discontinuation related to adverse events from discontinuation from other causes (mainly 
not maintaining response level of ≥30%). As a result, discontinuation rates were lower in the SOC arm than 
in the THC:CBD spray arm. The Gompertz model was used in concordance with the model used for dis-
continuation in the THC:CBD spray arm. To test the impact of the assumption of differential discontinuation 
on the results, discontinuation rates in the SOC arm was set equal to discontinuation in the THC:CBD spray 
arm in a scenario analysis. 
Figure 4. Discontinuation for responders on THC:CBD spray 
 
* the solid line represents the average proportion of treatment responders over the first 2 years of treatment. **dotted lines represent 
the upper and lower values for the 95% confidence interval. 
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Serious Adverse events 
Only serious adverse events (SAEs) were considered in the Swiss cost-effectiveness models, since the 
prevalence, duration and effects (in terms of costs and effects) of non-serious adverse events were negli-
gible. SAEs are events that result in death, are life-threatening, require inpatient hospitalisation, or cause 
prolongation of existing hospitalisation. SAE rates were derived from a published systematic literature re-
view by Wang et al., in line with the models developed by NICE.24 Yearly SAE rates were 0.37 for the 
THC:CBD spray arm and 0.25 for the SOC arm.71 The disutilities associated with SAEs were taken from 
the study by Hagiwara et al. as no usable Swiss utility data were identified.71 The disutility for a SAE was 
therefore set at 0.10 and was assumed to last for 3 days. SAEs were excluded in a scenario analysis. 
Search for model input on utilities, resource use and unit costs 
A comprehensive search was performed to identify the most recent Swiss utility and cost data available to 
use as input in the Swiss cost-effectiveness models. The search terms, methods, and results of this sys-
tematic literature search are provided in Appendix 15.5. The search aimed to identify the following utility, 
costs and resource use inputs for the Swiss context:  
 Costs of treatment with THC:CBD spray;  
 Resource use and related unit costs of treatment of patients with chronic pain or spasticity, stratified 
by NRS score; 
 Resource use and related unit costs of patients with SAEs attributable to THC:CBD spray treatment  
 Utilities in patients with chronic pain or spasticity, stratified by NRS score; and 
 Disutilities in patients with SAEs attributable to THC:CBD spray.   
As no relevant inputs were identified specifically for the Swiss context, expert opinion and public databases 
were used to derive Swiss cost inputs. For resource use and utilities, the inputs from the NICE models were 
assumed.  
 
9.1.4.2 Model input chronic pain  
Treatment effectiveness 
In the chronic pain model, treatment effects were modelled using the mean change in NRS pain score from 
baseline. Baseline NRS pain scores were simulated using a beta distribution (n=10,000) with a mean NRS 
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pain score at baseline of 6.9 and an SE of 1.3 for the neuropathic pain model based on the pooled mean 
NRS pain scores at baseline in Langford et al. and Nurmikko et al..46,49 The mean NRS pain score at base-
line reported in the Blake et al. study was used for the musculoskeletal pain model (mean=5.3, SD=1.1).51 
The resulting density plot of baseline NRS pain scores are presented in Appendix 15.8. 
The SR on the efficacy, effectiveness, and safety of medical cannabis identified two studies that provided 
the (adjusted) mean change in pain score for the neuropathic subpopulation of chronic pain patients. Lang-
ford et al. found mean changes in NRS pain score for chronic pain patients of -1.93 and -1.76 for patients 
receiving THC/CBD spray and placebo, respectively.46 Nurmikko et al. reported an adjusted mean change 
in NRS pain score of -1.42 for the THC:CBD spray arm and -0.52 for the placebo arm.49 In this study, 
patients remained on their existing stable analgesia regardless of the treatment arm. Neither study reported 
the associated SDs, which were needed for the cost-effectiveness model. However, the studies did report 
the proportion of patients that responded to treatment, defined as a reduction in NRS pain score of ≥30%. 
Assuming mean changes in NRS pain scores to be distributed normally, the SDs were determined for both 
studies. This resulted in SDs for THC:CBD spray and SOC of 2.0 and 1.5 in the study of Langford et al. and 
1.0 and 1.5 in the Nurmikko et al. study, respectively.46,49 Using the mean treatment effects, estimated SDs 
and studies’ sample sizes, pooled estimates for the treatment effect were calculated, to be used in the base 
case analysis for neuropathic pain. The pooled estimates were -1.71 (SD=1.10) for the THC:CBD spray 
arm, and -1.17 (SD=1.5) for the SOC arm. 
The SR on the efficacy, effectiveness, and safety of medical cannabis identified one study in patients with 
musculoskeletal pain. Blake et al. reported median changes in NRS pain score of -2.2 and -1.2 for THC:CBD 
spray and placebo in patients with musculoskeletal pain.51 According to the authors, NRS pain scores were 
distributed nonparametrically, and median changes in NRS pain scores were reported rather than mean 
changes. In addition, the data provided by Blake et al. did not include the variation around the reported 
median treatment effect. Although the data from the Blake et al. study has several limitations, this study 
was the only study available for musculoskeletal pain and a significant (median) treatment effect of 
THC:CBD spray on morning pain at rest (on an NRS score) was reported. In absence of better-quality data, 
the study was nonetheless used to inform the cost-effectiveness model in musculoskeletal pain patients. 
Since the model required mean change in NRS pain score (and SD), the median value reported in Blake 
et al. was used as the mean value, ignoring the non-parametric distribution of change in NRS pain score in 
the trial. The SD was assumed 20% of the median change in NRS pain score. 
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The SR on the efficacy, effectiveness, and safety of medical cannabis identified two studies in (chronic) 
cancer pain patients. These studies provided an adjusted mean change in NRS pain score between 
THC:CBD spray and placebo as their main clinical outcome. However, as these studies did not report the 
mean changes in NRS pain score for each of the study arms separately (nor the associated SDs), we were 
unable to investigate cost-effectiveness of THC:CBD spray for cancer pain patients. 
To calculate the NRS pain scores of the simulated patients after the first cycle in both models, the simulated 
change in NRS pain scores was added to the beta distribution of baseline NRS pain scores. The number 
of patients achieving the treatment response criteria of ≥30% change in NRS pain score was determined 
to be 0.49 and 0.46 in the neuropathic pain model for the THC:CBD spray arm and SOC arm, respectively. 
The response rates in the musculoskeletal pain model were 0.86 and 0.17 for THC:CBD spray and SOC, 
respectively.  
If patients achieved the ≥30% change in NRS pain score criterion (i.e. responders), patients were assumed 
to retain the reduction in NRS pain score for patients’ model lifetime or until patients discontinued treatment. 
If patient did not achieve the response criterion (i.e. non-responders), patients’ NRS pain scores were as-
sumed to revert to baseline values for the remainder of the patients’ model lifetime.  
Mortality 
As there was no data on whether THC:CBD spray affects a patient’s mortality risk and THC:CBD spray was 
not expected to fundamentally modify the patient’s disease, mortality was assumed to be constant between 
both treatment arms. In line with Torrance et al., a standardised mortality ratio (SMR) of 1.32 (SD 0.08) was 
applied to Swiss population life tables published by mortality.org.72,73  
Utility inputs 
In the absence of usable Swiss utility estimates, health state utilities values were based on the study by Gu 
et al., which included adult patients with neuropathic pain from the United States of America (USA).74 Gu 
et al. estimated utility values using regression techniques (ordered logistic models and ordinary least 
squares) with the different NRS pain score, age, and gender as independent variables.74 The regression 
estimates and corresponding standard errors are reported in Table 24.  
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Table 24. Regression coefficients to determine utilities for chronic pain 
 Mean Lower CI Upper CI 
Constant 0.684 0.617 0.751 
NRS 0 0.000   
NRS 1 -0.005 -0.62 0.052 
NRS 2 -0.088 -0.143 -0.033 
NRS 3 -0.098 -0.151 -0.045 
NRS 4 -0.138 -0.191 -0.085 
NRS 5 -0.152 -0.205 -0.099 
NRS 6 -0.188 -0.239 -0.137 
NRS 7 -0.260 -0.313 -0.207 
NRS 8 -0.328 -0.381 -0.275 
NRS 9 -0.398 -0.461 -0.335 
NRS 10 -0.464 -0.525 -0.403 
Age 0.003 0.001 0.005 
Gender -0.034 -0.048 -0.020 
Keys: NRS = numeric rating scale, CI = confidence interval  
The simulated NRS pain scores were used to determine mean utility scores for responders and non-re-
sponders. In accordance with the NICE model, we assumed the NRS pain scores of chronic pain patients 
did not increase over time. However, using the age coefficient from the Gu et al. study the utility values did 
increase over time.74 Average utility values are presented in Table 25. 
Table 25. Mean utility values for responders and non-responders 




SOC responders SOC non-responders 
Neuropathic pain 0.755 0.598 0.759 0.605 
Musculoskeletal pain 0.803 0.689 0.807 0.720 
Keys: THC = tetrahydrocannabinol, CBD = cannabidiol, SOC = standard of care, THC = tetrahydrocannabinol, CBD = cannabidiol 
Cost and resource use inputs 
As presented in Appendix 15.5, the non-systematic literature search did not yield usable Swiss data on 
resource use in chronic pain. Resource use was therefore derived from literature sources from other coun-
tries, details are described in the next paragraphs. To obtain Swiss cost estimates, the resource use was 
multiplied with unit costs provided by the FOPH (Table 26).  
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Treatment costs THC:CBD spray 
A weighted pooled estimate of 9.79 daily doses of THC:CBD spray was used based on the Langford et al. 
and Nurmikko et al. studies.46,49 This resulted in a per cycle cost of 659 CHF in the neuropathic pain model. 
The musculoskeletal model used a mean daily dose of 5.4 THC:CBD sprays as reported in the Blake et al. 
study51, resulting in a per cycle cost of 363 CHF. 
Health state costs 
Resource use was calculated for different levels of pain in line with the modelled health states. As usable 
Swiss data on the resource use of chronic pain patients were not identified, the NICE committee’s resource 
use estimates were used in the model. The NICE committee estimated the number of community-based 
visits, outpatient clinic visits, accident & emergency (A&E) visits, hospital admissions and home care visits 
associated with the following pain scores: NRS 0-2, NRS 3-4, NRS 5-6, NRS 7-8, and NRS 9-10. The 
overall management cost for a patient in each 4-week cycle was equal to the weighted average of their pain 
distribution multiplied by the corresponding resource use costs. Table 26 provides an overview of the re-
source use and costs applied in the Swiss cost-effectiveness models. Costs of background medication (i.e. 
analgesics or anti-spasticity drugs) were not included in the model as THC:CBD spray was evaluated as 
an add-on therapy to SOC and hence no significant differences between the THC:CBD spray arm and the 
SOC arm were anticipated. Furthermore, medication costs only account for a small proportion of the total 
treatment costs and excluding medication costs was therefore expected to only have a minor influence on 
the cost-effectiveness results.   
Table 26. Unit costs, annual resource use per health state and associated costs per 4-week cycle 






A&E visits Hospitalisations 
Home care (per 
hour) 
 













hours (annual)  
Total cost per 4-
week cycle (CHF) 
NRS 0-2 0 0 0 0 0 0.00 
NRS 3-4 0 1 0 0 0 18.46 
NRS 5-6 0 2 1 0.5 0 264.31 
NRS 7-8 0 4 2 1 0 528.62 
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NRS 9-10 12 8 4 2 52 1’220.89 
Keys: NRS = numeric rating scale, A&E = accident & emergency, CHF = Swiss Franc  
Serious adverse events costs 
SAEs were assumed to be related to additional resource use. It was assumed that all patients experiencing 
an SAE would require an A&E visit, and 50% of patients require an ambulance transfer. Combined with 
Swiss unit costs, this resulted in an average cost of 1’245 CHF per SAE. 
9.1.4.3 Model input spasticity  
Treatment effectiveness 
Treatment response was defined as an NRS spasticity score reduction of ≥30%. The proportion of respond-
ers was derived from the literature for each subpopulation. For MS spasticity, the SR on efficacy, effective-
ness, and safety identified two studies that reported the proportion of responders based on this criterion. In 
one study, 40%  of patients treated with THC:CBD spray obtained a reduction in NRS spasticity score of 
≥30% or more, compared to 22% of patients treated with placebo.52 In the other study, 31% of patients on 
THC:CBD spray had a ≥30% reduction in NRS spasticity score, versus 25% of SOC patients.11 The pooled 
estimate of these two studies was used in the Swiss cost-effectiveness model for MS spasticity; base case 
values for response were 35% and 24% for THC:CBD spray arm SOC arm respectively. Both studies in-
vestigated the efficacy of THC:CBD spray in adults with advanced spasticity in MS who did not gain ade-
quate relief using current therapy. In scenario analyses, alternative response rates were used. 
For motor neuron disease spasticity, the SR on efficacy, effectiveness, and safety identified one study that 
reported the proportion of responders based on a ≥30% reduction in NRS spasticity score. In this study, 
21% of patients treated with THC:CBD spray obtained treatment response, compared to 13% treated with 
placebo.54 The study investigated the efficacy of THC:CBD spray in adults with spasticity due to motor 
neuron disease that was incompletely controlled by therapy.  
Patients that obtained response according to the ≥30% criterion could have a reduction in NRS spasticity 
score anywhere between 30% and 100%. The response level (i.e. relative reduction in NRS spasticity 
score) was therefore simulated using long-term follow-up data on MS patients of a large observational study 
in Italy (SA.FE study).70 All responders had a response of at least 30%. The proportion of patients reaching 
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higher response criteria diminished as the response criterion increased. This pattern is similar to a survival 
curve, in which 100% of patients have a survival of zero time and the proportion of patients decreased with 
increasing time. The analogy to survival analyses led to fitting a survival curve on the data to determine the 
treatment response level. For this purpose, the response levels were interpreted as survival time and ob-
servations were interpreted as an event. In line with the NICE model, the gamma curve was used to predict 
the level of response. Figure 5 provides a graphical presentation of the modelled response level, for MS 
patients that obtained at least a 30% reduction in NRS spasticity score. 
 
Mortality 
Patients diagnosed with MS and motor neuron disease experience a higher mortality risk than the general 
population. For MS, SMRs were applied to Swiss mortality rates from the general population to correct for 
increased mortality. Background mortality was based on the all-cause mortality rates derived from Swiss 
lifetables.73 The SMR for MS was obtained from a published meta-analysis.75 Since an SMR was unavail-
able for Switzerland specifically, the overall SMR was used, which was determined at a level of 2.81 (95% 
CI 2.74-2.87) and based on cohorts of mostly Northern Europe and Canada.  
For motor neuron disease, mortality data were retrieved from an Italian population-based study involving 
483 patients.76 Based on Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC), a 
lognormal model proved to best fit the survival data. The survival curve for motor neuron disease patients 
is provided in Figure 6. The SR on efficacy, effectiveness, and safety found no evidence for an impact of 
Figure 5. Response levels for responders (≥30% reduction in NRS spasticity score) 
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THC:CBD spray on survival, therefore the same mortality risk was applied for both the THC:CBD spray arm 
and the SoC arm. 
Utility inputs 
In the absence of usable Swiss utility estimates, health state utilities were based on a published regression 
model of the EQ-5D in MS patients in Sweden, with EDSS (Expanded Disability Status Scale) scores and 
NRS spasticity scores as independent variables.77 The mean EDSS score observed in the overall sample 
of the SA.FE study (i.e. 6.5) was used to estimate utility values for each NRS class.70 This approach was 
also adopted by NICE, as their expert committee judged that it was unlikely that THC:CBD spray would 
affect EDSS scores. The regression coefficients and corresponding standard errors are reported in Table 
27.  
Table 27. Regression coefficients to determine utilities for spasticity  
Parameter Coefficient Standard error 
Constant 0.9229 0.2551 
NRS -0.0505 0.0109 
EDSS 5 -0.0293 0.2779 
EDSS 5.5 -0.3417 0.3020 
EDSS 6 -0.1305 0.2532 
EDSS 6.5 -0.2521 0.2520 
EDSS 7 -0.3353 0.2656 
Figure 6. Survival for motor neuron disease patients 
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Keys: NRS = numeric rating scale, EDSS = Expanded Disability Status Scale 
To determine utility values for the responder and non-responder health state, NRS spasticity scores were 
simulated for both arms. The baseline NRS spasticity score for each health state was simulated by applying 
a beta distribution (n=10’000) on the baseline NRS spasticity scores in the SA.FE study (mean=7.5, 
SD=1.45).70 The resulting density plot of baseline NRS spasticity scores is presented in 15.8. 
 
For responders, these baseline NRS spasticity scores were combined with the simulated response levels 
(presented in Figure 5). In addition, for both responder and non-responder health states, NRS spasticity 
scores were assumed to progress over time. Progression in spasticity was calculated using data from a 
large registry, containing 35’000 patients, in which progression of several MS symptoms, including spastic-
ity, was quantified over a period of 30 years.78 Prevalence of symptoms as reported in the study was con-
sidered a proxy for severity, and was transformed into NRS spasticity scores. The calculated yearly pro-
gression in NRS spasticity scores was 0.07. In scenario analyses, alternative NRS progression rates were 
investigated. Due to the natural progression in both study arms, utilities decreased over time. Using the 
NRS spasticity scores for responders and non-responders, average utility values were estimated to be 0.39 
for responders and 0.24 for non-responders. 
For motor neuron disease, the same methodology was used, but the baseline values were based on aver-
age NRS spasticity scores obtained from a study with motor neuron disease patients (mean=5.7, SD=1.7, 
THC:CBD spray arm).54 As a result, utility values were estimated to be 0.48 for responders and 0.37 for 
non-responders.  
Cost and resource use inputs 
As presented in Appendix 15.5, the non-systematic literature search did not yield usable Swiss data on 
resource use in spasticity. Resource use was therefore derived from literature sources from other countries, 
details are described in the next paragraphs. To obtain Swiss cost estimates, the resource use was multi-
plied with unit costs provided by the FOPH (Table 28).  
 
EDSS 7.5 -0.5260 0.2673 
EDSS 8 -0.8124 0.2542 
EDSS 8.5 -0.9408 0.2849 
EDSS 9 -0.7648 0.2853 
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Treatment costs THC:CBD spray 
Treatment costs for THC:CBD spray were provided by FOPH and was equal to 0.89 CHF per milligram of 
THC (2.40 CHF per dose). Patients with MS were assumed to receive 6.3 doses per day70, resulting in a 
per 4-week cycle treatment costs of 423.89 CHF. Patients with motor neuron disease were assumed to 
receive 5.5 doses per day79 resulting in a per 4-week cycle costs of 370.06 CHF. 
Health state costs 
Background resource use was based on a study from the UK, in which health care specialists were asked 
to estimate health care consumption for various NRS classes.80 Reported levels of resource use was mul-
tiplied with Swiss specific unit costs to obtain health state costs per NRS class. The NICE committee argued 
that resource use reported by Stevenson et al. (2015) was not attributable fully to spasticity, but was likely 
to be attributable to other symptoms as well, due to the methodology used to relate costs to NRS spasticity 
levels. This argument was further substantiated by evidence from the literature. Health state costs were 
therefore attributed to spasticity for 50% in the base case analyses. This proportion was varied in scenario 
analyses. The adapted resource use cost estimates were combined with the simulated NRS spasticity lev-
els, similar to utilities. As with utilities, the natural progression of NRS spasticity affected health state costs; 
the increase in NRS spasticity scores over time resulted in an increase of health state costs over time. 
Average per 4-week cycle health state cost were estimated to be 935 CHF for responders and 2’714 CHF 
for non-responders. Table 28 provides the unit costs of the included cost categories and the cost estimates 
per NRS level. 
Table 28. Unit costs, annual resource use per health state and associated costs per 4-week cycle 






A&E visits Hospitalisations Home care 
(per hour) 
 
Unit cost 140.00 240.00 995.00 3920.00 64.75    










Total cost per 
4-week  cycle 
(CHF) 
0-2 0.04 0.28 0.01 0.00 0.00 6.27 
3-4 0.06 0.92 0.02 0.01 34.42 191.23 
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5-6 0.42 1.61 0.05 0.25 156.43 822.61 
7-8 4.00 1.83 0.08 0.11 342.59 1’817.49 
9-10 9.33 2.21 0.12 0.18 680.48 3’584.18 
Keys: NRS = numeric rating scale, A&E = accident & emergency, CHF = Swiss Franc  
The same methodology was used for motor neuron disease patients, assuming that the relation between 
NRS spasticity score and costs was equal in motor neuron disease and MS. However, since the baseline 
NRS spasticity score was different compared to MS patients, health state costs were different. Per 4-week 
cycle health state costs were estimated to be 343 CHF for responders and 1’242 CHF for non-responders.  
Adverse event costs 
SAEs were assumed to be related to additional resource use. It was assumed that all patients experiencing 
a SAE would require an A&E visit, 25% of patients require an ambulance transfer and 25% require an 
inpatient stay. Combined with Swiss unit costs, this resulted in a cost of 2’100 CHF per SAE. 
9.1.4.4 Analytical methods  
Base case analyses 
The base case analyses were conducted using the settings for the input parameters and assumptions as 
described in the previous sections. This implies that the Swiss cost-effectiveness models were run using a 
lifetime time horizon and discounting of costs and effects with a discount factor of 3% from the second year 
onwards. For each patient population subgroup a separate base case analysis was performed. To show 
the impact of changing the assumptions and parameter uncertainty on the cost-effectiveness results, sce-
nario and sensitivity analyses were run.  
Scenario analyses 
Several scenario analyses were performed to explore the impact of structural uncertainty on the cost-effec-
tiveness outcomes. In these analyses, key model assumptions were varied. An overview of the scenario 
analyses is provided in Table 29.  
Table 29. Description of base case and scenario analyses 
Parameter Base case analysis  Scenario analysis  
Time horizon Lifetime  5 years 
 10 years  
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 20 years  
 30 years 
 
Discount rate 3% discount rate for costs and out-
comes 
 No discounting 
 5% discount rate for costs and outcomes 
Effect estimates  Chronic pain (neuropathic pain): 
weighted pooled estimate based on 
Langford 201346 and Nurmikko 
200749. 
Spasticity (MS): pooled estimate 
from Collin 200752 and Collin 201011 
Spasticity (Motor neuron disease): 
Riva 201954 
 
Chronic pain (neuropathic): 
 estimate from Langford 201346 and Nur-
mikko 200749 separately.  
Spasticity (MS): 
 Collin 200752 only (THC:CBD spray: 40% 
vs SOC: 22%) 
 Collin 201011 only (THC:CBD spray: 31% 
vs SOC: 25%) 
 NICE estimate60 (THC:CBD spray: 28% 
vs SOC: 24%) 
Spasticity (Motor neuron disease): 
 MC response increased by 50% 
 SOC response increased by 50% 
Standard deviations effect esti-
mates (chronic pain model only) 
Chronic pain (neuropathic): pooled 
estimate of SDs provided by Lang-
ford 201346 and Nurmikko 200749. 
Chronic pain (neuropathic): alternative SD 
equal to 20% of the mean change in NRS 
pain score. 
Chronic pain (musculoskeletal): varied SD to 
10% and 50% of median change in NRS pain 
score. 
Adverse events Only serious adverse events No adverse events 
Natural progression (spasticity 
model only) 
Spasticity: 0.073 NRS spasticity 
score reduction per year 
Spasticity:  
 No natural progression 
 NICE estimates for natural progression 
(0.227 NRS spasticity score per year) 
Discontinuation of THC:CBD spray 
and standard of care 
Differential discontinuation: SOC 
only non-AE related discontinuation  
Equal discontinuation: AE-related and non-AE 
related discontinuation in both arms 
Proportion of costs attributable to 
spasticity (spasticity model only) 
50%  100% 
 25% 
Keys: MS = multiple sclerosis, SOC = standard of care, SD = standard deviation, NRS = numeric rating scale, AE = adverse event, 
THC = tetrahydrocannabinol, CBD = cannabidiol  
One-way sensitivity analyses 
Parameter values included in the cost-effectiveness model are typically surrounded with uncertainty. Un-
certainty of individual parameters was tested using one-way sensitivity analyses (OWSA); model parame-
ters were systematically and independently varied using plausible ranges based on 95% confidence inter-
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vals from appropriate distributions (also used in probabilistic sensitivity analysis) or a 20% increase/de-
crease of the parameter value used in the base case. Incremental costs and effects were recorded at the 
upper and lower limits to produce tornado diagrams. 
Probabilistic sensitivity analysis 
In probabilistic sensitivity analysis (PSA) the impact of parameter uncertainty on the incremental cost-ef-
fectiveness ratio was assessed. In this analysis, all parameters to which probability distributions were as-
signed were varied jointly. For this purpose, 1’000 model iterations were performed. Results were plotted 
on the cost-effectiveness plane (CE-plane). From these results, a cost-effectiveness acceptability curve 
(CEAC) was estimated. Table 30 and Table 31 provide the distributions, deterministic value and uncertainty 
surrounding the parameter values. Where standard errors were unknown, they were estimated as 20% of 
the mean. 






Uncertainty Alpha Beta Source 
Chronic pain input (general) 
Standardised mor-
tality ratio 
Normal 1.32 SD: 0.08   Torrance 200672 
SAE rate THC:CBD 
spray  
Beta 0.370  164 281 Wang 200824 
SAE rate SOC  Beta 0.250  60 179 Wang 200824 
SAE duration Gamma 3.0  25 0.12 Assumption 
SAE disutility Gamma 0.10  1.638 0.058 Assumption 
Utility constant Normal 6.84 SD: 0.034   Gu 201274 
Disutility NRS 1 Normal -0.005 SD: 0.029   Gu 201274 
Disutility NRS 2 Normal -0.088 SD: 0.028   Gu 201274 
Disutility NRS 3 Normal -0.098 SD: 0.027   Gu 201274 
Disutility NRS 4 Normal -0.138 SD: 0.027   Gu 201274 
Disutility NRS 5 Normal -0.152 SD: 0.027   Gu 201274 
Disutility NRS 6 Normal -0.188 Sd: 0.026   Gu 201274 
Disutility NRS 7 Normal -0.260 SD: 0.027   Gu 201274 
Disutility NRS 8 Normal -0.328 SD: 0.027   Gu 201274 
Disutility NRS 9 Normal -0.398 SD: 0.032   Gu 201274 
Disutility NRS 10 Normal -0.464 SD: 0.031   Gu 201274 
Disutility Gender Normal -0.034 SD: 0.007   Gu 201274 
 






Uncertainty Alpha Beta Source 
Background medi-
cal consumption 
Gamma   25 (Mean/5)^2/Mean Assumption 
Outpatient visit 
costs (CHF) 
Uniform 240 Range: 180-300   FOPH 
Emergency visit 
costs (CHF) 
Uniform 995    FOPH 
Hospitalisation per 
day costs (CHF 
Uniform 6’469 Range: 5’431-7’507   FOPH 
GP visit costs 
(CHF) 
Uniform 140 Range: 105-173   FOPH 
Home care per 
hour costs (CHF) 




Gamma 500  25 (Mean/5)^2/Mean Assumption 
Neuropathic pain specific input 
Patient age Normal 51.05 SD: 12.86   Pooled estimate Lang-
ford 201346, Nurmikko 
200749 
NRS baseline Beta 6.9 SD: 1.33 7.65 3.44 Pooled estimate Lang-




Normal -1.7158 SD: 1.1   Pooled estimate Lang-




Normal -1.16976 SD: 1.5   Pooled estimate Lang-
ford 201346, Nurmikko 
200749 
Number of doses 
THC:CBD spray 
Gamma 9.79  25 1/0.3916 Pooled estimate Lang-
ford 201346, Nurmikko 
200749 
Musculoskeletal pain specific input 
Patient age Normal 62.8 SD: 9.8   Blake 200651 
NRS baseline Beta 5.3 SD: mean/5 11.22 9.95 Blake 200651 
Treatment effect 
THC:CBD spray 
Normal -2.2 SD: mean/5   Blake 200651 
Treatment effect 
SOC 
Normal -1.2 SD: mean/5   Blake 200651 
Number doses 
THC:CBD spray 
Gamma 5.4  41.37 1/0.131 Blake 200651 
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Keys: SAE = serious adverse event, SOC = standard of care, GP = general practitioner, NRS = numeric rating scale, SE = standard 
error, SD= standard deviation, THC = tetrahydrocannabinol, CBD = cannabidiol 








Alpha Beta Source 
Spasticity input (general) 
SAE rate THC:CBD 
spray 
Beta 0.370  164 281 Wang 200824 
SAE rate SOC Beta 0.250  60 179 Wang 200824 
SAE duration Gamma 3.0  25 0.12 Assumption 
NRS coefficient utility Normal -0.0505 SE: 0.0109   Svensson 201477 
SAE disutility Gamma 0.10  1.638 0.058 Assumption 
Proportion of costs at-
tributable to spasticity 
Beta 0.50 SE: 0.1 12 12 Assumption 
Background medical 
consumption 
Gamma   25 Mean/5)^2/Mean Assumption 
Outpatient visit costs 
(CHF) 
Uniform 240 Range: 180-
300 
  FOPH 
Emergency visit costs 
(CHF) 
Uniform 995    FOPH 
Hospitalisation per day 
costs (CHF) 
Uniform 3’920 Range: 
3’216-5’032 
  FOPH 
GP visit costs (CHF) Uniform 140 Range: 105-
173 
  FOPH 
Home care per hour 
costs (CHF) 
Uniform 64.75 Range: 
52.60-76.90 
  FOPH 
Ambulance transporta-
tion costs (CHF) 
Gamma 500  25 (Mean/5)^2/Mean Assumption 
SAE – proportion pts 
ambulance 
Beta 0.25  75 224 Assumption 
SAE – proportion pts 
hospitalised 
Beta 0.25  75 224 Assumption 
Multiple sclerosis specific input 
Patient age Gamma 48.4 SE: 0.41 16’133 0.003 Collin 200752 & Collin 
201011 
NRS baseline Beta 7.5  5.93 1.98 Messina 201770 
Response THC:CBD 
spray  
Beta 40.0%  48 72 Pooled estimate Collin 
200752, Collin 201011 
Response SOC Beta 21.9%  14 50 Pooled estimate Collin 
200752, Collin 201011 
NRS progress Normal 0.073 SD: 0.121   Kister 201378 
 








Alpha Beta Source 
Standardised mortality 
ratio 
Normal 2.81 SD: 0.03   Manouchehrinia 201675 
Number of doses 
THC:CBD spray 
Gamma 6.3 SE: 0.115 3.150 0.002 Messina 201770 
Motor neuron disease specific input 
Patient age Gamma 58.0 SE: 1.97 865.672 0.067 Riva 201954 
NRS baseline Beta 5.7  4.26 3.22 Riva 201954 
Response THC:CBD 
spray 
Beta 20.7%  6 23 Riva 201954 
Response SOC Beta 13.3%  4 26 Riva 201954 
NRS progress Normal 0.073 SD: 0.121   Kister 201378 
Number of doses 
THC:CBD spray 
Gamma 5.5 SE: 0.769 50.926 0.108 Meyer 201979 
Keys: SAE = serious adverse event, SOC = standard of care, GP = general practitioner, NRS = numeric rating scale, SE = standard 
error, SD= standard deviation, THC = tetrahydrocannabinol, CBD = cannabidiol 
9.1.5 Methodology budget impact analysis   
The budget impact (BI) model allowed the calculation of the projected population-level five-year overall 
costs of reimbursing THC:CBD spray for the Swiss chronic pain population and for the moderate to severe 
spasticity population. The BI model was built as an extension to the Swiss cost-effectiveness model, which 
was described previously. Hence, the core model characteristics for the BI model were largely the same as 
those used for the cost-effectiveness model (i.e. one-month cycle time, 3% discounting, same transition 
probabilities, discontinuation rates, same resource use, and unit costs). The time horizon of the BI model 
was restricted to five years. The BI was restricted to treatment-resistant adults, i.e. adults were assumed to 
be eligible for THC:CBD spray when first-line treatment (and if applicable second or third line treatment) did 
not work sufficiently or stopped working.   
To perform the budget impact analyses, additional input was required (illustrated in Table 32). First, the 
current number of adults with treatment-resistant chronic pain or moderate to severe spasticity in the Swiss 
population was determined. Subsequently, these patient populations were differentiated for the different 
subpopulation groups according to the underlying cause of the chronic pain (i.e. cancer pain, neuropathic 
pain, musculoskeletal pain) or spasticity symptoms (i.e. MS, motor neuron disease). Finally, information 
was required on the expected proportion of the patient (sub)populations using THC:CBD spray over the 
course of the five-year time horizon of the BI model. To obtain the required input, a survey was constructed. 
Clinical experts were selected and contacted by FOPH and were invited to fill out the survey. The survey 
 
HTA Report 91 
responses were averaged and sent out to additional experts, who were asked to validate the retrieved 
values, or provide alternative estimates if deemed appropriate. The base case values were based on the 
combination of initial responses and responses from the validation procedure. In the base case, the average 
values of the clinical experts were used. All respondents were weighted equally. To reflect uncertainty 
around the input values of the budget impact estimates, sensitivity analyses were performed, in which min-
imum and maximum values of clinical expert input were used. 
Table 32. Input for the budget impact analysis 
Parameter Source 
Prevalence of treatment-resistant chronic pain and treatment-
resistant moderate to severe spasticity in adults 
Clinical expert opinion 
Distribution of subpopulations over the total chronic pain / spas-
ticity population  
Clinical expert opinion 
Proportion of the cohort of patients that are expected to be re-
ceiving THC:CBD spray (for the upcoming five years) 
Clinical expert opinion, assumption: equal demand for all sub-
populations 
Keys: THC = tetrahydrocannabinol, CBD = cannabidiol 
At each cycle, the BI model estimated the number of patients that were using THC:CBD spray. These 
population-level numbers were calculated from the specific input parameters of the BI model, informed by 
expert opinion as described above. Hereby the BI model could calculate the following results: 
1. The projected (cumulative) population level budget impact estimates for up to five years, which 
incorporate the total amount of cumulative costs from the cost-effectiveness model, as well as the 
estimated number of patients using THC:CBD spray, at each year.  
2. The difference between the budget impact estimate of a scenario where THC:CBD spray was to be 
reimbursed and the budget impact of the status quo, where THC:CBD spray is not generally reim-
bursed for patients with treatment-resistant chronic pain and moderate to severe spasticity. This dif-
ference reflects the projected increase in the overall budget spent on these patient populations in 
Switzerland, when THC:CBD spray would be reimbursed for (subgroups of) patients with treatment-
resistant chronic pain and treatment-resistant moderate to severe spasticity.  
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9.2 Results cost-effectiveness and budget impact 
9.2.1 Findings cost-effectiveness SR  
PRISMA flow diagram 
Chronic pain 
In total, 112 unique records were identified in PubMed (MEDLINE), Embase.com and NHS EED on the use 
of medical cannabis in chronic pain. Of those, 109 records were excluded based on their title and abstract, 
resulting in three studies to be screened in full-text. After applying the inclusion and exclusion criteria, one 
study was included. The other studies were no economic evaluations and where therefore excluded. Finally, 
one additional study was included after identification through a search on the website of HTA agencies, 
resulting in the inclusion of a total of two studies. A complete overview of the selected literature is enclosed 















n = 106 
Included study based on search 
on HTA websites n = 1 
Figure 7. PRISMA flowchart of the cost-effectiveness systematic literature search on the use 
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Full-text articles assessed for  
eligibility  
n = 3 
Excluded articles: n = 2 
- No economic evaluation n = 2 
Total included studies 
n = 2 
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Spasticity  
In total, 28 unique records were identified in PubMed (MEDLINE), Embase.com, and NHS EED on the use 
of medical cannabis in spasticity. Of those, 21 records were excluded based on their title and abstract, 
resulting in seven studies to be screened in full-text. After applying the inclusion and exclusion criteria, five 
economic evaluations were included. Two studies were excluded for the following reasons: wrong outcome 
(n=1) and conference abstract (n=1). Finally, one additional study was included after identification through 
a search on the website of HTA agencies, resulting in the inclusion of a total of six studies. A complete 
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n = 6 
Unique records  
after duplicates removal 
n = 28 
n = 873 
Records excluded based on 
title and abstract 
n = 21 
Full-text articles assessed for  
eligibility  
n = 7 
Excluded articles: n = 2 
- Wrong outcome n = 1 
- Conference abstract n = 1 
Total included studies 
n = 6 
Figure 9. PRISMA flowchart of the cost-effectiveness systematic literature search on the use 
of medical cannabis for the symptom spasticity 
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Study characteristics tables  
The characteristics from the studies included on the cost-effectiveness of medical cannabis use in popu-
lations with the chronic pain and spasticity are presented in Table 33 and Table 34 respectively. The find-
ings are described in more detail below.  
Chronic pain 
Two economic evaluations were included in the cost-effectiveness systematic literature search.81,82 The 
study and model characteristics are presented in Table 33. One study looked at adjunctive (smoked) can-
nabis versus standard of care (first-line, second-line if first-line failed, or third-line if first and second-line 
failed) in treatment-naïve patients with chronic neuropathic pain with mixed aetiology.81 The other study 
considered different medical cannabis products in addition to standard of care versus standard of care in 
people with chronic pain (all aetiologies) whose pain was not adequately controlled by conventional pain 
management.82  
One economic evaluation was conducted for the USA81 setting, and one was conducted for the UK.82 Both 
economic evaluations were cost-utility analyses (CUAs), expressing outcomes in QALYs. One economic 
evaluation used a decision tree81 and the other constructed a Markov model.82 The decision tree employed 
a one-year time horizon, and the Markov model considered a lifetime time horizon. The health states in the 
decision tree were moderate to severe pain, mild pain, or death. The Markov model used the following 
health states: on treatment and responder, on treatment non-responder, discontinued and responder, dis-
continued non-responder, or death. Treatment response was defined as achieving ≥30% reduction in the 
NRS pain score. Both studies were published in 2019.  
The ICERs were £24’474 for the UK model (lifetime horizon) and $48’594 for the USA model (1-year hori-
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Keys: CUA = cost utility analysis, USA = Unites States of America, QALY = quality-adjusted life year, SOC = standard of care, NHS 
= national health service, PSS = personal social services, NRS = numeric rating scale, ICER = incremental cost-effectiveness ratio, 
THC = tetrahydrocannabinol, CBD = cannabidiol 
Spasticity 
Six economic evaluations were included in the cost-effectiveness systematic literature search.82–87 The 
study and model characteristics are presented in Table 34. All studies compared THC:CBD spray in addition 
to standard of care to standard of care alone. The patient population in the models consisted of patients 
who had moderate to severe spasticity in MS and demonstrated a clinically significant improvement in 
spasticity-related symptoms during an initial trial of therapy lasting four weeks (according to the prescription 
requirement). The study design of all included studies was a CUA, expressing outcomes in QALYs. All 
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studies were model-based economic evaluations and adopted Markov models. Health states were based 
on the severity of the spasticity symptoms, but studies varied in the definition of the health states. In all but 
one study, patients could transition between health states that represent the level of severity, ranging from 
mild to severe in either three or five levels. In the other study, health states were defined as either respond-
ers (≥30% reduction in NRS spasticity score) or non-responders.  
Two of the studies were performed for the UK setting, one study for Wales, two studies for Germany, one 
for Italy, and one study was conducted for Spain. Five studies applied a 5-year time horizon, one study 
used a time horizon of 30 years. One of the studies was conducted by NICE.82 The most recent model-
based study was from 2019.82  
Among the models using a time horizon of 5 years, the ICERs ranged from £1’580 to £49’300. The incre-
mental QALYs ranged from 0.081 to 0.443 for the same time horizon, and incremental costs ranged from 
£1’580 to £7’600.  
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Keys: SOC = standard of care, NRS = numeric rating scale, NHS = national health service, PSS = personal social services, ICER = 
incremental cost-effectiveness ratio, QALY = quality-adjusted life year, THC = tetrahydrocannabinol, CBD = cannabidiol 
Input parameters 
Chronic pain 
An overview of the inputs reported in the included economic evaluations is displayed in Appendix 15.6. The 
economic evaluations used different sources for the efficacy data. NICE conducted an SR to identify model 
inputs (i.e. efficacy estimates, and adverse event parameters and costs).82 The study by Tyree et al. based 
the costs of standard therapy agents, health state utilities, and utility decrements due to adverse events on 
a study by Bellows et al..88 More detailed input parameters were presented, which were based on several 
other trials and/or cost-effectiveness analyses. Both economic evaluations included costs and diminished 
utilities related to adverse events. Neither of the studies included the potential effect of medical cannabis 
products on mortality or potential beneficial side-effects.  
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Spasticity 
An overview of the inputs reported in the included trial-based studies is displayed in Appendix 15.6. Five 
studies used efficacy data from the trial by Novotna et al..12 NICE conducted a SR to identify model input 
(i.e. efficacy, adverse event parameters and costs, and costs of background spasticity management per 
health state).82 All studies reported the intervention (in this case, Sativex®) and the comparator costs (in 
this case, standard of care). The studies differed in the resource use that was taken into account as part of 
the background costs of MS for both arms (e.g. anti-spasticity drugs, hospital visits, general practitioner 
visits, laboratory tests, home care, physiotherapy). The study by NICE 2019 was the only one to include 
the costs and disutilities related to adverse events. None of the studies included the potential effect of 
THC:CBD spray on mortality.  
Quality appraisal 
The results from the quality appraisal of the studies included on the cost-effectiveness of medical canna-
bis use in populations with chronic pain or spasticity are presented in Appendix 15.7. The economic eval-
uations that were included in the systematic literature search were assessed with the CHEC. The findings 
are described in more detail below.  
Chronic pain 
Overall, the study comparison was sufficiently described and the study design was appropriate for the 
stated objectives. Only the NICE model included a lifetime time horizon, which is generally the preferred 
option for economic evaluations.82 Both studies scored a 0.5 on item 5 (“Is the chosen time horizon appro-
priate in order to include relevant costs and consequences?”), as they did not apply the generally preferred 
societal perspective.  
The economic evaluations both included all relevant costs considering the perspective taken, although ad-
verse event costs were included as an aggregate as opposed to single specific adverse event costs.81,82 
The costs in the NICE model were based on the national tariff list.82 Tyree et al. 2019 based their costs on 
the cost inputs of several other studies.81 Both economic evaluations included costs and diminished utilities 
related to adverse events.  
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The economic evaluations included an incremental analysis of costs and outcomes, and costs and out-
comes were discounted to account for inflation. Sensitivity analyses were conducted to account for the 
uncertainty of model inputs. The study by Tyree et al. included analyses using alternate time horizons, 
alternate adverse event modifiers, and cannabis wastage.81 The NICE assessment included analyses using 
different treatment effects, discontinuation thresholds, QoL coefficients, dosing regimen, response values, 
and baseline pain scores amongst many more.82 The studies did not report on the ethical and distributional 
issues associated with the reimbursement of medical cannabis. 
Spasticity 
The economic evaluations that were included in the systematic literature search for economic evaluations 
were assessed with the CHEC. The studies were judged on whether the criteria were fulfilled (“1”), not 
fulfilled (“0”), or inconclusive (“0.5”). An overview of the preliminary critical quality appraisal is enclosed in 
Appendix 15.7.  
Among the study design items, all studies scored 0.5 on item 5 (“Is the chosen time horizon appropriate in 
order to include relevant costs and consequences?”) and 6 (“Is the actual perspective chosen appropri-
ate?”) as the generally preferred perspective (societal) and time horizon (lifetime) were not applied. 17,82–
85,87 In addition, two did not provide a clear description of the study population (e.g. mean age or age range, 
gender distribution).83,85 
Only in the NICE model, the effectiveness and cost related model inputs were based on a systematic liter-
ature search.82 In other studies, the effectiveness inputs were derived from one or two trials. Four studies 
based their resource use input on their own Delphi Panel or clinical opinion, one study used a literature 
source to obtain resource use input. All but one study used publicly available sources for obtaining unit 
costs. The other study derived unit costs from their own Delphi Panel. The study by NICE was the only one 
to include the costs and diminished utilities related to adverse events.82  
The included studies performed well regarding reporting and interpreting the results; all studies performed 
incremental analyses and their conclusions followed from the reported data. Further, almost all studies 
discounted both costs and effects and most studies subjected all important uncertain variables to sensitivity 
analyses. However, almost half of the studies did not discuss generalisability of the results and only one 
study discussed ethical and distributional issues. Furthermore, in four studies at least some of the authors 
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were sponsored by pharmaceutical companies. Also, the studies did not report on the ethical and distribu-
tional issues associated with the reimbursement of medical cannabis. 
9.2.2 Findings cost-effectiveness modelling  
This paragraph describes the results of the cost-effectiveness analyses performed with the cost-effective-
ness models developed for the symptoms chronic pain and spasticity.  
9.2.2.1 Findings chronic pain models 
Deterministic analysis 
Table 35 presents the total costs, life years and QALYs for the THC:CBD spray arm and the SOC arm in 
the chronic pain models for the neuropathic and musculoskeletal pain etiologies. In the base case analysis 
for neuropathic pain (lifetime time horizon, starting age 51), patients lived on average for another 19.5 (31.6 
undiscounted) years in both arms. THC:CBD spray resulted in a QALY loss of 0.020 at higher costs (50’883 
CHF). Therefore, THC:CBD spray in addition to SOC was dominated by SOC alone (i.e. less effective and 
more costly than SOC alone). In contrast to the findings of the SR on the efficacy of medical cannabis, 
THC:CBD resulted in slightly lower QALYs in the cost-effectiveness model. This was attributable to different 
factors, in particular the difference in (long-term) discontinuation rates between the two treatment arms 
(discontinuation due to adverse events was only assumed to occur in the THC:CBD arm) and a minimal 
difference in utility values between the two arms resulting from the underlying simulated NRS scores. The 
impact of these model assumptions on the ICER values were assessed in the scenario analyses. The 
Markov traces in Appendix 15.8 show the patient flows over time.  
For musculoskeletal pain, patients lived on average for another 15 (21 undiscounted) years in both groups 
in the base case analysis (lifetime time horizon, starting age 63 years). THC:CBD spray resulted in a QALY 
gain of 0.452 at higher costs (23’093 CHF) resulting in an ICER of 51’038 CHF per QALY. The Markov 





HTA Report 102 
Table 35. Base case cost-effectiveness results chronic pain (discounted) 
 






Neuropathic pain  
SOC 19.490 12.570  153’709   
THC:CBD spray + 
SOC 
19.490 12.550 -0.0205 204’593 50’883 Dominated 
Musculoskeletal pain 
SOC 15.008 11.012  66’663   
THC:CBD spray + 
SOC 
15.008 11.465 0.452 89’757 23’093 51’038 
Keys: SOC = standard of care, ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life year, THC = tetrahydrocan-
nabinol, CBD = cannabidiol 
Probabilistic sensitivity analyses 
The results of the PSA for the chronic pain models are presented in Table 36 and in the cost-effectiveness 
planes in Figure 10 and Figure 11. For neuropathic pain, the mean incremental costs and incremental 
QALYs were 82’471 CHF and -0.105, respectively. As a result, THC:CBD spray + SOC got dominated (i.e. 
less effective and more costly than SOC alone ). In the probabilistic sensitivity analyses the incremental 
QALYs were relatively similar compared to the deterministic analyses. In contrast, the incremental costs 
were higher compared to the deterministic results. For musculoskeletal pain, the mean incremental costs 
and incremental QALYs were 32’691 CHF and 0.27, respectively. This resulted in a much higher ICER 
compared to the deterministic ICER of 51’038 CHF per QALY. The probabilistic results for musculoskeletal 
pain show a higher ICER compared to the deterministic ICER.  
                                                     
 
 
5 * A QALY loss is counterintuitive based on the clinical efficacy, effectiveness and safety data presented in Chapter 8, however this 
can be explained through two main assumptions made for the neuropathic pain base case model. First, the pooled SD estimates were 
rather sizeable with 1.0 and 1.5 for THC:CBD spray and SOC, respectively. The difference in SD between the model arms, in con-
junction with the relatively small difference in treatment effects, causes the SOC arm to have a slightly lower NRS score on average 
compared to the THC:CBD spray arm, despite the fact that there are more responders in the latter arm. Second, patients in the 
THC:CBD spray arm could discontinue treatment due to a loss of effectiveness and due to adverse events. Whereas in the SOC arm 
of the model, patients could only discontinue due to the loss of treatment effectiveness. These two assumptions were tested in scenario 
analyses to show their impact on the model outcomes – see Table 36. 
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Table 36. Results probabilistic sensitivity analysis – chronic pain 
 









SOC 18.95 12.02  129’209   
THC:CBD spray 
+ SOC 




SOC 14.86 10.82  42’205   
THC:CBD spray 
+ SOC 
14.86 11.62 0.27 
69’574 32’691 
121’380 
Keys: SOC = standard of care, ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life year, THC = tetrahydrocan-
nabinol, CBD = cannabidiol. 
Figure 10 and Figure 11 present the incremental costs and incremental effects of the PSA in a cost-effec-
tiveness plane. Cost-effectiveness acceptability curves are presented in Appendix 15.10. The average 
probabilistic and deterministic values are indicated by the orange and green triangles, respectively. The 
results of the PSA for the neuropathic pain model shows that 46.8% of the iterations result in a positive 
incremental cost and incremental QALY, representing the north-east quadrant of the cost-effectiveness 
plane. Another 52.8% of the iterations resulted in positive incremental costs and negative incremental 
QALYs (dominated). A total of 0.3% of the iterations resulted in negative incremental costs and negative 
incremental QALYs.  
Approximately 79% of the PSA iterations for the musculoskeletal pain model resulted in positive incremental 
costs and incremental QALYs for THC:CBD spray in addition to SOC versus SOC alone, which represents 
the iterations in the north-eastern quadrant of the cost-effectiveness plane. None of the iterations resulted 
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Figure 10. Cost-effectiveness plane – neuropathic pain 
* Costs in CHF, average ICER displayed as a red triangle; deterministic ICER displayed as a green triangle.  
Figure 11. Cost-effectiveness plane – musculoskeletal pain 
 
* Costs in CHF, average ICER displayed as a red triangle; deterministic ICER displayed as a green triangle.  
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Scenario analyses 
Various scenario analyses were conducted to assess the impact of structural uncertainty on the incremental 
cost-effectiveness ratio. In the first scenario analyses, the trials included in the pooled estimate for neuro-
pathic pain were modelled separately using the treatment effects, patient characteristics (age, gender, NRS 
baseline score), and THC:CBD spray dosing reported in the individual trials. As a result, a small increase 
in the negative incremental QALYs and positive incremental costs was observed using the Langford et al.46 
input data, due to the smaller treatment effect compared to the base case analysis. The resulting ICER 
indicates that THC:CBD spray was still dominated by SOC (i.e. less effective and more costly than SOC 
alone). By using the input from Nurmikko et al.49, with a larger treatment effect compared to the base case 
analysis, the model showed a small positive incremental QALY, as well as a small increase in incremental 
costs, resulting in an ICER of 827’166 CHF per QALY.  
Table 37. Results scenario analyses chronic pain models 
Scenario description Incremental QALYs Incremental costs (CHF) ICER (CHF / QALY) 
Neuropathic pain 
Base case -0.020 50’883 Dominated 
Apply 0% discount rates -0.035 82’408 Dominated 
Apply 5% discount rates -0.015 39’422 Dominated 
Apply 5 year time horizon -0.001 12’297 Dominated 
Apply 10 year time horizon -0.006 22’392 Dominated 
Apply 20 year time horizon -0.014 37’424 Dominated 
Apply 30 year time horizon -0.018 46’575 Dominated 
Efficacy data from Langford et al. 
2013 
-0.193 68’260 Dominated 
Efficacy data from Nurmikko et al. 
2007 
0.066 32’617 493’583 
Change SD of TE  to 20% of TE 0.110 25’343 230’508 
Apply same discontinuation rates 
for SOC and THC:CBD spray 
arms 
0.101 44’250 439’990 
Exclude SAEs -0.020 50’029 Dominated 
Mean utility and cost values for re-
sponders & non-responders  
0.102 44’325 435’930 
Increased THC:CBD cost (1.57 
CHF per mg THC) 
-0.020 88’414 Dominated 
Musculoskeletal pain 
Base case 0.452 23’093 51’038 
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Apply 0% discount rates 0.638 32’672 51’175 
Apply 5% discount rates 0.374 19’027 50’938 
Apply 5 year time horizon 0.139 7’277 52’310 
Apply 10 year time horizon 0.249 12’833 51’514 
Apply 20 year time horizon 0.395 20’179 51’137 
Apply 30 year time horizon 0.448 22’877 51’046 
Change SD to 10% of median 0.365 28’569 78’333 
Change SD to 50% of median 0.436 22’290 51’124 
Apply same discontinuation rates 
for SOC and THC:CBD spray 
arms 
0.483 21’393 44’247 
Exclude SAEs 0.453 21’601 47’641 
Mean utility and cost values for re-
sponders & non-responders 
0.775 6’945 8’956 
Increased THC:CBD spray cost 
(1.52 CHF per mg THC) 
0.452 59’218 130’875 
Keys: ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life year, SOC = standard of care, SD = standard devia-
tion, TE = treatment effect, SAE = serious adverse event, THC = tetrahydrocannabinol, CBD = cannabidiol. Values represent 
rounded incremental QALYs, Costs and ICERs. 
In the base case, the discount rate for costs and effects was 3%. Scenario analyses were conducted using 
discounts rates of 0% and 5%, for both costs and effects, respectively. In general, using a 0% discount rate 
increased the incremental QALYs and incremental costs. Conversely, using 5% discounting both the incre-
mental QALYs and incremental costs decreased. Alternative discount rates did not change the ICERs for 
both the neuropathic and musculoskeletal pain models in a meaningful way.  
A lifetime time horizon was used in the base case analysis. To test the influence of the time horizon on the 
model output scenario analyses were conducted for time horizons of 5, 10, 20 and 30 years. Although both 
incremental QALYs and incremental costs decreased for the shorter time horizons, the ICERs were not 
impacted in a meaningful way.  
For the neuropathic pain model we tested the influence of using the treatment effect observed in the Lang-
ford et al. and Nurmikko et al. studies separately.46,49 Using the treatment effect from the Langford et al. 
study did not change the ICER in a meaningful way as THC:CBD spray was still dominated by SOC. The 
treatment effect observed in the Nurmikko et al. study did change the ICER from dominated to 493’583 
CHF per QALY.  
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In the base case, the SDs surrounding the treatment effect (for both THC:CBD spray and SOC) were de-
termined using the response rates from the clinical studies, because the studies used for the treatment 
effect of THC:CBD spray for neuropathic pain (Langford et al.46 and Nurmikko et al.49) and musculoskeletal 
pain (Blake et al.51) did not report SDs. The SDs were adjusted in scenario analyses. To test the assumption 
concerning SD, a scenario analysis was performed in which the SD was set equal to 20% of the pooled 
treatment effect for the neuropathic pain model. For THC:CBD spray this resulted in an SD of 0.34 (1.1 in 
base case) and of 0.23 (1.5 in base case) for SOC. The incremental QALYs increased and were positive 
for THC:CBD spray, while the incremental cost decreased. The ICER moved from SOC dominating 
THC:CBD spray to a positive ICER of 230’508 CHF per QALY in patients with neuropathic pain.  
In the musculoskeletal pain model, the SD of the treatment effect was assumed 20% of the median change 
in NRS pain score reported in Blake et al..51 In scenario analyses, SDs of 10% and 50% of the median 
change in NRS pain score were used. Using 10% of the median change in NRS pain score as input for the 
SD, incremental QALYs decreased and incremental costs increased. Consequently, the ICER increased to 
78’333 CHF per QALY. Using the 50% of the median change in NRS pain score as input for the SD instead, 
resulted in a smaller decrease in incremental QALYs and a larger increase in incremental costs, and an 
ICER of 51’124 CHF per QALY.  
In the base case analyses, differential discontinuation was used for the responders on THC:CBD spray in 
addition to SOC and responders on SOC alone: responders on THC:CBD spray in addition to SOC could 
discontinue because of lack of maintained response or because of adverse events, whereas responders 
on SOC alone were assumed to only discontinue because of lack of maintained response. When the same 
discontinuation rates were applied to both arms (i.e. SOC alone responders also discontinued due to ad-
verse events), more patients using SOC alone switched from responder state to the non-responder state. 
This health state is associated with higher utilities and lower costs. Due to this change in discontinuation in 
the neuropathic pain model the ICER moved from THC:CBD spray being dominated by SOC (i.e. less 
effective and more costly than SOC alone) to a positive ICER of 439’990 CHF per QALY. The same change 
in discontinuation resulted in a slightly lower ICER in the musculoskeletal pain model of 44’247 CHF per 
QALY.  
For the neuropathic pain model, not taking into account SAEs in the model did not change the results; 
because of the low prevalence and short duration of SAEs and limited associated disutilities and costs. For 
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this aetiology of chronic pain SOC remained dominant over THC:CBD spray. In contrast, for musculoskel-
etal pain a small decrease in incremental costs resulted in a lower ICER of 47’641 CHF per QALY.  
In the base case, separate utility values are calculated for THC:CBD spray responders and non-responders 
and SOC responders and non-responders using an underlying micro-simulation model. In a simple Markov 
model, responders and non-responders would be assigned a utility value regardless of the treatment arm. 
We tested the effect of this assumption in a scenario by calculating a mean utility value for responders and 
non-responders. For the neuropathic pain model, using a mean utility value for responders and non-re-
sponders resulted in ICER of 435’930 CHF per QALY. For the musculoskeletal pain model, the ICER was 
8’956 CHF per QALY. 
Last, a scenario analysis was performed to assess the impact of the cost of THC:CBD spray on the out-
comes of the models. In this analysis we increased the cost of THC:CBD spray from 0.89 CHF per mg THC 
to 1.57 CHF per mg THC, based on the cost of a pharmaceutical preparation which includes the same 
amount of THC and CBD. For the neuropathic pain model, this increased the incremental costs to 88’414 
CHF, however, this did not impact the ICER in a meaningful way as THC:CBD spray remained dominated 
by SOC. For the musculoskeletal pain model, the incremental costs increased to 59’218 CHF, which is 
more than double the base case value. As a result, the ICER increased to 130’875 CHF per QALY. 
One-way sensitivity analyses 
In one-way sensitivity analyses, uncertainty of individual parameters was assessed. For the neuropathic 
pain model only five parameters were able to change the ICERs in a relevant way. These parameters were 
the NRS baseline score, treatment effect of THC:CBD spray, treatment effect of SOC, the discontinuation 
shape parameter for THC:CBD spray, and the discontinuation rate parameter for SOC. For the other pa-
rameters, THC:CBD spray remained dominated by SOC for both the lower and upper limits of the one-way 
sensitivity analyses. In Appendix 15.11 15.11 separate tornado diagrams are presented for incremental 
QALYs and incremental costs. 
In Figure 12 the results of the one-way sensitivity analyses for the eight most influential parameters for 
musculoskeletal pain model are presented. The three most influential parameters on the ICER were the 
utility values attached to the NRS pain scores 2, 4, and 5. Using the lower limit, the ICER changed from 
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51’093 CHF per QALY (base case) to an ICER where THC:CBD spray was dominated by SOC. Further-
more, the treatment effects of both THC:CBD spray and SOC had a large impact on the ICERs. In Appendix 
15.11 tornado diagrams are presented for incremental QALYs and incremental costs separately.  
Figure 12. Tornado diagram ICERs – Musculoskeletal pain 
Keys: NRS = numeric rating scale, SOC = standard of care, MC = medical cannabis (THC:CBD spray)  
9.2.2.2 Findings spasticity models  
Deterministic analysis 
Table 38 presents the total costs, life years and QALYs for the THC:CBD spray arm and the SOC arm in 
the MS and motor neuron disease models. In the base case analysis for MS (lifetime time horizon, starting 
age 48.4), patients lived on average for another 27.9 years (undiscounted; discounted 18.0 years) in both 
arms. THC:CBD spray resulted in a QALY gain of 0.135 at an additional costs of 7’401 CHF. The associated 
cost-effectiveness ratio was 54’675 CHF per QALY gained. The Markov traces in Appendix 15.8 show the 
patient flows over time.  
For motor neuron disease, patients lived on average for another 4.5 years (undiscounted; discounted 4.0 
years) in both arms in the base case analysis (lifetime time horizon, starting age 58). THC:CBD spray in 
addition to SOC resulted in a QALY gain of 0.019 at an additional cost of 1’598 CHF. The associated ICER 
was 84’628 CHF per QALY gained. The Markov traces in Appendix 15.8 show the patient flows over time.  
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Table 38. Base case cost-effectiveness results spasticity (lifetime time horizon; 3% discounting) 
 
Life years Total QALYs Incremental 
QALYs 
Total costs (CHF) Incremental 
costs (CHF) 
ICER (CHF / 
QALY) 
Multiple sclerosis 
SOC 17.961 4.924  552’369   
THC:CBD 
spray + SOC 
17.961 5.059 0.135 559’770 7’401 54’675 
Motor neuron disease 
SOC 3.991 1.523  60’516   
THC:CBD 
spray + SOC 
3.991 1.542 0.019 62’114 1’598 84’628 
Keys: SOC = standard of care, ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life year, CHF = Swiss Franc 
Probabilistic sensitivity analysis 
The results of the PSA for the spasticity models are presented in Table 39 and in the cost-effectiveness 
planes and CEAC Figure 13 and Figure 14. For MS, the mean incremental costs were 11’910 CHF and 
incremental QALYs were 0.122, resulting in an ICER of 97’375 CHF per QALY. For motor neuron disease, 
mean incremental costs were 1’565 CHF and incremental QALYs were 0.018, resulting in an ICER of 
85;613 CHF per QALY. For MS, incremental QALYs were slightly lower and incremental costs were higher 
in the PSA compared to the deterministic analyses, leading in a higher ICER. For motor neuron disease, 
deterministic and probabilistic analyses yielded similar results. Deviations result from non-normal distribu-
tions of various parameters in the models. 
Table 39. Results probabilistic sensitivity analysis - spasticity 
 









SOC 17.970 5.269  515’326   
THC:CBD spray 
+ SOC 
17.970 5.391 0.122 
527’236 11’910 
97’375 
Motor neuron disease 
SOC 4.000 1.529  61’443   
THC:CBD spray 
+ SOC 
4.000 1.548 0.018 
63’009 1’565 
85’613 
Keys: SOC = standard of care, ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life year 
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Figure 13 and Figure 14 present the incremental costs and incremental effects of the PSA in a cost-effec-
tiveness planes for MS and motor neuron disease, respectively. Cost-effectiveness acceptability curves are 
presented in Appendix 15.10. The average probabilistic and deterministic values are indicated by the or-
ange and green triangles, respectively. The cost-effectiveness plane for MS spasticity shows that a large 
proportion of iterations (25%) resulted in positive incremental effects and cost savings, leading to dominant 
ICERs (southeast quadrant of the cost-effectiveness plane). On the other hand, 24% of iterations result in 
negative incremental effects and positive incremental costs, leading to a dominated ICER (northwest quad-
rant of the cost-effectiveness plane).  
 
* Costs in CHF, average ICER displayed as a red triangle; deterministic ICER displayed as a green triangle  
For motor neuron disease, 29% of iterations resulted in a dominant ICER. In contrast, THC:CBD spray in 
addition to SOC was dominated by SOC alone in 31% of iterations. At a threshold of zero, 29% of iterations 
yielded cost-effective results. With a threshold of 100’000 CHF per QALY, 52% of iterations were cost-
effective. 
Figure 13. Cost-effectiveness plane – MS spasticity 
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* Costs in CHF, average ICER displayed as a red triangle; deterministic ICER displayed as a green triangle.  
Scenario analyses 
Various scenario analyses were conducted to assess the impact of structural uncertainty on the incremental 
cost-effectiveness ratio. Table 40 presents the outcomes for the scenario analyses for the multiple sclerosis 
and motor neuron disease models.  
Table 40. Results scenario analyses spasticity models 
Scenario description Incremental QALYs Incremental costs (CHF) ICER (CHF/QALY) 
Multiple sclerosis 
Base case 0.135 7’401 54’675 
Apply 0% discount rates 0.209 11’536 55’129 
Apply 5% discount rates 0.107 5’829 54’339 
Apply 5 year time horizon 0.038 2’381 62’702 
Apply 10 year time horizon 0.068 3’990 58’913 
Apply 20 year time horizon 0.110 5’887 53’805 
Apply 30 year time horizon 0.130 6’866 52’836 
Efficacy data from Collin et al. 
2007 
0.280 -10’841 Dominant 
Figure 14. Cost-effectiveness plane – Motor neuron disease spasticity 
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Efficacy data from Collin et al. 
2010 
0.029 20’442 718’650 
Efficacy data from NICE  0.265 -17’962 Dominant 
Apply same discontinuation rates 
for SOC and THC:CBD spray 
arms 
0.228 -6’817 Dominant 
No spasticity progression 0.141 10’017 70’951 
NRS progression 0.227/year 0.081 15’498 191’303 
100% of resource use associated 
to spasticity 
0.135 -13’376 Dominant 
25% of resource use associated to 
spasticity 
0.135 17’789 131’421 
Exclude SAEs 0.136 6’168 45’408 
Increased MC cost (1.57 CHF per 
mg THC) 
0.135 27’988 206’768 
Motor neuron disease 
Base case 0.019 1’598 84’628 
Apply 0% discount rates 0.021 1’792 84’334 
Apply 5% discount rates 0.018 1’501 84’807 
Apply 5 year time horizon 0.014 1’319 92’534 
Apply 10 year time horizon 0.017 1’539 88’678 
Apply 20 year time horizon 0.019 1’602 85’966 
Apply 30 year time horizon 0.019 1’601 85’005 
Apply same discontinuation rates 
for SOC and THC:CBD spray 
arms 
0.027 767 28’212 
No spasticity progression 0.019 1’805 96’014 
Spasticity progression 0.227 NRS 
per year 
0.018 1’360 73’659 
100% of resource use associated 
to spasticity 
0.019 -248 Dominant 
25% of resource use associated to 
spasticity 
0.019 2’522 133’509 
Exclude SAEs 0.019 1’427 75’267 
Increased MC cost (1.57 CHF per 
mg THC) 
0.019 4’099 217’035 
Keys: ICER = incremental cost-effectiveness ratio, QALY = quality-adjusted life year, MC = medical cannabis, SOC = standard of 
care, SD = standard deviation, TE = treatment effect, SAE = serious adverse event. Values represent rounded incremental QALYs, 
Costs and ICERs. 
In the first scenario analyses, the discount rates were changed. In the base case, the discount rate for costs 
and effects was 3%.In scenario analyses discounts rates of 0% and 5% were applied, for both costs and 
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effects. For both MS and motor neuron disease, when a discount rate of 0% was used (no discounting) 
both incremental QALYs and costs savings increased, and incremental QALYs and costs savings de-
creased with a discount rate of 5%. The effect on the ICER was limited, since the same discount rate was 
applied in both arms. 
A lifetime time horizon was used in the base case analysis. For MS, shorter time horizons resulted in lower 
incremental QALYs and incremental costs. Shorter time horizons ignore differences in QALYs and costs 
that occur in later model cycles. Using a 5-year time horizon increased the ICER to 62’702 CHF per QALY; 
a 15% increase compared to the lifetime horizon used in the base case.  
For motor neuron disease, shorter time horizons (i.e. 5 years, 10 years, 20 years, 30 years) resulted in a 
slight reduction in the number of QALYs gained and incremental costs. The impact on the ICER was mod-
est. Effects of alternative time horizons was limited, because costs and effects incurred during the first years 
of the model were incorporated. Due to the high mortality rates, the effects of taking a shorter time horizon 
were modest, as most patients have died within the first years of the model.  
In the base case analyses for MS, response rates from Collin et al. 200752 and Collin et al. 201011 were 
pooled to obtain one overall estimate. In scenario analyses, different response rates were used. Using the 
response rates reported by Collin et al. (2007)52 only, resulted in larger QALY gains and cost savings (-
10’841 CHF). This was due to the larger difference in response rates, compared to the base case. In this 
scenario, THC:CBD spray in addition to SOC was dominant (larger effects, lower costs) over SOC alone. 
Alternatively, using only the response rates from Collin et al. (2010)11, incremental QALYs decreased to 
0.029 and incremental costs increased to 20’442 CHF. This resulted in an ICER of 718’650 CHF per QALY. 
The ICER increased because differences in response rates in the Collin et al. (2010)11 study were smaller 
than in the base case. Finally, when using the response rates used in the NICE submission82, incremental 
QALYs increased and incremental costs were negative (-17’962 CHF). The associated ICER was dominant.  
In the base case analyses, differential discontinuation was used for the responders on THC:CBD spray in 
addition to SOC and responders on SOC alone: responders on THC:CBD spray in addition to SOC could 
discontinue because of lack of maintained response or because of adverse events, whereas responders 
on SOC alone were assumed to only discontinue because of lack of maintained response. When the same 
discontinuation rates were applied to both arms (i.e. SOC alone responders also discontinued due to ad-
verse events), more patients using SOC alone switched from responder state to the non-responder state, 
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which is associated with lower utilities and higher costs. For MS, incremental QALYs increased to 0.228 
and incremental cost decreased to -6’817 CHF. THC:CBD spray in addition to SOC was dominant over 
SOC alone. For motor neuron disease, incremental QALYs increased to 0.027 and incremental cost de-
creased to 767 CHF, leading to a reduced ICER of 28’212 CHF per QALY. 
NRS spasticity score was assumed to progress over time due to natural disease progression in both treat-
ment arms. In the base case analyses, deterioration of 0.073 NRS points per year was used. In the NICE 
dossier submission, a much higher NRS spasticity progression was used (i.e. 0.227 points per year). With 
a lifetime time horizon used in the base case, this resulted in all patients eventually ending up in the most 
severe NRS spasticity score, which was not considered realistic. Nonetheless, the value used in the NICE 
submission82 was tested in the scenario analysis. Using a higher NRS spasticity progression rate particu-
larly impacted results. Incremental QALYs decreased to 0.081 and incremental costs more than doubled 
compared to the base case. The ICER increased to 191’303 CHF per QALY.  
For motor neuron disease, natural progression of spasticity was assumed equal to the progression mod-
elled in MS (i.e. 0.073 NRS points per year). Changing NRS progression only had a modest impact on the 
outcomes. Due to the high mortality in the motor neuron disease population, only a minority of patients 
progressed to more severe NRS spasticity states, limiting the impact on both incremental QALYs and costs. 
Health state costs were calculated from resource use as identified by Stevenson et al. (2015)80 multiplied 
by unit costs. In the base case analyses, 50% of resource use was assumed to be related to spasticity. 
Attributing more resource use to spasticity increased health state costs. As resource use costs were more 
than linearly related to NRS spasticity states, this particularly affected the SOC arm, in which NRS spasticity 
scores were higher. When resource use was assumed to be fully associated with spasticity in MS, incre-
mental costs were negative (-13’376 CHF). In this scenario, THC:CBD spray in addition to SOC was dom-
inant over SOC alone. The scenario which assumed that only 25% of resource use was attributed to spas-
ticity resulted in incremental costs of 17’789 CHF. The ICER increased to 131’421 CHF per QALY. 
The same pattern was observed in motor neuron disease. THC:CBD spray in addition to SOC resulted in 
costs savings of 248 CHF when all resource use costs were attributed to spasticity, resulting in dominance 
of THC:CBD spray in addition to SOC over SOC alone. When only 25% of resource was attributed to 
spasticity, incremental costs were 2’522 CHF, leading to an ICER of 133’509 CHF per QALY. 
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For both MS spasticity and motor neuron disease spasticity, not taking into account SAEs in the model 
resulted in lower incremental costs. Incremental QALYs were virtually unaffected because of the low prev-
alence and short duration of SAEs, and limited associated disutilities. In this scenario, the ICERs decreased 
to 45’408 CHF per QALY for MS and 75’267 CHF per QALY for motor neuron disease spasticity. 
Last, a scenario analysis was performed to assess the impact of the cost of THC:CBD spray on the out-
comes of the models. In this analysis we increased the cost of THC:CBD spray from 0.89 CHF per mg THC 
to 1.57 CHF per mg THC, based on the cost of a pharmaceutical preparation which includes the same 
amount of THC and CBD. For the MS spasticity model, this increased the incremental costs to 27’988 CHF 
and the ICER to 206’768 CHF per QALY. For the motor neuron disease model, the incremental costs 
increased to 4’099 CHF, and the ICER to 217’035 CHF per QALY. 
One-way sensitivity analyses 
In one-way sensitivity analyses, uncertainty of individual parameters was assessed. In Figure 15, the results 
of the one-way sensitivity analyses for the eight most influential parameters for the MS spasticity are pre-
sented. The response rates of THC:CBD spray and SOC were the most influential parameters for both 
incremental QALYs and incremental costs. In addition, the utility decrement per NRS spasticity state and 
the natural progression rate of NRS spasticity had an important impact on incremental QALYs. The amount 
of homecare patients received in the highest NRS spasticity states and the proportion of costs attributed to 
spasticity were major influencers of incremental costs. 
Figure 15. Tornado diagram ICERs – Multiple sclerosis 
Keys: NRS = numeric rating scale, MC = medical cannabis (THC:CBD spray)  
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In Figure 16 the results of the one-way sensitivity analyses for the eight most influential parameters for 
motor neuron disease spasticity are presented. Treatment response rates were the parameters with the 
most impact on both incremental QALYs and incremental costs. Furthermore, the baseline NRS spasticity 
score and the utility decrement per NRS spasticity state had a large impact on incremental  QALYs. The 
baseline NRS spasticity score and the dosage of THC:CBD spray were important variables with regards to 
incremental costs. 
Figure 16. Tornado diagram ICERs – Motor neuron disease 
 
Keys: NRS = numeric rating scale, MC = medical cannabis (THC:CBD spray)  
9.2.3 Findings budget impact analysis 
In the budget impact analysis, a situation in which THC:CBD spray is reimbursed is compared to the current 
situation for the years 2022 – 2026. The budget impact analysis was informed by data provided by Swiss 
experts, on eligible patients and uptake of THC:CBD spray. Data on the projected number of patients with 
chronic pain and spasticity were provided by three experts, and data on distribution over subpopulations 
were provided by five (chronic pain) and three (spasticity) experts. Data on uptake in chronic pain were 
provided by five experts, and data on uptake in spasticity were provided by four experts. 
Table 41 presents the estimated number of patients projected to use THC:CBD spray in the period 2022-
2026. Due to increasing uptake of THC:CBD spray, the number of users was expected to increase over 
time. In 2026, over 17’000 patients with chronic pain were expected to use THC:CBD spray if it were to be 
available on the Swiss market. In addition, over 3’000 patients with spasticity were expected to use 
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THC:CBD spray if reimbursed. The patient numbers reported indicate the total number of patients that 
initiated THC:CBD spray use, and thus comprise incidence and prevalence of THC:CBD spray users. For 
the proportion of patients who discontinue treatment and background medical costs, the cost-effectiveness 
model inputs were used.  
Table 41. Estimated number of patients to use THC:CBD spray in years 2022 through 2026 
 2022 2023 2024 2025 2026 
Chronic pain 
Neuropathic pain 3’056 3’849 4’642 6’012 7’093 
Musculoskeletal pain 4’428 5’577 6’726 8’711 10’277 
Spasticity 
Multiple sclerosis 1’564 1’831 2’098 2’293 2’560 
Motor neuron disease 304 356 408 446 498 
All parameter values, including costs of THC:CBD spray treatment, health state costs, discontinuation and 
mortality, were derived from the cost-effectiveness model. Patients who discontinued THC:CBD spray treat-
ment, regardless of underlying reason (i.e. death, reduced effectiveness, adverse events), did no longer 
incur costs of THC:CBD spray from the moment of discontinuation. A 3% discount rate was applied. Table 
42 provides the estimated spending on for the THC:CBD spray arm of the model. These costs included 
costs of THC:CBD spray treatment and background medical costs. The proportion of costs associated to 
THC:CBD spray differed between the subpopulations and changed over the years (neuropathic pain: 
24.8%-28.4%; musculoskeletal pain: 53.6%-58.1%; MS spasticity: 6.2%-7.6%; and motor neuron disease 
spasticity: 4.3%-6.4%). Background medical costs thus comprised the majority (neuropathic pain, MS spas-
ticity and motor neuron disease spasticity) or a considerable proportion (musculoskeletal pain) of total costs. 
The majority of these background costs will also be incurred in the scenario without THC:CBD spray.  
Table 42. Estimated total costs of THC:CBD spray use, including background medical costs (in CHF) 
 2022 2023 2024 2025 2026 
Chronic pain 
Neuropathic pain 31’841’461 37’921’329 43’391’721 53’763’994 60’430’582 
Musculoskeletal pain 26’416’703 31’065’155 35’406’819 43’774’794 48’981’362 
Spasticity 
Multiple sclerosis 103’618’160 129’554’567 153’851’817 194’802’660 225’266’478 
Motor neuron disease 4’028’515 3’965’707 3’662’194 3’236’151 3’071’366 
 
HTA Report 119 
The results of the budget impact analysis are presented in Table 43. The budget impact for THC:CBD spray 
in neuropathic pain patients was estimated to be 8.6 million CHF in 2022, increasing to 15.2 million CHF in 
2026. The budget impact for musculoskeletal pain patients increased from 8.3 million CHF in 2022 to 12.9 
million CHF in 2026. The rising budget impact was caused by the increasing number of users.  
For spasticity patients with MS, the budget impact in 2022 was estimated to be 2.8 million, and was esti-
mated to increase to 4.5 million CHF in 2026. The budget impact for patients with motor neuron disease is 
expected to be 0.2 million CHF in 2022 and 0.1 million CHF in 2026. The budget impact for patients with 
spasticity due to motor neuron disease is estimated to decrease over time despite increasing numbers of 
patients, due to discontinuation and to limited life expectancy in this patient population. 
Table 43. Estimated budget impact of THC:CBD spray in addition to SOC compared to SOC alone 
(in CHF) 
 2022 2023 2024 2025 2026 
Chronic pain 
Neuropathic pain 8’594’223 9’575’058 10’914’803 13’600’193 15’183’981 
Musculoskeletal pain 8’253’084 8’231’119 9’338’521 11’722’143 12’888’973 
Spasticity 
Multiple sclerosis 2’816’269 2’857’710 3’258’035 4’084’013 4’526’129 
Motor neuron disease 173’572 118’900 106’713 89’728 86’231 
The budget impact estimates were informed by data retrieved from a limited number of respondents. This 
resulted in highly uncertain outcomes of this budget impact analyses. Uncertainty existed around both the 
number of eligible patients and the projected uptake of THC:CBD spray. To assess this uncertainty, input 
data were varied in scenario analyses, using minimum and maximum values provided by experts (Table 
44). Using the minimum values, projected budget impact of reimbursing THC:CBD spray decreased con-
siderably, with reductions in 2026 between 91% (motor neuron disease) and 98% (musculoskeletal pain) 
compared to mean values. Using maximum values, the projected budget impact would be much larger 
compared to mean values, with increases of 122% (motor neuron disease) to 496% (neuropathic pain).  
Table 44. Minimum and maximum estimated budget impact of THC:CBD spray in addition to SOC 
compared to SOC alone (in CHF) 




516’694 445’519 417’640 391’627 366’994 
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Maximum BI neuro-
pathic pain 
53’145’647 58’724’240 66’603’527 85’824’579 90’420’809 
Minimum BI musculo-
skeletal pain 
489’209 364’686 342’061 318’884 296’715 
Maximum BI musculo-
skeletal pain 
36’126’197 35’699’164 40’309’567 52’555’867 53’926’437 
Spasticity 
Minimum BI multiple 
sclerosis 
166’937 127’346 120’224 112’202 105’934 
Maximum BI multiple 
sclerosis 
12’327’646 12’396’132 14’065’632 18’297’360 18’967’280 
Minimum BI motor 
neuron disease 
39’941 20’751 14’705 10’311 7’351 
Maximum BI motor 
neuron disease 
380’393 289’953 277’651 222’276 191’703 
Keys: BI = budget impact  
9.3 Summary statement cost-effectiveness and budget impact 
 
The systematic literature search on the cost-effectiveness of medical cannabis use in chronic pain 
and spasticity did not provide evidence for Switzerland. Therefore, cost-effectiveness models were 
developed, characterising the natural history of the disease in a patient’s lifetime in Swiss clinical 
practice. The models were used to determine the cost-effectiveness of medical cannabis in addition 
to standard of care (SOC) to SOC alone for all subpopulations for which usable efficacy evidence 
was available. The absolute change in numeric rating scale (NRS) score was the preferred efficacy 
outcome measure in chronic pain models, and the proportion of responders at ≥30% reduction in 
NRS score was the preferred efficacy outcome in spasticity models. Usable efficacy evidence for 
cost-effectiveness modelling was available for two chronic pain populations (neuropathic pain and 
musculoskeletal pain) and two spasticity populations (MS and motor neuron disease). These stud-
ies reported the efficacy of THC:CBD spray (Sativex®). No usable efficacy data were available for 
modelling the cost-effectiveness of medical cannabis in cancer pain.  
Separate, although similar, cost-effectiveness models were developed for chronic pain and spas-
ticity. Two chronic pain populations (neuropathic pain and musculoskeletal pain) and two spasticity 
populations (MS and motor neuron disease) were modelled separately. A systematic review was 
conducted to identify Swiss cost and utility data, however, neither were identified. Instead, expert 
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opinion and public databases were used to derive Swiss cost inputs. In three models, the effects of 
THC:CBD spray in addition to SOC compared to SOC alone were modest. In the neuropathic pain 
model, a small negative effect was found. This negative effect can be explained through two model 
assumptions concerning the SDs of the treatment effects and the discontinuation of treatment due 
to adverse events. Furthermore, THC:CBD spray in addition to SOC was associated with increased 
costs compared to SOC alone in all four models. Incremental cost-effectiveness ratios were 51’038 
CHF per QALY for musculoskeletal pain, 54’675 CHF per QALY for spasticity in MS, 84’628 CHF per 
QALY for motor neuron disease. For neuropathic pain, THC:CBD spray was dominated (i.e. less 
effective and more costly than SOC alone) due to the small QALY loss. In general, these findings 
(i.e. modest effects at increased costs) were in concordance with findings from the cost-effective-
ness systematic literature search.  
Uncertainty in the models was assessed in scenario analyses, one-way sensitivity analyses, and 
probabilistic sensitivity analyses. Treatment effects, utility values, and NRS baseline scores were 
important parameters in the cost-effectiveness models. If THC:CBD spray was to be reimbursed, it 
would be associated with a considerable budget impact for the chronic pain population. For spas-
ticity, the budget impact would be relatively modest. Budget impact estimates were prone to con-
siderable uncertainty. The generalisability of the cost-effectiveness and budget impact estimates 
to other populations, other medical cannabis products or other routes of administration is un-
known. 
 
10 Legal, social, ethical, and organisational issues 
10.1 Methodology legal, social, ethical, and organisational issues 
To address the legal, social, ethical, and organisational aspects of medical cannabis in the treatment of 
chronic pain and spasticity, a grey literature search was conducted. The search was aimed at identifying 
clinical guidelines and HTA documents by health authorities on the topic of medical cannabis in at least one 
of the symptoms of interest for this HTA report (i.e. chronic pain and spasticity). Websites of HTA agencies 
were searched for potentially relevant web-pages and documents, using the websites’ database or search 
bar using combinations of keywords relating to the intervention (cannabis, marijuana, cannabinoids, can-
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nabidiol, nabiximols, dronabinol, tetrahydrocannabinol, nabilone, THC:CBD spray, THC, CBD, Sativex, Ep-
idiolex, Cesamet, Marinol). Websites that did not have a database or search bar were  searched manually. 
Reference lists of the included documents were checked to find any other clinical guidelines or HTA docu-
ments that were not captured with our web search. Documents identified during the targeted web search 
were included for data extraction if they met the eligibility criteria as described in Table 45. PRISMA flow 
charts are not provided given the non-systematic nature of the grey literature search. Each included report 
was screened for information on legal, social, ethical, and organisational issues or consequences regarding 
the prescription and reimbursement of medical cannabis. The EUnetHTA Core Model was used to concep-
tualise the four HTA domains, i.e. the description and questions provided in the EUnetHTA Core Model 
were used as framework for the screening of documents. The results of the literature searches were sum-
marised using narrative synthesis.  
Table 45. Inclusion and exclusion criteria applied during the grey literature search 
Inclusion 
Published by a government or non-governmental organisations (NGO) at either the regional, national or international level 
Available in English, Dutch, German, or French 
Evidence-based clinical guideline or HTA document on medical cannabis in at least one of the following symptoms: chronic 
pain, spasticity 
Exclusion 
Document was a draft or summary version or has been replaced with another document  
Newsletters, news releases, or memoranda 
10.2 Results legal, social, ethical, and organisational issues 
Reports from 13 different institutes in Europe, Australia, Canada, and the USA were found with the grey 
literature search. A total of 16 documents were included. Seven reports covered a range of symptoms or 
diagnoses for which medical cannabis can be prescribed, whereas eight reports focused on a specific indi-
cation of medical cannabis. Medical cannabis use in chronic pain was addressed in 10 documents and 13 
documents evaluated medical cannabis use in spasticity (Appendix 15.10). All included reports were pub-
lished between 2016 and 2019. The findings on legal, social, ethical and organisational issues are de-
scribed below. However, the issues identified in the documents were not specific to pain or spasticity pop-
ulations, nor were they specific for THC:CBD spray. Hence, the results should be interpreted as general 
issues that may need to be considered when allowing the use of cannabis for medical purposes. The rele-
vance of each issue may differ depending on the medical cannabis products and/or patient population 
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concerned. Furthermore, while the issues may provide valuable input beyond its original place of origin, it 
should be noted that issues can be specific to a particular context (i.e. law, culture, healthcare system, 
epidemiology) and transferability may be limited in these cases.  
10.2.1 Findings legal issues  
According to the EUnetHTA Core Model, the objective of the legal domain is to identify rules and regulations 
that need to be considered when evaluating the healthcare technology.40 This information should provide 
insight into the areas of healthcare legislation in need of harmonisation, and delivers tools for legislative 
and policy reforms. As the Swiss medical cannabis legislation is currently being reviewed, the legal analysis 
will be targeted at identifying general legal barriers to reimbursing medical cannabis that are not specific to 
the Swiss context.  
Four documents discussed legal issues or provided information on regulatory regimes in place to allow the 
use of medical cannabis in various countries. In July 2018, the FOPH announced its intention to broaden 
access to medical cannabis, and a new law was proposed in 2019.89 Laws that may need to be considered 
when broadening patient access include laws on drugs and psychoactive substances, as well as regulations 
on quality control and marketing.  
Drug laws 
In general, national drug laws are in place to ensure that patients have access to high-quality, safe and 
effective medicines. As medical cannabis contains substances that may produce psychoactive effects, ad-
ditional restrictions may apply under laws such as Controlled Substances Act (USA)15, Opioid act (the Neth-
erlands), or Misuse of Drugs act (Ireland).90 If a country considers to permit the use of cannabis for medic-
inal purposes, such regulations need to be taken into account as these may affect the import, production, 
supply and possession of medical cannabis. The legal framework for allowing medical cannabis differs 
across countries, as can be observed from the overviews of regulatory regimes documented in the 
EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) report and the HPRA (Health Prod-
ucts Regulatory Authority, Ireland) reports on medical cannabis.89,90 Some countries restrict the products 
that can be used to pharmaceutical-quality cannabinoids or standardised plant extracts89 which may be 
supplied through the regulated pharmacy system. Other countries initiated government-run programs to 
supply quality-controlled cannabis91, and/or allow patients to grow their own cannabis. In many cases, 
growing, processing and supply of medical cannabis are controlled and operated under government tenders 
supervised by the Health Ministry.90 The HPRA recommends that one should be careful with circumventing 
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the medicines regulatory system in order to prevent unintended consequences and lower standards of 
patient protection. 
In Chapter 5, an outline is provided of different European countries which allow or consider allowing can-
nabis to be used for medical purposes. Information on the consequences of the various regimes on patients 
access to medical cannabis is described under the domain social issues.  
Quality control of medical cannabis products 
Regulations are required to ensure that the medical cannabis products supplied are of standardised quality. 
Questions that arise when cannabis is to be prescribed for medicinal purposes include what type of quality 
standards should be applied, if cannabis may be grown at home, for which products quality standards will 
be applicable and how these will be put into effect. Some countries restrict the cannabis products that can 
be used to pharmaceutical-quality cannabinoids or standardised plant extracts.89 For these products, the 
APPG (All-Party Parliamentary Group, UK) advices that as a minimum requirement the proportion and 
dosage of CBD and THC should be clearly labelled, so that the prescriber can easily determine these 
doses.22 Additional requirements that may be considered for medical cannabis products are listing any other 
minor cannabinoids and terpenes and presenting a Certificate of Analysis.  
Marketing 
Over the past few years, various cannabis-based products (i.e. tea, oils, gum, lotions) have been brought 
on the market.89 As these products contain a very low level of THC (i.e. below the legal minimum level), 
they are not restricted under national drug laws as they would have little or no psychoactive effect. Rather, 
these products may claim to have a high level of CBD, which is not controlled under drug law in most 
countries. The suggestion may however be made that these low-THC / high-CBD products would be ben-
eficial for treating a wide range of illnesses or symptoms for which there is currently insufficient evidence 
to make proper assessments. For example, marketing of these products could contain non-specific words 
or phrases, such as ‘health and well-being’, ‘wellness’, or ‘nutraceuticals’. More substantial claims, i.e. that 
the product prevents or treats disease or relieves symptoms, would bring these products under medicines 
law and a license for sale would then be required.89 It should be clear to consumers that these products, 
which are readily available in a wide range of shops22, have not been assessed for use for medical pur-
poses. Food safety and other regulations may be required to regulate these products to ensure that they 
contain what it is claimed.89 Advertising of unlicensed products can be prohibited. 
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10.2.2 Findings social issues 
The EUnetHTA Core Model describes the social domain as involving issues relevant to the receivers of the 
healthcare technology and their caregivers (patient aspect) as well as issues related to broader social 
groups such as elderly, ethnic minorities, or people with learning disabilities (social aspect).40 The social 
domain covers issues regarding experiences, expectations and perceptions of patients, as well as caregiver 
burden, accessibility of the intervention, and adherence.  
Three documents addressed social issues that are relevant when considering reimbursement of medical 
cannabis. The discrepancy between scientific research and public perception is described, as patient ex-
periences and patient expectations regarding the effectiveness of medical cannabis might not be substan-
tiated by scientific evidence. Consequently, as scientific data are mandatory to determine the role of can-
nabis as a medicine, patients with an unmet medical need might not have access to medical cannabis even 
though they expect to benefit from it.  
Patient aspects 
The HPRA addressed a gap between “the public perception of effectiveness and safety, and the position 
of many medical experts that further scientific research is required to determine the role of cannabis as a 
medical treatment”.90 While the public interest in medical cannabis is generally acknowledged, the patient 
demand may have been sparked by compelling anecdotal reports of effectiveness in individual patients 
rather than on scientific research. That is, while popular media refers to a growing body of evidence regard-
ing the effectiveness of medical cannabis, the HPRA points to the limitations of the scientific data and notes 
that at the time of writing (2017) the effectiveness of medical cannabis has not yet been proven for a large 
number of medical conditions. After reviewing access programs for medical cannabis use, the HPRA con-
cluded that changes in this field have been led by patient demand rather than requests from healthcare 
professionals. At the same time, the Medical Cannabis Clinicians Society (MCCS) (UK) points out it should 
not be lightly missed that cannabis has been used for centuries by many millions of people and that much 
is known about efficacy and side-effects from this accumulated experience.22 In contrary, the EMCDDA 
report describes that while several pharmaceutical cannabinoids have been approved for medical use, 
these are generally not widely used because patients find it difficult to achieve the desired therapeutic 
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Social group aspects  
The EMCDDA described that in Europe access to medical cannabis is usually granted for the treatment of 
a narrow range of medical conditions. As many governments are faced with demand from patients who 
want to use cannabis and cannabinoids to treat symptoms of illnesses for which there is currently little or 
no evidence of efficacy or safety, patients with these conditions may resort to black market cannabis prod-
ucts. In some countries this has led to the development of special access schemes to allow unauthorised 
medical cannabis products on prescription. However, the accessibility through these schemes may be hin-
dered by physicians’ reluctance to prescribe cannabis for ethical and medico-legal reasons. Furthermore, 
the access to medical cannabis can be influenced by the burden of the approval processes, the quality and 
the cost of the cannabis and cannabinoids that are available, and restrictions on the cannabis products that 
they are allowed to use. 
10.2.3 Findings ethical issues 
The ethical domain is described in the EUnetHTA Core Model as considering the consequences of imple-
menting or not implementing a healthcare technology with regard to prevailing societal values (shaped by 
the socio-political, cultural, legal, religious, and economic context) and with regard to the unintended con-
sequences that may arise in the use of the specific healthcare technology.40 Ethically relevant issues and 
conflicts may include medicalisation, trade-offs between benefit and harms, distribution of health care re-
sources, and impact on broader outcomes (i.e. wellbeing, working, social, and family life). The ethical do-
main may overlap with the evaluation of legal, patient’s, and social aspects (legal and social domains). For 
this ethical analysis, the impact of medical cannabis on public health will be the main focus.  
Illicit use 
Cannabis is the most commonly used illicit drug in Europe with the prevalence of cannabis use being about 
five times higher than that of other substances among people entering addiction services.89 The risk of 
abuse of medical cannabis should therefore be considered when intending to broaden access. More par-
ticularly, medical cannabis programmes have been reported as a major source for the drug’s illicit use in 
the USA, particularly among young people.90 According to the WHO, there is strong scientific support for 
concluding that cannabis has high potential for abuse and is addictive90, and as such, normalisation of 
cannabis use might lead to unintended consequences. Citing a study from Volkow et al., the HPRA drew a 
comparison with alcohol and tobacco: it is not the increased toxicity, but rather the easy access and wide-
spread availability that make these drugs account for the greatest burden to society. As broader access to 
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medical cannabis may lead to an increase in recreational use of cannabis through diversion to non-author-
ised individuals, the societal impact should be taken into account.  
Black market  
If patients with an unmet medical need find it difficult to legally obtain cannabis for medical purposes, they 
may resort to the black market.89 A potential risk of resorting to the black market is that medical cannabis 
might turn into a ‘gateway drug’, as patients may have more opportunities to use other illicit drugs when 
these are supplied by the same black market as cannabis.90 The risk of resorting to black market cannabis 
products should therefore be considered as an unintended consequence when patients cannot obtain can-
nabis for medicinal purposes legally.  
Substitution for other drugs 
It has been suggested that medical cannabis may substitute drugs with more severe side-effects, such as 
other analgesics (i.e. opioids) in people with chronic pain. While a study from the USA found indications 
that medical cannabis laws might be associated with a temporal lower rate of opioid overdose deaths, 
further research is needed to confirm these findings as it is uncertain whether other state-specific factors 
might have contributed.89 Furthermore, rather than substituting other analgesics as fully, medical cannabis 
may be viewed as add-on to existing treatment, with the potential to lower the required dose of other anal-
gesics.  
Vulnerable populations 
The HPRA warns that while increasing access to medical cannabis may benefit individual patients that have 
an unmet medical need, unintended consequences may arise including a negative impact on vulnerable 
populations who are at increased risk of both short-term and long-term side-effects, resulting in a negative 
impact on public health.90 Adolescents have been identified as a vulnerable population, as a small number 
of studies investigating sustained (recreational) cannabis use in young adults suggest that the age of onset 
is a critical factor for potential adverse effects on brain development and cognitive function.89,90 However, 
there are only few prospective studies on this matter, and the risks of recreational and/or chronic use of 
cannabis may not necessarily be transferable to the use of medical cannabis products by patients90. An-
other population that may be particularly vulnerable are people with pre-existing cognitive dysfunction, as 
cognitive impairment is considered to be one of the key safety issues with cannabis use outside the setting 
of clinical trials. Finally, people with a history of psychosis disorders (i.e. schizophrenia) or with a genetic 
predisposition to psychosis can be regarded a vulnerable population, as continued medical cannabis use 
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might be associated with a high number of relapses, hospital admission, and more severe positive symp-
toms (i.e. hallucinations or delusions).90 The risk for relapse in patients with psychosis and for developing 
psychosis in people with a genetic predisposition, respectively, mainly depends on the frequency of use, 
the potency of the cannabis product (THC-rich) and the THC:CBD ratio.92 However, for studies assessing 
impaired cognitive functioning and psychotic disorders in relation to cannabis, difficulties in accounting for 
important confounders occur and reverse causation is generally difficult to exclude. Nevertheless, when 
allowing medical cannabis for children or adolescents, patients with a (history of) psychiatric disorders or 
patients with a genetic predisposition to psychosis disorders, the pharmacological effects of the individual 
cannabinoids should be further considered given the potential effects on the development of psychosis 
disorder, worsening of symptoms, and effects on cognitive function. 
Quality of scientific evidence 
Preservation of blinding might be an issue in studies investigating medical cannabis. While placebo prod-
ucts are available that mimic the smell of medical cannabis, the psychoactive and vasoactive effects pose 
a considerable challenge for effective blinding, as study participants who experience these adverse events 
may surmise that they are receiving medical cannabis and not a placebo.15 Strategies to promote effective 
blinding exist. For example, a higher ratio of CBD to the concentration of THC may reduce the psychoactive 
effects of THC. Furthermore, the effectiveness of blinding might be assessed by asking study participants 
to guess to which study arm they are randomised. However, by asking this question study participants might 
infer that attempts of blinding were ineffective which may in turn make the study results invalid. As the 
NASEM (National Academies of Sciences, USA) summarises, whether or not investigators applied these 
methods, study results of medical cannabis studies are at risk of being undermined. Asking study partici-
pants to guess their study-arm might uncover concerns on unmasking, while journal reviewers might dis-
count study results if such tests were not conducted under the assumption that unmasking cannot be ruled 
out. 
10.2.4 Findings organisational issues 
The organisational domain of the EUnetHTA Core Model encompasses the ways in which different kinds 
of resources need to be mobilised and organised when implementing a technology, as well as the conse-
quences the health technology implementation may have for the organisation and the health care system 
as a whole.40 Organisational issues may include the process of health delivery (i.e. work processes, patient 
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flow, quality assurance, communication, co-operation) and organisation of the health care system (i.e. sus-
tainability, centralisation, accessibility, allocation of resources). As the budget impact of technology imple-
mentation is described in Chapter 9, this will not be explored as part of the organisational domain.  
Two organisations described organisational issues that may arise when cannabis is to be allowed for me-
dicinal purposes. Aspects that need to be considered when organising medical cannabis on prescription 
include deciding on the access scheme, controlling the quality of medical cannabis products, and educating 
prescribing physicians.  
Schemes for allowing patient access 
There is considerable variation between countries in the approaches taken to organise access to cannabis 
for medicinal purposes, reflecting a variety of historical and cultural factors. In most countries, the provision 
of cannabis and cannabinoid products and preparations for medical purposes has evolved over time, often 
in response to patient demand or product developments, and the situation continues to change rapidly. In 
general three broad types of approach can be seen, however, often countries will use more than one of 
these in parallel: 1) Allowing the use of medicinal products containing cannabinoids, 2) Allowing the medical 
use of unauthorised products or preparations, 3) De novo stand-alone medical cannabis programmes.89 
Depending on how access to medical cannabis is organised, the issues described in this chapter might be 
of more or less relevance. For example, when unauthorised products or preparations are allowed, questions 
need to be answered on whether patients are allowed to grow their own cannabis for medical purposes, 
whether and how the quality of these products will be controlled, and how physicians may prescribe these 
products. When medicinal cannabis preparations are allowed, the distribution of products should be decided 
on (i.e. through any pharmacy, through specific pharmacies, or other distribution channels), and pharma-
covigilance schemes need to be considered. In all cases, one should think of how medical cannabis fits 
into existing treatment, whether and how prescriptions should be limited, and whether, how and by whom 
monitoring of patients (i.e. effects and adverse events) should be carried out to strengthen the evidence 
base.89  
Education of physicians   
The EMCDDA and HPRA referred to studies which indicate that healthcare professionals are cautious of 
recommending cannabis for medical use. Physicians may be reluctant to prescribe cannabis for ethical 
reasons (i.e. concerns about the mental health consequences of cannabis use, and the potential for misuse 
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and abuse) or for medico-legal reasons (i.e. are they liable for any harms that the patient may experi-
ence).89,90 Moreover, especially when prescribing cannabis preparations, physicians might be uncertain 
about for which clinical indications medical cannabis should be used, in what doses, and for how long.89 
Therefore, when allowing the prescription of medical cannabis, guidelines and training of physicians might 
be required to ensure medical cannabis is prescribed appropriately.  
10.3  Summary statement legal, social, ethical, and organisational issues 
 
When considering reimbursement of medical cannabis for certain populations, relevant legal, so-
cial, ethical, and organisational issues should also be considered. For example, reimbursement of 
medical cannabis may provoke legal issues as the cultivation, consumption, distribution, and reim-
bursement of medical cannabis will be subject to different laws in Switzerland which are intercon-
nected. In addition, it should be noted that a change in the reimbursement policy of medical canna-
bis may have social and ethical consequences including the gap between patient expectations and 
scientific evidence, accessibility restrictions, vulnerable populations at risk of unintended conse-
quences, and illicit use. Furthermore, organisational challenges may arise in the supply and quality 
control of medical cannabis products. It should be noted that the applicability of the issues identi-
fied might differ depending on the context, for instance on the type of medical cannabis product, 
on the national laws, and on the organisation of the healthcare system. 
 
11 Additional issues 
Due to our broad search for legal, social, ethical, and organisational issues related to medical cannabis, no 
additional issues were encountered that were not already covered in the previous chapters. 
12 Discussion 
The present HTA evaluated the efficacy, safety, cost-effectiveness, and budget impact of medical cannabis 
compared to placebo, no treatment, or standard of care, in patients of all ages with chronic pain or spasticity, 
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based on available scientific literature. In this section, the main strengths, limitations, and evidence gaps of 
this HTA are discussed.  
12.1 Strengths 
One of the main strengths of this HTA is the systematic literature search for studies on the efficacy, safety, 
and cost-effectiveness of medical cannabis for chronic pain and spasticity in multiple peer-reviewed scien-
tific literature databases. A rigorous methodology, adhering to international methodological standards such 
as Cochrane and PRISMA, was applied to identify, critically appraise, analyse, and summarise pertinent 
evidence on predefined outcomes of interest in order to minimise bias. Another strength of this HTA is that 
the cost-effectiveness modelling was performed specifically for the Swiss context. This was an improvement 
compared to previous cost-effectiveness studies for numerous reasons, including the use of a lifetime hori-
zon, using up-to-date and, where possible, Swiss-specific clinical and economic input parameters, model 
input provided by the SR on the efficacy and safety of medical cannabis for chronic pain and spasticity, and 
accompanied with extensive scenario and sensitivity analyses. Finally, this HTA provided an overview of 
relevant legal, social, ethical, and organisational issues regarding the use of cannabis for medical purposes.  
12.2 Limitations 
The efficacy and safety data reported in the included studies were heterogeneous (i.e. between studies in 
outcomes and outcome measures), incomplete (i.e. studies omitting to report detailed results such as treat-
ment effects in the intervention and placebo arms or measures of variability), inconsistent (i.e. studies with 
comparable patient populations and similar type of medical cannabis did not show consistent results), and 
inconclusive (i.e. none of the studies were able to draw a definitive conclusion on the efficacy of medical 
cannabis).The incompleteness and heterogeneity of the data precluded the calculation of pooled estimates. 
Furthermore, unpredictable bias and uncertainty in the evidence base arise in research on medication with 
a characteristic well-known adverse event profile like medical cannabis (e.g. dizzy/light-headedness, fa-
tigue, ‘feeling high’). Since these adverse events may occur in both the medical cannabis arm as well as in 
the SOC arm (e.g. these complaints may occur due to the underlying disease or as side-effect of other 
drugs patients use), this possibly leads to patients speculating about their treatment allocation. Adding to 
this, the SR on the efficacy of medical cannabis shows that up to half of the patients in the SOC group 
reaches the ≥30% response criterion which may suggest a considerable placebo effect. The patient-re-
ported outcomes for the symptoms chronic pain and spasticity further increased this unpredictability and 
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uncertainty, however, no fully objective measures are available for these symptoms. Hence, future studies 
on medical cannabis in these symptoms will likely be exposed to similar challenges and limitations, of which 
only part can be solved with improved study designs and complete reporting of results. While the various 
factors described here increase the risk of bias, the extent as well as the direction of the potential bias are 
difficult to comprehend.  
Due to the limited available data and other limitations, the cost-effectiveness model represents a simplifi-
cation of the complex reality of the symptoms chronic pain and spasticity. Information on treatment re-
sponse was based on the SR on the efficacy, and safety of medical cannabis for chronic pain and spasticity, 
and consequently was prone to the limitations described above. Furthermore, when input for a certain pa-
rameter was not available for the subpopulations musculoskeletal pain and motor neuron disease, the input 
from the neuropathic pain and MS cost-effectiveness models were assumed, respectively which introduces 
additional uncertainty. Finally, assumptions had to be made on various important model input parameters, 
particularly concerning (distribution of) treatment effects, discontinuation, disease progression, resource 
use, and utility estimates, which could not be based on input specific to the Swiss system. The most im-
portant assumptions were therefore assessed in scenario analyses and parameter uncertainty was as-
sessed in sensitivity analyses.  
The budget impact estimates had to be based on expert opinion, since other data sources were not avail-
able. Only a few experts who were approached for providing input for the budget impact analysis were able 
to provide estimates on the prevalence of the studied symptoms chronic pain and spasticity or on the ex-
pected uptake of THC:CBD spray. Furthermore, the legal, social, ethical, and organisational issues identi-
fied were not specific for the products and symptoms studied within this HTA report, nor where they specific 
for the Swiss situation. Hence, the applicability of each issue to the current research question is unknown. 
Furthermore, given the non-systematic approach of the literature search for these domains, not all relevant 
consequences might have been identified.   
Finally, it should be noted that THC and CBD can trigger a variety of physiological actions and medical 
cannabis may therefore have a health effect beyond the dimensions of pain or spasticity alone (i.e. benefi-
cial side-effects, for example on sleep). This HTA report was focused on the use of medical cannabis for 
treating pain and spasticity, and additional effects were therefore not investigated in the SR nor were they 
captured in the cost-effectiveness estimates.  
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12.3 Evidence gaps 
The evidence base for the use of medical cannabis was lacking for the symptoms nausea and vomiting and 
unintentional weight loss, and therefore complete data extraction and cost-effectiveness modelling was not 
performed. Moreover, no studies were included in the SR on efficacy and safety of medical cannabis that 
examined botanical cannabis or its crude extract. Furthermore, to proceed with cost-effectiveness model-
ling a decision had to be made on the preferred outcome measure of efficacy and after selecting the articles 
with (complete) data on the specified outcome measure only studies evaluating THC:CBD spray remained. 
As a result, the cost-effectiveness model and budget impact analysis evaluated only one isolated medical 
cannabis product. Also, no other route of administering cannabis was explored apart from the oromucosal 
route. Thus, it is unknown if the findings of this HTA will be generalisable to patients who use different 
medical cannabis preparations or different routes of administration.  
13 Conclusions  
While the research question encompassed all chronic pain populations and all spasticity populations there 
was only sufficient evidence to assess the efficacy and safety of the use of medical cannabis for patients 
with neuropathic pain, musculoskeletal pain, cancer pain, spasticity in MS and spasticity in motor neuron 
disease. However, due to incomplete, inconclusive, and inconsistent study findings, no conclusions could 
be drawn on the efficacy and safety of medical cannabis in these patient populations. Cost-effectiveness 
modelling was performed for THC:CBD spray only (2.7mg THC / 2.5mg CBD), and resulted in a minimal 
QALY loss for neuropathic pain and only small QALY gains for musculoskeletal pain, MS spasticity, and 
motor neuron disease spasticity, combined with higher costs in all models compared to SOC alone. ICERs 
ranged from THC:CBD spray being dominated by SOC alone for neuropathic pain (i.e. more costly and less 
effective) to 51’038 CHF per QALY for musculoskeletal pain. The time horizon, discounting, discontinuation, 
effectiveness of THC:CBD spray in reducing NRS pain or spasticity scores, and the costs of THC:CBD 
spray had the largest impact on the cost-effectiveness estimates. If THC:CBD spray was to be reimbursed, 
the projected estimated budget impact would be substantial for neuropathic pain, whereas the budget im-
pact for musculoskeletal pain, MS spasticity, and motor neuron disease would be limited. Besides the pa-
tient population for which THC:CBD spray is reimbursed, the budget impact depends on the uptake of 
THC:CBD spray in real-life (i.e. what proportion of eligible patients would be interested in getting THC:CBD 
spray prescribed). Data on these aspects is scarce and had to be based on projections from experts, which 
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increases the uncertainty surrounding the estimated budget impact. The generalisability of the cost-effec-
tiveness and budget impact estimates to other medical cannabis products or other routes of administration 
is unknown.  
When considering reimbursement of medical cannabis for certain patient populations, relevant legal, social, 
ethical, and organisational issues should also be considered. For example, reimbursement of medical can-
nabis will be subject to different and interconnected Swiss laws with regard to cultivation, consumption, 
distribution, and prescription. In addition, reimbursement of medical cannabis may have social and ethical 
consequences, for example as a result of a gap between patient expectations and scientific evidence. Other 
concerns include accessibility restrictions, vulnerable populations at risk of unintended consequences, and 
illicit use. Furthermore, organisational challenges may arise in the supply and quality control of medical 
cannabis products. 
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15 Appendices 
15.1 Search strategy efficacy, effectiveness, and safety  
Table I. Search strategy for the efficacy, effectiveness, and safety systematic literature searches: 
PubMed (MEDLINE) 
 
Medical cannabis for chronic pain Medical cannabis for spasticity 
Population "Chronic Pain"[Mesh] OR "Analgesia"[Mesh] OR 
pain*[tiab] OR analgesia[tiab] 
"Muscle Spasticity"[Mesh] OR spastic*[tiab] 
Intervention: 
cannabis 
"Medical Marijuana"[Mesh] OR "Cannabinoids"[Mesh] OR "Nabilone"[Supplementary Concept] OR "HU 
211"[Supplementary Concept] OR cannab*[tiab] OR marijuana[tiab] OR marihuana[tiab] OR hash*[tiab] 
OR hemp[tiab] OR dronabinol[tiab] OR Marinol®[tiab] OR tetrahydrocannabinol[tiab] OR THC[tiab] OR 
THCV[tiab] OR delta-9-tetrahydrocannabinol[tiab] OR delta-9-THC[tiab] OR 9-ene-tetrahydrocanna-
binol[tiab] OR delta(1)-thc[tiab] OR delta(1)-tetrahydrocannabinol[tiab] OR 9-delta-tetra-hydrocanna-
binol[tiab] OR 9-delta-THC[tiab] OR 9-ene-tetrahydrocannabinol[tiab] OR nabilone[tiab] OR 
Cesamet®[tiab] OR Sativex®[tiab] OR HU 211[tiab] OR HU211[tiab] OR dexanabinol[tiab] OR CBD[tiab] 
OR CBDV[tiab] OR Epidiolex®[tiab] OR nabiximols[tiab] OR abalone[tiab] OR tilray[tiab] OR bedrocan[tiab] 
OR bedrobinol[tiab] OR bediol[tiab] OR bedrolite[tiab] OR syndros[tiab] OR tetrahydrocannabivarin[tiab] 
OR THC:CBD spray[tiab] 
Comparison No search string 
Outcomes No search string 
Limits Study design RCTs: 
("randomized controlled trial"[pt] OR "controlled clinical trial"[pt] OR RCT[tiab] OR RCTs[tiab] OR ran-
dom*[tiab] OR controlled[tiab] OR control-treated[tiab] OR placebo[tiab] OR cross-over studies[Mesh] OR 
"single-blind method"[Mesh] OR single-blind*[tiab] OR singleblind*[tiab] OR single-masked[tiab] OR dou-
ble-blind method[Mesh] OR double-blind*[tiab] OR doubleblind*[tiab] OR double-masked[tiab] OR triple-
blind*[tiab] OR tripleblind*[tiab] OR triple-masked[tiab]) 
Publication period:  
1980 – 22 January 2020 
Language:  
English, French, German, Dutch 
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No animal studies:  
NOT (Animals[Mesh] NOT (Humans[Mesh] AND Animals[Mesh])) 
No reviews and meta-analyses:  
NOT ("systematic review"[pt] OR review[ti] OR "meta-analysis"[pt] OR meta-analysis[ti]) 
 
Table II. Search strategy for the efficacy, effectiveness, and safety systematic literature searches: 
Embase.com 
 
Medical cannabis for chronic pain Medical cannabis for spasticity 
Population 'chronic pain'/exp OR 'analgesia'/exp OR 
pain*:ti,ab OR analgesia:ti,ab 
'spasticity'/exp OR spastic*:ti,ab 
Intervention: 
cannabis 
'medical cannabis'/exp OR 'cannabinoid'/exp OR 'nabilone'/exp OR 'dexanabinol'/exp OR cannab*:ti,ab 
OR marijuana:ti,ab OR marihuana:ti,ab OR hash*:ti,ab OR hemp:ti,ab OR dronabinol:ti,ab OR 
Marinol®:ti,ab OR tetrahydrocannabinol:ti,ab OR THC:ti,ab OR THCV:ti,ab OR ‘delta-9-tetrahydrocanna-
binol’:ti,ab OR ‘delta-9-THC’:ti,ab OR ‘9-ene-tetrahydrocannabinol’:ti,ab OR ‘delta(1)-thc’:ti,ab OR 
‘delta(1)-tetrahydrocannabinol’:ti,ab OR ‘9-delta-tetra-hydrocannabinol’:ti,ab OR ‘9-delta-THC’:ti,ab OR ‘9-
ene-tetrahydrocannabinol’:ti,ab OR nabilone:ti,ab OR Cesamet®:ti,ab OR Sativex®:ti,ab OR ‘HU 211’:ti,ab 
OR ‘HU211’:ti,ab OR dexanabinol:ti,ab OR CBD:ti,ab OR CBDV:ti,ab OR Epidiolex®:ti,ab OR nabixi-
mols:ti,ab OR abalone:ti,ab OR tilray:ti,ab OR bedrocan:ti,ab OR bedrobinol:ti,ab OR bediol:ti,ab OR bed-
rolite:ti,ab OR syndros:ti,ab OR tetrahydrocannabivarin:ti,ab OR ‘THC:CBD spray’:ti,ab 
Comparison No search string 
Outcomes No search string 
Limits Study design RCTs: 
('randomized controlled trial'/exp OR 'controlled clinical trial'/exp OR RCT:ti,ab OR RCTs:ti,ab OR ran-
dom*:ti,ab OR controlled:ti,ab OR control-treated:ti,ab OR placebo:ti,ab OR 'crossover procedure'/exp OR 
'single blind procedure'/exp OR single-blind*:ti,ab OR singleblind*:ti,ab OR single-masked:ti,ab OR 'double 
blind procedure'/exp OR double-blind*:ti,ab OR doubleblind*:ti,ab OR double-masked:ti,ab OR 'triple blind 
procedure'/exp OR triple-blind*:ti,ab OR tripleblind*:ti,ab OR triple-masked:ti,ab) 
Publication period: 
1980 – 22 January 2020 
Language:  
English, French, German, Dutch 
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No animal studies:  
NOT ([animal cell]/lim OR [animal experiment]/lim OR [animal model]/lim OR [animal tissue]/lim) 
No reviews and meta-analyses:  
NOT ('systematic review'/exp OR review:ti OR 'meta analysis'/exp OR meta-analysis:ti) 
 
15.2 Excluded RCTs efficacy, effectiveness, and safety 
Table I. Excluded RCTs found with the efficacy, effectiveness, and safety systematic literature 
search on medical cannabis use for chronic pain 
Reference Reason for exclusion 
No author. Marijuana eases HIV-related nerve pain. The AIDS reader. 
2004;14(4):164-5. 
Non-pertinent publication type 
Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, et al. Cannabis in 
painful HIV-associated sensory neuropathy: A randomized placebo-controlled 
trial. Neurology. 2007;68(7):515-21. 
Short treatment duration (<2 weeks) 
Bar-Sela G, Zalman D, Semenysty V, Ballan E. The Effects of Dosage-Con-
trolled Cannabis Capsules on Cancer-Related Cachexia and Anorexia Syn-
drome in Advanced Cancer Patients: Pilot Study. Integr Cancer Ther. 
2019;18:1534735419881498. 
No RCT 
Berman JS, Symonds C, Birch R. Efficacy of two cannabis based medicinal 
extracts for relief of central neuropathic pain from brachial plexus avulsion: 
results of a randomised controlled trial. Pain. 2004;112(3):299-306. 
Cross-over trial without washout periods 
Conte A, Bettolo CM, Onesti E, Frasca V, Iacovelli E, Gilio F, et al. Canna-
binoid-induced effects on the nociceptive system: A neurophysiological study 
in patients with secondary progressive multiple sclerosis. European Journal of 
Pain. 2009;13(5):472-7. 
No data on review objectives 
Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, et al. 
Smoked cannabis for spasticity in multiple sclerosis: A randomized, placebo-
controlled trial. CMAJ. 2012;184(10):1143-50. 
Short treatment duration (<2 weeks) 
Côté M, Trudel M, Wang C, Fortin A. Improving Quality of Life With Nabilone 
During Radiotherapy Treatments for Head and Neck Cancers: A Randomized 
Double-Blind Placebo-Controlled Trial. Ann Otol Rhinol Laryngol. 
2016;125(4):317-24. 
Data presented in a Figure, not possible to 
extract all exact data from the text 
De Vries M, Van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, Van 
Goor H. Single dose delta-9-tetrahydrocannabinol in chronic pancreatitis pa-
tients: Analgesic efficacy, pharmacokinetics and tolerability. Br J Clin Pharma-
col. 2016;81(3):525-37. 
No data on review objectives 
De Vries M, van Rijckevorsel DCM, Vissers KCP, Wilder-Smith OHG, van Small sample size (n<50) & no sufficient size 
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Goor H. Tetrahydrocannabinol Does Not Reduce Pain in Patients With 
Chronic Abdominal Pain in a Phase 2 Placebo-controlled Study. Clinical Gas-
troenterology and Hepatology. 2017;15(7):1079-86.e4. 
as in power calculation 
Ellis RJ, Toperoff W, Vaida F, Van Den Brande G, Gonzales J, Gouaux B, et 
al. Smoked medical cannabis for neuropathic pain in HIV: A randomized, 
crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672-80. 
Short treatment duration (<2 weeks) 
Frank B, Serpell MG, Hughes J, Matthews JNS, Kapur D. Comparison of an-
algesic effects and patient tolerability of nabilone and dihydrocodeine for 
chronic neuropathic pain: randomised, crossover, double blind study. BMJ. 
2008;336(7637):199-201. 
No useful results for efficacy 
Good P, Haywood A, Gogna G, Martin J, Yates P, Greer R, et al. Oral medic-
inal cannabinoids to relieve symptom burden in the palliative care of patients 
with advanced cancer: a double-blind, placebo controlled, randomised clinical 
trial of efficacy and safety of cannabidiol (CBD). BMC Palliat Care. 
2019;18(1):110. 
Study protocol 
Guy G, Gover J, Rogerson M, Atwell B, Dineen J. Positive data in Sativex® 
phase IIb trial: Support advancing into phase III development in cancer pain. 
Revista de la Sociedad Espanola del Dolor. 2010;17(4):219-21. 
Non-pertinent publication type 
Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, et al. Pain 
relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia. 
1997;52(5):483-6. 
Case report 
Issa MA, Narang S, Jamison RN, Michna E, Edwards RR, Penetar DM, et al. 
The subjective psychoactive effects of oral dronabinol studied in a random-
ized, controlled crossover clinical trial for pain. Clin J Pain. 2014;30(6):472-8. 
No data on review objectives 
Johnson JR, Burnell-Nugent M, Lossignol D, Ganae-Motan ED, Potts R, Fal-
lon MT. Multicenter, double-blind, randomized, placebo-controlled, parallel-
group study of the efficacy, safety, and tolerability of THC:CBD extract and 
THC extract in patients with intractable cancer-related pain. J Pain Symptom 
Manage. 2010;39(2):167-79. 
Short treatment duration (<2 weeks) 
Johnson JR, Lossignol D, Burnell-Nugent M, Fallon MT. An open-label exten-
sion study to investigate the long-term safety and tolerability of THC/CBD oro-
mucosal spray and oromucosal THC spray in patients with terminal cancer-
related pain refractory to strong opioid analgesics. J Pain Symptom Manage. 
2013;46(2):207-18. 
Open-label extension study of an excluded 
RCT 
Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U. Analgesic Effect 
of the Synthetic Cannabinoid CT-3 on Chronic Neuropathic Pain: A Random-
ized Controlled Trial. Journal of the American Medical Association. 
2003;290(13):1757-62. 
Short treatment duration (<2 weeks) 
Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-con-
trolled, crossover pilot trial with extension using an oral mucosal cannabinoid 
extract for treatment of chemotherapy-induced neuropathic pain. J Pain 
Symptom Manage. 2014;47(1):166-73. 
Small sample size (n<50) without power 
calculation 
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Malik Z, Bayman L, Valestin J, Rizvi-Toner A, Hashmi S, Schey R. Dronabinol 
increases pain threshold in patients with functional chest pain: A pilot double-
blind placebo-controlled trial. Diseases of the Esophagus. 2017;30(2). 
No useful results for efficacy 
Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, et al. 
Efficacy of Dronabinol as an Adjuvant Treatment for Chronic Pain Patients on 
Opioid Therapy. Journal of Pain. 2008;9(3):254-64. 
No data on review objectives 
Nitecka-Buchta A, Nowak-Wachol A, Wachol K, Walczyńska-Dragon K, 
Olczyk P, Batoryna O, et al. Myorelaxant Effect of Transdermal Cannabidiol 
Application in Patients with TMD: A Randomized, Double-Blind Trial. J Clin 
Med. 2019;8(11):1886. 
No population of interest 
Pini LA, Guerzoni S, Cainazzo MM, Ferrari A, Sarchielli P, Tiraferri I, et al. 
Nabilone for the treatment of medication overuse headache: results of a pre-
liminary double-blind, active-controlled, randomized trial. J Headache Pain. 
2012;13(8):677-84. 
No population of interest 
Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W. Benefits of 
an add-on treatment with the synthetic cannabinomimetic nabilone on patients 
with chronic pain--a randomized controlled trial. Wien Klin Wochenschr. 
2006;118(11-12):327-35. 
Small sample size (n<50) without power 
calculation 
Pittler MH. No effect of cannabis on induced inflammatory pain. Focus on Al-
ternative and Complementary Therapies. 2009;14(1):19-20. 
Non-pertinent publication type 
Portenoy RK, Ganae-Motan ED, Allende S, Yanagihara R, Shaiova L, 
Weinstein S, et al. Nabiximols for opioid-treated cancer patients with poorly-
controlled chronic pain: a randomized, placebo-controlled, graded-dose trial. 
J Pain. 2012;13(5):438-49. 
No efficacy data reported for the complete 
group of patients, only stratified for different 
doses 
Rintala DH, Fiess RN, Tan G, Holmes SA, Bruel BM. Effect of dronabinol on 
central neuropathic pain after spinal cord injury: a pilot study. American journal 
of physical medicine & rehabilitation / Association of Academic Physiatrists. 
2010;89(10):840-8. 
Small sample size (n<50) without power cal-
culation 
Rog DJ, Nurmikko TJ, Young CA. Oromucosal delta9-tetrahydrocanna-
binol/cannabidiol for neuropathic pain associated with multiple sclerosis: an 
uncontrolled, open-label, 2-year extension trial. Clin Ther. 2007;29(9):2068-
79. 
Non-comparative extension trial and no use-
ful results for safety 
Salim K, Schneider U, Burstein S, Hoy L, Karst M. Pain measurements and 
side-effect profile of the novel cannabinoid ajulemic acid. Neuropharmacol-
ogy. 2005;48(8 SPEC. ISS.):1164-71. 
Secondary analyses of RCT excluded in the 
systematic review 
Schulz V. Cannabis inhalation against neuropathic pains: Randomized double 
blind study on the benefit-risk assessment. Zeitschrift fur Phytotherapie. 
2009;30(2):75-6. 
Non-pertinent publication type 
Selvarajah D, Gandhi R, Emery CJ, Tesfaye S. Randomized placebo-con-
trolled double-blind clinical trial of cannabis-based medicinal product (Sa-
tivex®) in painful diabetic neuropathy: depression is a major confounding fac-
tor. Diabetes Care. 2010;33(1):128-30. 
Number of patients and number of dropouts 
in treatment arms not reported 
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Skrabek RQ, Galimova L, Ethans K, Perry D. Nabilone for the treatment of 
pain in fibromyalgia. J Pain. 2008;9(2):164-73. 
Subjects were titrated up on medical 
cannabis over 4 weeks, of which only the last 
week of treatment was at 1 mg twice daily 
Svendsen KB, Jensen TS, Bach FW. Does the cannabinoid dronabinol reduce 
central pain in multiple sclerosis? Randomised double blind placebo controlled 
crossover trial. British Medical Journal. 2004;329(7460):253-7. 
Small sample size (n<25) with power 
calculation 
Toth C, Mawani S, Brady S, Chan C, Liu C, Mehina E, et al. An enriched-
enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-con-
trolled, parallel assignment efficacy study of nabilone as adjuvant in the treat-
ment of diabetic peripheral neuropathic pain. Pain. 2012;153(10):2073-82. 
Small sample size (n<50) & no sufficient size 
as in power calculation 
Turcotte D, Doupe M, Torabi M, Gomori A, Ethans K, Esfahani F, et al. Na-
bilone as an adjunctive to gabapentin for multiple sclerosis-induced neuro-
pathic pain: a randomized controlled trial. Pain Med. 2015;16(1):149-59. 
No data on review objectives 
Van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, 
Beumer TL, et al. Effects on Spasticity and Neuropathic Pain of an Oral For-
mulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple 
Sclerosis. Clin Ther. 2018;40(9):1467-82. 
No population of interest 
Van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. 
An experimental randomized study on the analgesic effects of pharmaceuti-
cal-grade cannabis in chronic pain patients with fibromyalgia. Pain. 
2019;160(4):860-9. 
No data on review objectives 
Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based 
medicinal extracts have general or specific effects on symptoms in multiple 
sclerosis? A double-blind, randomized, placebo-controlled study on 160 pa-
tients. Mult Scler. 2004;10(4):434-41. 
Small sample size (n<50) & no sufficient size 
as in power calculation 
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled 
study to determine whether whole-plant cannabis extracts can improve intrac-
table neurogenic symptoms. Clin Rehabil. 2003;17(1):21-9. 
Small sample size (n<50) without power 
calculation 
Wallace MS, Marcotte TD, Umlauf A, Gouaux B, Atkinson JH. Efficacy of In-
haled Cannabis on Painful Diabetic Neuropathy. Journal of Pain. 
2015;16(7):616-27. 
No data on review objectives 
Ware MA, Wang T, Shapiro S, Robinson A, Ducruet T, Huynh T, et al. Smoked 
cannabis for chronic neuropathic pain: A randomized controlled trial. CMAJ. 
2010;182(14):E694-E701. 
Short treatment duration (<2 weeks) 
Weizman L, Dayan L, Brill S, Nahman-Averbuch H, Hendler T, Jacob G, et al. 
Cannabis analgesia in chronic neuropathic pain is associated with altered 
brain connectivity. Neurology. 2018;91(14):E1285-E94. 
No data on review objectives 
Wilsey B, Marcotte T, Deutsch R, Gouaux B, Sakai S, Donaghe H. Low-dose 
vaporized cannabis significantly improves neuropathic pain. Journal of Pain. 
2013;14(2):136-48. 
No data on review objectives 
Wilsey B, Marcotte T, Tsodikov A, Millman J, Bentley H, Gouaux B, et al. A 
Randomized, Placebo-Controlled, Crossover Trial of Cannabis Cigarettes in 
No data on review objectives 
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Neuropathic Pain. Journal of Pain. 2008;9(6):506-21. 
Wilsey B, Marcotte TD, Deutsch R, Zhao H, Prasad H, Phan A. An Exploratory 
Human Laboratory Experiment Evaluating Vaporized Cannabis in the Treat-
ment of Neuropathic Pain From Spinal Cord Injury and Disease. Journal of 
Pain. 2016;17(9):982-1000. 
No data on review objectives 
Wilsey BL, Deutsch R, Samara E, Marcotte TD, Barnes AJ, Huestis MA, et al. 
A preliminary evaluation of the relationship of cannabinoid blood concentra-
tions with the analgesic response to vaporized cannabis. J Pain Res. 
2016;9:587-98. 
No data on review objectives 
Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, et al. Low dose 
treatment with the synthetic cannabinoid Nabilone significantly reduces spas-
ticity-related pain : a double-blind placebo-controlled cross-over trial. J Neurol. 
2006;253(10):1337-41. 
Small sample size (n<50) without power 
calculation 
Zadikoff C, Wadia PM, Miyasaki J, Chen R, Lang AE, So J, et al. Cannabinoid, 
CB1 agonists in cervical dystonia: Failure in a phase IIa randomized controlled 
trial. Basal Ganglia. 2011;1(2):91-5. 
No population of interest 
Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, et al. Cannabinoids 
for treatment of spasticity and other symptoms related to multiple sclerosis 
(CAMS study): Multicentre randomised placebo-controlled trial. Lancet. 
2003;362(9395):1517-26. 
No population of interest 
Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG. MUltiple sclerosis 
and extract of cannabis: Results of the MUSEC trial. Journal of Neurology, 
Neurosurgery and Psychiatry. 2012;83(11):1125-32. 
No population of interest 
 
Table II. Excluded RCTs found with the efficacy, effectiveness, and safety systematic literature 
search on medical cannabis use for spasticity symptoms 
Reference  Reason for exclusion 
No author. Latest trial suggests cannabis does not relieve spasticity of multiple scle-
rosis. Pharmaceutical Journal. 2002;268(7198):675. 
Non-pertinent publication type 
Ball S, Vickery J, Hobart J, Wright D, Green C, Shearer J, et al. The Cannabinoid Use 
in Progressive Inflammatory brain Disease (CUPID) trial: A randomised double-blind 
placebo-controlled parallel-group multicentre trial and economic evaluation of canna-
binoids to slow progression in multiple sclerosis. Health Technology Assessment. 
2015;19(12):1-187. 
Non-pertinent publication type 
Corey-Bloom J, Wolfson T, Gamst A, Jin S, Marcotte TD, Bentley H, et al. Smoked 
cannabis for spasticity in multiple sclerosis: A randomized, placebo-controlled trial. 
CMAJ. 2012;184(10):1143-50. 
Short treatment duration (<2 weeks) 
Farrar JT, Troxel AB, Stott C, Duncombe P, Jensen MP. Validity, reliability, and clinical 
importance of change in a 0-10 numeric rating scale measure of spasticity: a post hoc 
No data on review objectives 
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analysis of a randomized, double-blind, placebo-controlled trial. Clinical Therapeutics. 
2008;30(5):974-85. 
Grotenhermen F. Cannabinoids do not reduce objective measurements in muscle 
spasticity, but people with multiple sclerosis perceive some benefit. Evidence-Based 
Healthcare. 2004;8(3):159-61. 
Non-pertinent publication type 
Hagenbach U, Luz S, Ghafoor N, Berger JM, Grotenhermen F, Brenneisen R, et al. 
The treatment of spasticity with Δ9-tetrahydrocannabinol in persons with spinal cord 
injury. Spinal Cord. 2007;45(8):551-62. 
No data on review objectives 
Haupts M, Vila C, Jonas A, Witte K, Álvarez-Ossorio L. Influence of Previous Failed 
Antispasticity Therapy on the Efficacy and Tolerability of THC:CBD Oromucosal Spray 
for Multiple Sclerosis Spasticity. Eur Neurol. 2016;75(5-6):236-43. 
(Irrelevant) post-hoc analysis of an 
RCT included in the systematic liter-
ature search 
Killestein J, Hoogervorst ELJ, Reif M, Kalkers NF, Van Loenen AC, Staats PGM, et al. 
Safety, tolerability, and efficacy of orally administered cannabinoids in MS. Neurology. 
2002;58(9):1404-7. 
Small sample size (n<50) without 
power calculation 
Leocani L, Nuara A, Houdayer E, Schiavetti I, Del Carro U, Amadio S, et al. Sativex(®) 
and clinical-neurophysiological measures of spasticity in progressive multiple sclero-
sis. J Neurol. 2015;262(11):2520-7. 
Small sample size (n<50) & no 
sufficient size as in power calculation 
Markovà J, Essner U, Akmaz B, Marinelli M, Trompke C, Lentschat A, et al. Sativex(®) 
as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant 
multiple sclerosis spasticity: a double-blind, placebo-controlled randomised clinical 
trial. Int J Neurosci. 2019;129(2):119-28. 
High risk of selection bias and no 
useful results for efficacy 
Notcutt W, Langford R, Davies P, Ratcliffe S, Potts R. A placebo-controlled, parallel-
group, randomized withdrawal study of subjects with symptoms of spasticity due to 
multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult Scler. 
2012;18(2):219-28. 
No useful results for efficacy 
Novotna A, Mares J, Ratcliffe S, Novakova I, Vachova M, Zapletalova O, et al. A ran-
domized, double-blind, placebo-controlled, parallel-group, enriched-design study of 
nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity 
caused by multiple sclerosis. Eur J Neurol. 2011;18(9):1122-31. 
High risk of selection bias and no 
useful results for efficacy 
Petro DJ, Ellenberger Jr C. Treatment of human spasticity with delta 9-tetrahydrocan-
nabinol. Journal of clinical pharmacology. 1981;21(8-9 Suppl):413S-6S. 
Small sample size (n<50) without 
power calculation 
Pooyania S, Ethans K, Szturm T, Casey A, Perry D. A randomized, double-blinded, 
crossover pilot study assessing the effect of nabilone on spasticity in persons with 
spinal cord injury. Arch Phys Med Rehabil. 2010;91(5):703-7. 
Small sample size (n<50) without 
power calculation 
Pryce G, Baker D. Cannabinoids fail to show evidence of slowing down the progres-
sion of multiple sclerosis. Evidence-Based Medicine. 2015;20(4):124. 
Non-pertinent publication type 
Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients 
with spasticity due to multiple sclerosis. J Neurol. 2013;260(1):285-95. 
Non-comparative extension trial and 
no useful results for safety 
Van Amerongen G, Kanhai K, Baakman AC, Heuberger J, Klaassen E, Beumer TL, et 
al. Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahy-
drocannabinol in Patients With Progressive Multiple Sclerosis. Clinical Therapeutics. 
2018;40(9):1467-82. 
Small sample size (n<25) with power 
calculation 
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Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, et al. 
Efficacy, safety and tolerability of an orally administered cannabis extract in the treat-
ment of spasticity in patients with multiple sclerosis: a randomized, double-blind, pla-
cebo-controlled, crossover study. Mult Scler. 2004;10(4):417-24. 
Small sample size (n<50) without 
power calculation 
Wade DT, Makela P, Robson P, House H, Bateman C. Do cannabis-based medicinal 
extracts have general or specific effects on symptoms in multiple sclerosis? A double-
blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 
2004;10(4):434-41. 
Small sample size (n<50) & no suffi-
cient size as in power calculation 
Wade DT, Makela PM, House H, Bateman C, Robson P. Long-term use of a cannabis-
based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. 
Mult Scler. 2006;12(5):639-45. 
Open-label extension study of an 
excluded RCT 
Wade DT, Robson P, House H, Makela P, Aram J. A preliminary controlled study to 
determine whether whole-plant cannabis extracts can improve intractable neurogenic 
symptoms. Clin Rehabil. 2003;17(1):21-9. 
Small sample size (n<50) without 
power calculation 
Zajicek J, Ball S, Wright D, Vickery J, Nunn A, Miller D, et al. Effect of dronabinol on 
progression in progressive multiple sclerosis (CUPID): A randomised, placebo-con-
trolled trial. The Lancet Neurology. 2013;12(9):857-65. 
No data on review objectives 
Zajicek JP, Hobart JC, Slade A, Barnes D, Mattison PG. MUltiple sclerosis and extract 
of cannabis: Results of the MUSEC trial. Journal of Neurology, Neurosurgery and Psy-
chiatry. 2012;83(11):1125-32. 
No population of interest (i.e. not 
aimed at spasticity) 
15.3 Search strategy cost-effectiveness  
Table I. Search strategy for the cost-effectiveness search: PubMed (MEDLINE)  
 Use of medical cannabis for 4 different symptoms 
I. Chronic pain 
 
"Chronic Pain"[Mesh] OR "Analgesia"[Mesh] OR 














"Medical Marijuana"[Mesh] OR "Cannabinoids"[Mesh] OR "Nabilone"[Supplementary Concept] OR "HU 211"[Sup-
plementary Concept] OR cannab*[tiab] OR marijuana[tiab] OR marihuana[tiab] OR hash*[tiab] OR hemp[tiab] OR 
dronabinol[tiab] OR Marinol®[tiab] OR tetrahydrocannabinol[tiab] OR THC[tiab] OR THCV[tiab] OR delta-9-tetrahy-
drocannabinol[tiab] OR delta-9-THC[tiab] OR 9-ene-tetrahydrocannabinol[tiab] OR delta(1)-thc[tiab] OR delta(1)-
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tetrahydrocannabinol[tiab] OR 9-delta-tetra-hydrocannabinol[tiab] OR 9-delta-THC[tiab] OR 9-ene-tetrahydrocanna-
binol[tiab] OR nabilone[tiab] OR Cesamet®[tiab] OR Sativex®[tiab] OR HU 211[tiab] OR HU211[tiab] OR dexanabi-
nol[tiab] OR CBD[tiab] OR CBDV[tiab] OR Epidiolex®[tiab] OR nabiximols[tiab] OR abalone[tiab] OR tilray[tiab] OR 
bedrocan[tiab] OR bedrobinol[tiab] OR bediol[tiab] OR bedrolite[tiab] OR syndros[tiab] OR tetrahydrocannabiva-




No search string 
Out-
comes 
No search string 
Limits Study design: 
“Technology Assessment, Biomedical”[Mesh] OR “Cost-Benefit Analysis”[Mesh] OR “Quality-Adjusted Life Years”[Mesh] 
OR “technology assessment” [tiab] OR “economic evaluation” [tiab] OR “economic value” [tiab] OR “cost-benefit” [tiab] OR 
“cost-effective” [tiab] OR “cost-effectiveness” [tiab] OR “cost-utility” [tiab] OR “cost-consequence” [tiab] OR “quality-adjusted 
life year” [tiab] OR “QALY” [tiab] OR "budget impact" [tiab] OR “health-related quality of life” [tiab] 
Publication period:  
1980 – 22 January 2020 
Language:  
English, French, German, Dutch 
No animal studies:  
NOT (Animals[Mesh] NOT (Humans[Mesh] AND Animals[Mesh])) 
No reviews and meta-analyses:  
NOT ("systematic review"[pt] OR review[ti] OR "meta-analysis"[pt] OR meta-analysis[ti]) 
Table II. Search strategy for the cost-effectiveness search: Embase  
 Medical cannabis indicat Use of medical cannabis for 4 different symptoms ion 
I. Chronic pain 
 













'medical cannabis'/exp OR 'cannabinoid'/exp OR 'nabilone'/exp OR 'dexanabinol'/exp OR cannab*:ti,ab OR mariju-
ana:ti,ab OR marihuana:ti,ab OR hash*:ti,ab OR hemp:ti,ab OR dronabinol:ti,ab OR Marinol®:ti,ab OR tetrahydro-
cannabinol:ti,ab OR THC:ti,ab OR THCV:ti,ab OR ‘delta-9-tetrahydrocannabinol’:ti,ab OR ‘delta-9-THC’:ti,ab OR ‘9-
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can-
nabis 
ene-tetrahydrocannabinol’:ti,ab OR ‘delta(1)-thc’:ti,ab OR ‘delta(1)-tetrahydrocannabinol’:ti,ab OR ‘9-delta-tetra-hy-
drocannabinol’:ti,ab OR ‘9-delta-THC’:ti,ab OR ‘9-ene-tetrahydrocannabinol’:ti,ab OR nabilone:ti,ab OR 
Cesamet®:ti,ab OR Sativex®:ti,ab OR ‘HU 211’:ti,ab OR ‘HU211’:ti,ab OR dexanabinol:ti,ab OR CBD:ti,ab OR 
CBDV:ti,ab OR Epidiolex®:ti,ab OR nabiximols:ti,ab OR abalone:ti,ab OR tilray:ti,ab OR bedrocan:ti,ab OR bed-





No search string 
Out-
comes 
No search string 
Limits Study design: 
('biomedical technology assessment'/exp OR 'economic evaluation'/exp OR 'quality adjusted life year'/exp OR 'pro-
gram cost effectiveness'/de OR ((technology NEAR/3 assessment*) OR (economic* NEAR/3 (evaluat* OR value)) 
OR ((cost OR costs) NEAR/3 (benefit* OR effectiv* OR efficien* OR efficac* OR minim* OR utilit* OR consequen*)) 
OR (budget* NEAR/3 impact*):ab,ti OR (qualit* NEAR/3 adjust* NEAR/3 (life-year* OR lifeyear*)) OR qaly*):ab,ti OR 
(health NEAR/3 relat* NEAR/3 qualit* NEAR/3 life*):ab,ti) 
Publication period:  
1980 – 22 January 2020 
Language:  
English, French, German, Dutch 
No animal studies:  
NOT ([animal cell]/lim OR [animal experiment]/lim OR [animal model]/lim OR [animal tissue]/lim) 
No reviews and meta-analyses:  
NOT ('systematic review'/exp OR review:ti OR 'meta analysis'/exp OR meta-analysis:ti) 
Table III. Search strategy for the cost-effectiveness search: NHSEED / DARE / HTA 
Search terms 
1. (“chronic pain” AND “cannabis”) in “Any field” 
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15.4 Excluded economic evaluations cost-effectiveness  
Table I. Excluded economic evaluations of medical cannabis use in chronic pain 
Reference Reason for exclusion 
Oral, Reduced Pain Sensitivity Following. AAPM 2018 Annual Meeting Ab-
stracts. Pain Medicine, 2018, 19: 818-905.  
No economic evaluation  
Bellnier, Terrance, Geoffrey W. Brown, and Tulio R. Ortega. "Preliminary eval-
uation of the efficacy, safety, and costs associated with the treatment of 
chronic pain with medical cannabis." Mental Health Clinician 8.3, 2018: 110-
115. 
No economic evaluation 
Table II. Excluded economic evaluations of medical cannabis use in spasticity 
Reference Reason for exclusion 
Ball, Susan, et al. "The Cannabinoid Use in Progressive Inflammatory Brain 
Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-
group multicentre trial and economic evaluation of cannabinoids to slow pro-
gression in multiple sclerosis." Health technology assessment (Winchester, 
England) 19.12, 2015: vii. 
No economic evaluation  
Oppe, Mark, et al. PND86 cost-utility analysis of delta-9-tetrahidrocannabinol 
and cannabidiol oromucosal spray. Value in Health, 2019, 22: S753. 
Conference abstract  
15.5 Non-systematic search of Swiss utility and resource use inputs 
15.5.1 Methods search for Swiss resource use  
To identify the most recent Swiss cost data available to use as input in the cost-effectiveness model, a 
comprehensive search for resource use and costs data of medical cannabis in Switzerland was performed. 
This Appendix provides more information on the methods and the results of this search. The tables below 
show the search strings that were utilised to conduct the systematic search. 
Table I. Search string costing studies PubMed 
PubMed (MEDLINE) Costing studies 
Medical cannabis "Medical Marijuana"[Mesh] OR "Cannabinoids"[Mesh] OR "Nabilone"[Supplementary Concept] OR "HU 
211"[Supplementary Concept] OR cannab*[tiab] OR marijuana[tiab] OR marihuana[tiab] OR hash*[tiab] 
OR hemp[tiab] OR dronabinol[tiab] OR marinol[tiab] OR tetrahydrocannabinol[tiab] OR THC[tiab] OR 
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THCV[tiab] OR delta-9-tetrahydrocannabinol[tiab] OR delta-9-THC[tiab] OR 9-ene-tetrahydrocanna-
binol[tiab] OR delta(1)-thc[tiab] OR delta(1)-tetrahydrocannabinol[tiab] OR 9-delta-tetra-hydrocanna-
binol[tiab] OR 9-delta-THC[tiab] OR 9-ene-tetrahydrocannabinol[tiab] OR nabilone[tiab] OR 
cesamet[tiab] OR sativex[tiab] OR HU 211[tiab] OR HU211[tiab] OR dexanabinol[tiab] OR CBD[tiab] OR 
CBDV[tiab] OR epidiolex[tiab] OR nabiximols[tiab] OR abalone[tiab] OR tilray[tiab] OR bedrocan[tiab] 
OR bedrobinol[tiab] OR bediol[tiab] OR bedrolite[tiab] OR syndros[tiab] OR tetrahydrocannabivarin[tiab] 
OR THC:CBD spray[tiab] 
Costing studies ((economics OR “economic aspect” OR cost OR “health care cost” OR “drug cost” OR “hospital 
cost” OR socioeconomics OR “health economics” OR “pharmacoeconomics” OR “fee” OR “budget” 
OR “eco-nomic evaluation” OR “hospital finance” OR “financial management” OR “health care fi-
nancing”) OR (“healthcare costs” OR (healthcare AND cost) OR fiscal OR funding OR financial 
OR finance) OR ((cost AND estimate*) OR “cost estimate” OR “cost variable” OR (unit AND cost)) 
OR (economic* OR pharmacoeconomic* OR price* OR pricing) OR ((healthcare OR “health care”) 
AND (utilisation OR utilisation)) OR (cost* AND (treat* OR therap*)) OR ((direct OR indirect) AND 
cost*) OR (“resource use” OR “resource utilisation" OR “resource utilisation”) OR (“treatment costs” 
OR “costs of treatment” OR “cost of treatment” OR “costs of therapy” OR “cost of therapy” OR 
“cost of treating”)) 




Table II. Search string costing studies Embase.com 
EMBASE.com Costing studies 
Medical cannabis 'medical cannabis'/exp OR 'cannabinoid'/exp OR 'nabilone'/exp OR 'dexanabinol'/exp OR cannab*:ti,ab 
OR marijuana:ti,ab OR marihuana:ti,ab OR hash*:ti,ab OR hemp:ti,ab OR dronabinol:ti,ab OR 
marinol:ti,ab OR tetrahydrocannabinol:ti,ab OR THC:ti,ab OR THCV:ti,ab OR ‘delta-9-tetrahydrocanna-
binol’:ti,ab OR ‘delta-9-THC’:ti,ab OR ‘9-ene-tetrahydrocannabinol’:ti,ab OR ‘delta(1)-thc’:ti,ab OR 
‘delta(1)-tetrahydrocannabinol’:ti,ab OR ‘9-delta-tetra-hydrocannabinol’:ti,ab OR ‘9-delta-THC’:ti,ab OR 
‘9-ene-tetrahydrocannabinol’:ti,ab OR nabilone:ti,ab OR cesamet:ti,ab OR sativex:ti,ab OR ‘HU 
211’:ti,ab OR ‘HU211’:ti,ab OR dexanabinol:ti,ab OR CBD:ti,ab OR CBDV:ti,ab OR epidiolex:ti,ab OR 
nabiximols:ti,ab OR abalone:ti,ab OR tilray:ti,ab OR bedrocan:ti,ab OR bedrobinol:ti,ab OR bediol:ti,ab 
OR bedrolite:ti,ab OR syndros:ti,ab OR tetrahydrocannabivarin:ti,ab OR ‘THC:CBD spray’:ti,ab 
Costing studies Economics/exp OR Cost/exp OR ‘Health Economics’/exp OR Budget/exp OR budget*:ab,ti OR 
(economic* OR cost OR costs OR costly OR costing OR price OR prices OR pricing OR phar-
macoeconomic* OR pharmaco-economic* OR expenditure OR expenditures OR expense OR ex-
penses OR financial OR finance OR finances OR financed):ab,ti OR (economic* OR cost OR costs 
OR costly OR costing OR price OR prices OR pricing OR pharmacoeconomic* OR pharmaco-
economic* OR expenditure OR expenditures OR expense OR expenses OR financial OR finance 
OR finances OR financed):ab,ti OR (cost* adj2 (effective* OR utilit* OR benefit* OR minimi* OR 
analy* OR outcome OR outcomes)):ab,ti OR (value adj2 (money OR monetary)):ab,ti 
Country Switzerland:ab,ti OR Swiss:ab,ti 
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Period N/A 
Hits 256 
15.5.2 Results search for Swiss resource use  
The selection of studies is illustrated in Figure I. The references and decisions of the 4 studies that were 
included in the full-text screening are reported in Table III. None of the studies that were included in the full-
text screening reported Swiss cost data. Hence, we did not extract any data from the identified studies. 
 
Figure I. PRISMA flowchart studies on healthcare costs 
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Table III. References and decisions of studies included in full-text screening of healthcare costs 
systematic literature search 
Reference Decision 
Elliott, J., McCoy, B., Clifford, T., Potter, B. K., Wells, G. A., & Coyle, D. (2020). Eco-
nomic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analy-
sis. PharmacoEconomics, 1-10. 
Exclude: no Swiss specific cost data 
Mantovani, L. G., Cozzolino, P., Cortesi, P. A., & Patti, F. (2020). Cost-Effectiveness 
Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in 
Subjects with Multiple Sclerosis. Clinical Drug Investigation, 1-8. 
Exclude: no Swiss specific cost data 
Neuberger, E. E., Carlson, J. J., & Veenstra, D. L. (2020). Cost-Effectiveness of Can-
nabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-
Gastaut Syndrome. PharmacoEconomics, 38(11), 1237-1245. 
Exclude: no Swiss specific cost data 
Herzog, S., Shanahan, M., Grimison, P., Tran, A., Wong, N., Lintzeris, N., ... & Morton, 
R. L. (2018). Systematic review of the costs and benefits of prescribed cannabis-based 
medicines for the management of chronic illness: lessons from multiple sclero-
sis. Pharmacoeconomics, 36(1), 67-78. 
Exclude: no Swiss specific cost data 
15.5.3 Methods search for Swiss utility values   
To identify the most recent Swiss utility data available to use as input in the cost-effectiveness model, a 
comprehensive search for baseline utilities for patients receiving medical cannabis and disutilties asso-
ciated with (serious) adverse events in Swiss patients was performed. The search terms are provided 
in Table IV and Table V. A search filter for utilities was added to the clinical search strings regarding 
medical cannabis. The search filter for utilities were based on the search string that was developed by 
CADTH to identify studies on the health utilities and/or quality of life of patients in Medline and Embase.f 
Table IV. Search terms utilities PubMed 
PubMed (MEDLINE) HRQoL studies 
Medical cannabis "Medical Marijuana"[Mesh] OR "Cannabinoids"[Mesh] OR "Nabilone"[Supplementary Concept] 
OR "HU 211"[Supplementary Concept] OR cannab*[tiab] OR marijuana[tiab] OR marihuana[tiab] 
OR hash*[tiab] OR hemp[tiab] OR dronabinol[tiab] OR marinol[tiab] OR tetrahydrocannabinol[tiab] 
OR THC[tiab] OR THCV[tiab] OR delta-9-tetrahydrocannabinol[tiab] OR delta-9-THC[tiab] OR 9-
ene-tetrahydrocannabinol[tiab] OR delta(1)-thc[tiab] OR delta(1)-tetrahydrocannabinol[tiab] OR 9-
delta-tetra-hydrocannabinol[tiab] OR 9-delta-THC[tiab] OR 9-ene-tetrahydrocannabinol[tiab] OR 
nabilone[tiab] OR cesamet[tiab] OR sativex[tiab] OR HU 211[tiab] OR HU211[tiab] OR dexanabi-
nol[tiab] OR CBD[tiab] OR CBDV[tiab] OR epidiolex[tiab] OR nabiximols[tiab] OR abalone[tiab] OR 
tilray[tiab] OR bedrocan[tiab] OR bedrobinol[tiab] OR bediol[tiab] OR bedrolite[tiab] OR 
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syndros[tiab] OR tetrahydrocannabivarin[tiab] OR THC:CBD spray[tiab] 
HRQoL/Utilities “Quality of Life"[Mesh] OR “Value of Life”[tiab] OR “Quality of Life”[tiab] OR utilit*[tiab] OR disu-
tilit*[tiab] OR eq5d[tiab] OR “eq 5d”[tiab] 




Table V. Search terms utilities Embase.com 
EMBASE.com HRQoL studies 
Medical cannabis 'medical cannabis'/exp OR 'cannabinoid'/exp OR 'nabilone'/exp OR 'dexanabinol'/exp OR can-
nab*:ti,ab OR marijuana:ti,ab OR marihuana:ti,ab OR hash*:ti,ab OR hemp:ti,ab OR 
dronabinol:ti,ab OR marinol:ti,ab OR tetrahydrocannabinol:ti,ab OR THC:ti,ab OR THCV:ti,ab OR 
‘delta-9-tetrahydrocannabinol’:ti,ab OR ‘delta-9-THC’:ti,ab OR ‘9-ene-tetrahydrocannabinol’:ti,ab 
OR ‘delta(1)-thc’:ti,ab OR ‘delta(1)-tetrahydrocannabinol’:ti,ab OR ‘9-delta-tetra-hydrocanna-
binol’:ti,ab OR ‘9-delta-THC’:ti,ab OR ‘9-ene-tetrahydrocannabinol’:ti,ab OR nabilone:ti,ab OR 
cesamet:ti,ab OR sativex:ti,ab OR ‘HU 211’:ti,ab OR ‘HU211’:ti,ab OR dexanabinol:ti,ab OR 
CBD:ti,ab OR CBDV:ti,ab OR epidiolex:ti,ab OR nabiximols:ti,ab OR abalone:ti,ab OR tilray:ti,ab 
OR bedrocan:ti,ab OR bedrobinol:ti,ab OR bediol:ti,ab OR bedrolite:ti,ab OR syndros:ti,ab OR tet-
rahydrocannabivarin:ti,ab OR ‘THC:CBD spray’:ti,ab 
HRQoL/Utilities ‘quality of life’/exp OR ‘Value of Life’:ab,ti OR ‘Quality of Life’:ab,ti OR utilit*:ab,ti OR disutilit*:ab,ti 
OR eq5d/exp OR eq5d:ab,ti OR ‘eq 5d’:ab,ti 
Country Switzerland:ab,ti OR Swiss:ab,ti 
Period N/A 
Hits 223 
15.5.4 Results search for Swiss utility values   
The selection of studies is illustrated in Figure II. The references and decisions of the 4 studies that were 
included in the full-text screening are reported in Table VI. These 4 studies were the exact same studies 
that were identified in the cost search. None of these studies reported Swiss utilities for the relevant 
health states as defined by our model structure. Hence, we did not extract any data from the identified 
studies.  
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Figure II. PRISMA flowchart costs on health-related quality of life 
 
 
Table VI. References and decisions of studies included in full-text screening of health-related 
quality of life systematic literature search 
Reference Decision 
Elliott, J., McCoy, B., Clifford, T., Potter, B. K., Wells, G. A., & Coyle, D. (2020). Eco-
nomic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analy-
sis. PharmacoEconomics, 1-10. 
Exclude: no Swiss specific utility data 
Mantovani, L. G., Cozzolino, P., Cortesi, P. A., & Patti, F. (2020). Cost-Effectiveness 
Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in 
Subjects with Multiple Sclerosis. Clinical Drug Investigation, 1-8. 
Exclude: no Swiss specific utility data 
Neuberger, E. E., Carlson, J. J., & Veenstra, D. L. (2020). Cost-Effectiveness of Can-
nabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-
Gastaut Syndrome. PharmacoEconomics, 38(11), 1237-1245. 
Exclude: no Swiss specific utility data 
Herzog, S., Shanahan, M., Grimison, P., Tran, A., Wong, N., Lintzeris, N., ... & Morton, 
R. L. (2018). Systematic review of the costs and benefits of prescribed cannabis-based 
medicines for the management of chronic illness: lessons from multiple sclero-
sis. Pharmacoeconomics, 36(1), 67-78. 
Exclude: no Swiss specific utility data 
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15.6 Input tables economic evaluations  
Table I. Cost inputs reported in economic evaluations of medical cannabis use in chronic pain 
 
Tyree 2019 NICE 2019 
Treatment-related costs 
Medical cannabis costs 1 1 
Comparator costs 1 1 
Adverse event-related treatment costs 1 1 
Future unrelated healthcare costs 
Future unrelated healthcare costs 0 0 
Non-health care costs 
Travel 0 0 
Time 0 0 
Informal care 0 0 
Productivity 0 0 
Keys: 1 = yes, 0 = no 














Treatment-related costs   
Medical Cannabis costs 1 1 1 1 1 1 
Comparator costs (SOC) 1 1 1 1 1 1 
Adverse event-related treatment 
costs 
0 0 0 0 1 0 
Future unrelated healthcare costs  
Future unrelated healthcare costs 0 0 0 0 0 0 
Non-health care costs  
Travel 0 0 0 0 0 0 
Time 0 0 0 0 0 0 
Informal care 0 0 0 0 0 0 
Productivity 0 0 0 0 0 0 
Keys: 1 = yes, 0 = no 
Table III. Effectiveness and utility inputs reported in economic evaluations of medical cannabis 
use in chronic pain  
 
Tyree 2019 NICE 2019 
Effectiveness 
Pain severity 1 1 
Mortality 0 0 
Adverse events 1 1 
Beneficial side-effects 0 0 
Utilities 
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Pain severity  1 1 
Adverse events 1 1 
Disutility of medical cannabis administration 0 0 
Beneficial side-effects  0 0 
Keys: 1 = yes, 0 = no  
Table IV. Effectiveness and utility inputs reported in economic evaluations of medical cannabis 








Effectiveness   
Spasticity severity  1 1 1 1 1 1 
Mortality 0 0 0 0 0 0 
Adverse events 0 0 0 0 1 0 
Beneficial side-effects 0 0 0 0 0 0 
Utilities  
Spasticity severity  1 1 1 1 1 1 
Adverse events 0 0 0 0 1 0 
Disutility of medical cannabis administration 0 0 0 0 0 0 
Beneficial side-effects 0 0 0 0 0 0 
Keys: 1 = yes, 0 = no  
15.7 Quality appraisal economic evaluations 
Table I. Critical appraisal of economic evaluations on medical cannabis use in chronic pain  
Item  
CHEC checklist Tyree 2019 NICE 2019 
  
Study design 
1 Is the study population clearly described? 0 0 
2 Are competing alternatives clearly described? 1 1 
3 Is a well-defined research question posed in answerable form? 0 0 
4 Is the economic study design appropriate to the stated objective? 1 1 
5 Is the chosen time horizon appropriate in order to include relevant costs and con-
sequences?g 
0.5 0.5 
6 Is the actual perspective chosen appropriate?h 0.5 1 
  
Costs 
                                                     
 
 
g 0.5 if not lifetime  
h 0.5 if not societal 
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7 Are all important and relevant costs for each alternative identified?  
 
See table Appendix 15.6 
8 Are all costs measured appropriately in physical units? 
9 Are costs valued appropriately? 
  
Outcomes 
10 Are all important and relevant outcomes for each alternative identified?  
See table Appendix 15.6 11 Are all outcomes measured appropriately? 
12 Are outcomes valued appropriately? 
  
Results  
13 Is an incremental analysis of costs and outcomes of alternatives performed? 1 1 
14 Are all future costs and outcomes discounted appropriately? 0 1 
15 Are all important variables, whose values are uncertain, appropriately subjected to 
sensitivity analysis? 
1 1 
16 Do the conclusions follow from the data reported? 1 1 
17 Does the study discuss the generalisability of the results to other settings and pa-
tient/client groups? 
1 1 
18 Does the article indicate that there is no potential conflict of interest of study re-
searcher(s) and funder(s)?i 
0 1 
19 Are ethical and distributional issues discussed appropriately? 0 0 
Keys: 1 = yes, 0 = no, 0.5 = inconclusive  


















Study design   
1 Is the study population clearly described? 0 1 0 1 1 1 
2 Are competing alternatives clearly described? 1 1 1 1 1 1 
3 Is a well-defined research question posed in answer-
able form? 
1 1 1 1 1 1 
4 Is the economic study design appropriate to the 
stated objective? 
1 1 1 1 1 1 
                                                     
 
 
i 0.5 if a conflict of interest is stated 
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5 Is the chosen time horizon appropriate in order to in-
clude relevant costs and consequences?j 
0.5 0.5 0.5 0.5 0.5 0.5 
6 Is the actual perspective chosen appropriate?k 0.5 0.5 0.5 0.5 0.5 0.5 
  
Costs 




See table Appendix 15.5 8 Are all costs measured appropriately in physical 
units? 









See table Appendix 15.5 1
1 
Are all outcomes measured appropriately? 
1
2 





Is an incremental analysis of costs and outcomes of 
alternatives performed? 
1 1 1 1 1 1 
1
4 
Are all future costs and outcomes discounted appro-
priately? 
1 1 1 1 1 0 
1
5 
Are all important variables, whose values are uncer-
tain, appropriately subjected to sensitivity analysis? 
1 1 1 1 1 1 
1
6 
Do the conclusions follow from the data reported? 1 1 1 1 1 1 
1
7 
Does the study discuss the generalisability of the re-
sults to other settings and patient/client groups? 
0 1 0 1 1 0 
1
8 
Does the article indicate that there is no potential 
conflict of interest of study researcher(s) and fun-
der(s)?l 
0.5 0.5 0.5 1 1 0.5 
1
9 
Are ethical and distributional issues discussed appro-
priately? 
0 0 0 0 0 0 
Keys: 1 = yes, 0 = no, 0.5 = inconclusive 
 
                                                     
 
 
j 0.5 if not lifetime 
k 0.5 if not societal 
l 0.5 if a conflict of interest is stated 
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15.8 Simulated NRS baseline values 
Figure 1. Simulated NRS baseline values neuropathic pain (n=10’000, mean=0.690, SD=0.135) 
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* The NRS baseline values simulated for MS spasticity were also applied to the motor neuron disease model 
15.9 Markov traces  
Figure 1. Musculoskeletal pain 
 
Figure 3. Simulated NRS baseline values MS spasticity (n=10’000) 
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Figure 2. Neuropathic pain 
 
 
Figure 4. Motor neuron disease spasticity 
 
Figure 3. MS spasticity 
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15.10  Cost-effectiveness acceptability curves 
The cost-effectiveness acceptability curve presents the number of iterations that fall below a cost-effec-
tiveness threshold (horizontal axis).  
Neuropathic pain 
At a threshold of zero, 0.7% of iterations yielded cost-effective results. As the threshold increases, the 
proportion of cost-effective iterations increase as well. With a threshold of 100’000 CHF per QALY, 
18.6% of iterations were cost-effective. 
Figure 1. Cost-effectiveness acceptability curve – neuropathic pain 
Musculoskeletal pain 
At a cost-effectiveness acceptability threshold of zero, 0.0 % of iterations yielded cost-effective results. 
As the threshold increases, the proportion of cost-effective iterations increase as well. With a threshold 
of 100’000 CHF per QALY, 59.1% of iterations were cost-effective. 
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MS spasticity 
At a threshold of zero, 25% of iterations yielded cost-effective results. This proportion is equal to the 
number of dominant ICERs. As the threshold increases, the proportion of cost-effective iterations in-
crease as well. With a threshold of 100’000 CHF per QALY 48% of iterations were cost-effective.   
Figure 3. Cost-effectiveness acceptability curve – MS spasticity 
 
Motor neuron disease spasticity 
For motor neuron disease,  29% of iterations yielded cost-effective results at a threshold of zero CHF 
per QALY. With a threshold of 100’000 CHF per QALY, 52% of iterations were cost-effective.  
Figure 4. Cost-effectiveness acceptability curve – Motor neuron disease 
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15.11 One-way sensitivity analysis additional tornado diagrams 
Neuropathic pain 
 
Figure 1. Tornado diagram incremental QALYs 
 
Keys: NRS = numeric rating scale, SOC = standard of care, MC = medical cannabis (THC:CBD spray)  
 
Figure 2. Tornado diagram incremental costs 
 
Keys: NRS = numeric rating scale, SOC = standard of care, MC = medical cannabis (THC:CBD spray)  
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Musculoskeletal pain 
 
Figure 3. Tornado diagram incremental QALYs 
 
Keys: NRS = numeric rating scale, SOC = standard of care, MC = medical cannabis (THC:CBD spray)  
 
Figure 4. Tornado diagram incremental costs 
 
Keys: NRS = numeric rating scale, SOC = standard of care, MC = medical cannabis (THC:CBD spray)  
 
Multiple sclerosis spasticity 
 
Figure 5. Tornado diagram incremental QALYs 
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Figure 6. Tornado diagram incremental costs 
 
 
Keys: NRS = numeric rating scale, SOC = standard of care, MC = medical cannabis (THC:CBD spray)  
Motorneuron disease spasticity 
 
Figure 7. Tornado diagram incremental QALYs 
 
Keys: NRS = numeric rating scale, SOC = standard of care, MC = medical cannabis (THC:CBD spray)  
Figure 8. Tornado diagram incremental costs 
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15.12 HTA reports and clinical guidelines   
Organisation, 
year 









Ireland  Clinical 
guidance 
Treatment-resistant spasticity in multiple 
sclerosis, treatment-resistant intractable 
nausea and vomiting associated with 
cancer chemotherapy, severe treatment-
resistant epilepsy  
Multiple 
products 




A wide range of indications (including 
chronic pain and spasticity)  
Multiple 
products 
CADTH, 2019 Canada Evidence 
review 
Chronic pain Multiple 
products 
CADTH, 2019 Canada Evidence 
review 
Spasticity in multiple sclerosis  Sativex  
DEP, 2016 Italy Evidence 
review 
A wide range of indications  (including 
chronic pain and spasticity) 
Multiple 
products 




A wide range of indications  (including 
chronic pain and spasticity) 
Multiple 
products 
G-BA, 2018 Germany Policy deci-
sion 
Spasticity in patients with multiple sclero-
sis 
Sativex 




A wide range of indications (including 
chronic pain and spasticity)  
Multiple 
products 
iQWiG, 2018 Germany Evidence 
review 









A wide range of indications (including 
chronic pain and spasticity)  
Multiple 
products 





A wide range of indications (including 
chronic pain and spasticity)  
Multiple 
products 






Chronic pain Multiple 
products 






Spasticity  Multiple 
products 




Chronic non-cancer pain Multiple 
products 




Multiple sclerosis Multiple 
products 




A wide range of indications (including 
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policy deci-
sion 
 
 
 
